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    Folate mediated one-carbon (1C) metabolism is required for the de novo synthesis 
of purines, thymidylate, and the remethylation of homocysteine to methionine.
Perturbations in folate mediated 1C metabolism are associated with pathologies and 
developmental defects including cardiovascular disease, cancers, and neural tube 
defects. Disruption of thymidylate biosynthesis is associated with genome instability 
resulting from the misincorporation of uracil into DNA. The de novo dTMP pathway 
consists of serine hydroxymethyltransferase, (SHMT), thymidylate synthase (TYMS), 
and dihydrofolate reductase (DHFR). Serine hydroxymethyltransferase 1 (SHMT1) 
expression is limiting for de novo thymidylate synthesis.
    Whereas the current literature describes nucleotide biosynthesis occurring in the 
cytoplasm, the results of these studies demonstrate that de novo dTMP biosynthesis is 
unique in that it occurs in the nucleus and mitochondria. The entire de novo 
thymidylate biosynthesis pathway is shown to undergo SUMO dependent nuclear 
translocation during S-phase. A novel isoform of SHMT, termed SHMT2α, was 
identified which provides functional redundancy with SHMT1 for nuclear de novo 
thymidylate biosynthesis and accounts for about 25% of nuclear SHMT activity. 
SHMT1 protein levels are shown to be regulated by the ubiquitin system where an 
interplay between SUMOylation and ubiquitination on SHMT1 signals proteasomal 
degradation, nuclear export, and mediates stability within the nucleus and cytosol. 
Nuclear thymidylate biosynthesis is coupled with the formation of multi-enzyme 
complexes associated with the nuclear lamina. SHMT1 serves as scaffold protein and 
is essential for metabolic complex formation. The enzymes for de novo dTMP
synthesis were found to be associated with PCNA and enriched at origins of 
replication.
    The nuclear compartmentation of de novo dTMP synthesis led to the hypothesis that 
there is a requirement for dTMP synthesis within the mitochondria. Purified 
mitochondria were capable of de novo thymidylate biosynthesis. A novel isoform of
DHFR previously thought to be a pseudogene called DHFR-like protein 1 (DHFRL1) 
was identified that is essential for mitochondrial thymidylate biosynthesis. In cells 
lacking mitochondrial SHMT activity (SHMT2) uracil levels in mtDNA were 
increased by 40%. These data support a role for de novo dTMP synthesis within the 
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Uracil: Friend or Foe? 
Introduction 
The presence of uracil in DNA is associated with genome instability and DNA mutagenesis 
(1). Two mechanisms account for the presence of uracil in DNA: cytidine deamination, and 
misincorporation of dUTP into DNA during DNA replication.  Spontaneous or enzymatic 
cytosine deamination can lead to genetic transitions upon DNA replication; U:G base mispairs 
result in C to T transitions. Deamination of cytidine occurs in both dsDNA and ssDNA 
(Figure 1.1). High dUTP/dTTP ratios in cells can also permit the misincorporation of uracil 
into DNA (Figure 1.1). While A:U base pairs do not lead to transitions or transversions, 
genome instability can result. Repair enzymes such as uracil DNA glycosylase (UNG) 





Figure 1.1. The presence of uracil in DNA is due to cytidine deamination and uracil 
misincorporation. Cytidine deamination can occur in dsDNA or ssDNA. During transcription, 
replication, or DNA breathing ssDNA can undergo spontaneous or enzymatic cytidine 
deamination. During replication, dUTP can be misincorporated into DNA in place of dTTP. 
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Under dTTP deplete conditions, a futile cycle of removal and replacement can result in double 
strand breaks. Double strand breaks (DSB) can give rise to chromosomal translocations, point 
mutations and/or cell death. It has been estimated that spontaneous cytidine deamination 
occurs 70-200 events per day (2) whereas incorporation of dUTP in place of dTTP has been 
observed to occur up to 10,000 times per genome per day (3) representing a quantitatively 
larger source of uracil in DNA (4). The presence of uracil in DNA elicits repair mechanisms 
which are 5-fold redundant. The four human genes encoding uracil repair enzymes include:  
thymine DNA glycosylase (TDG), methyl-CpG-binding domain protein 4 (MBD4), single 
strand selective monofunctional uracil DNA glycosylase 1 (SMUG1) and uracil DNA 
glycosylase (UNG). The UNG gene encodes both mitochondrial (UNG1) and nuclear (UNG2) 
isoforms. In mice, Nei-like glycosylase 1 (Neil1) has been determined to excise uracil from 
DNA (5) . Recent evidence also supports a role for NEIL1 in uracil repair in humans (6). 
Despite the redundancy in uracil repair mechanisms, uracil misincorporation is responsive to 
folate levels (7). Folate mediated one-carbon metabolism is a metabolic network required for 
the de novo synthesis of purines, thymidylate, and S-adenosylmethionine (8). The de novo 
dTMP pathway serves to limit uracil misincorporation by maintaining dTMP levels within 
compartments where DNA replication occurs: the nucleus and mitochondria (9,10). Although 
accumulation of uracil in DNA could lead to genome instability, uracil misincorporation may 
encode information within DNA. The focus of this review will be to outline what is known 
about uracil misincorporation limiting mechanisms, uracil repair mechanisms and possible 
outcomes, and the evidence that suggests uracil as an information encoder within DNA. 
Uracil misincorporation limiting mechanisms prior to DNA replication. 
The inability of DNA polymerase to discriminate between dUTP and dTTP indicates that the 
ratio of dUTP/dTTP is an important factor in the misincorporation of uracil in DNA (11). Two 
mechanisms exist that can lower the concentration of dUTP and increase dTTP: deoxyuridine 
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triphosphatase, (dUTPase) which hydrolyzes dUTP to dUMP and pyrophosphate (12) and the 
de novo thymidylate pathway which uses dUMP to make dTMP. Sources of dUMP include 
the deamination of dCMP by deoxycytidylate deaminase and the reduction of UDP by the 
action of ribonucleotide reductase to form dUDP. Following subsequent phosphorylation to 
dUTP, dUTPase can hydrolyze dUTP to make dUMP for de novo dTMP synthesis (Figure 
1.2). 
 
Figure 1.2. Pre-Replication Mechanisms for Limiting the Available dUTP Pool.  The de novo 
dTMP biosynthetic cycle is localized to the nucleus in S-phase and G2/M phases. SHMT1 and 
SHMT2α work to convert serine and THF to glycine and 5,10-methyleneTHF. TYMS uses 
5,10-methyleneTHF to methylate dUMP to form dTMP leaving DHF which can be reduced by 
DHFR to form THF for another round of dTMP synthesis. dTMP can subsequently be 
phosphorylated for incorporation into DNA. dUTPase can dephosphorylate dUTP to dUMP in 
order to allow TYMS to convert it to dTMP. Both of these mechanisms work to effectively 
lower the dUTP/dTTP ratio which governs how much uracil misincorporation can occur. 
 
dUTPase is conserved throughout vertebrate evolution (13) and is essential in E. coli (14) and 
S. cerevisiae (15). The dUTPase gene encodes two isozymes: a nuclear form, DUT-N and a 
mitochondrial form, DUT-M (16). These two isoforms are generated through alternative 5’ 
exon usage which contains either a nuclear localization signal or a mitochondrial localization 
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signal (17,18). DUT-N and DUT-M are regulated differently with DUT-M being 
constitutively expressed whereas DUT-N is expressed in replicating cells (19). These 
isozymes work to limit the available pools of dUTP for misincorporation in their respective 
compartments and increase the levels of dUMP which can be utilized for de novo thymidylate 
biosynthesis.  
     De novo thymidylate biosynthesis occurs in both the nucleus (9) and mitochondria (10). 
The three enzymes that constitute the de novo thymidylate biosynthetic pathway, serine 
hydroxymethyltransferase (SHMT), dihydrofolate reductase (DHFR), and thymidylate 
synthase (TYMS) also work to control the dUTP/dTTP ratio (Figure 2). SHMT catalyses the 
reversible conversion of serine and THF to glycine and 5,10-methyleneTHF. 5,10-
methyleneTHF is then used by TYMS to methylate dUMP to produce dTMP and 
dihydrofolate (DHF). DHFR subsequently reduces DHF to THF in a NADPH dependent 
reaction allowing for the de novo thymidylate biosynthetic cycle to continue (8).  For nuclear 
de novo dTMP synthesis, the entire de novo thymidylate biosynthetic cycle is localized to the 
nucleus in S and G2/M phases of the cell cycle (20)(Unpublished observation, Anderson et 
al.). Two cytosolic and nuclear isoforms of SHMT exists: one encoded by the SHMT1 gene, 
and another encoded by the SHMT2 gene we termed SHMT2α (9). SHMT2α was shown to 
account for ~25% of the thymidylate produced in nuclei. Through cell culture and mouse 
studies, SHMT1 has been observed to be rate-limiting for de novo dTMP biosynthesis.  
Increasing levels of SHMT1 in MCF-7 and SHSY5Y cells increases the efficiency of de novo 
dTMP synthesis whereas lowering SHMT1 levels in MCF-7 cells lowers efficiency of dTMP 
synthesis (21). In mouse models lacking Shmt1, levels of uracil misincorporation are increased 
further showing the importance of SHMT1 and de novo dTMP synthesis for limiting uracil 
within DNA (7). Both SHMT1 and SHMT2α are required as a scaffold protein for the 
formation of multi-enzyme complexes including SHMT, TYMS, and DHFR that co-localize 
5 
with the nuclear lamina. We have also identified SHMT1, TYMS, and DHFR as PCNA 
interacting proteins. PCNA acts as the sliding clamp for replicative DNA synthesis. Using a 
model system of replicating episomal DNA and tandem chromatin immunoprecipitation 
experiments, SHMT1, TYMS, and DHFR were all found to be in association with PCNA on 
DNA with high enrichment around origins of replication (Unpublished observation, Anderson 
et al.). These data confirm the presence of the nuclear de novo dTMP pathway at replication 
forks for the processive addition of dTTP into DNA when needed.   
    Mitochondrial de novo dTMP synthesis has been shown to occur in the human liver cell 
line, HepG2, and Chinese hamster ovary cells (CHO)(10). Our lab and others have identified 
TYMS and SHMT2 within mitochondria of mammalian cells (22-25). The entire de novo 
dTMP pathway also exists in plant mitochondria using a bi-functional TYMS-DHFR enzyme 
and SHMT2 (26). Within mammalian mitochondria identification of a mitochondrial DHFR 
was still undetermined until recently (10). We were able to identify a previously 
uncharacterized mitochondrial DHFR that was thought to be a pseudogene called 
dihydrofolate reductase-like protein 1 (DHFRL1). Confocal microscopy experiments 
identified that DHFRL1 localized to mitochondria. Knocking down DHFRL1 with siRNA in 
HepG2 cells eliminated DHFR activity within mitochondria. All three enzymes in 
mitochondrial de novo dTMP synthesis including DHFRL1, TYMS, and SHMT2 are available 
within matrix and inner membrane fractions of mitochondria with the matrix being the 
compartment in which mtDNA is housed (10). Furthermore, in mitochondria isolated from the 
glycine auxotrophic CHO cell line, glyA, which lack SHMT2 activity, it was observed that 
levels of mitochondrial de novo dTMP biosynthesis was essentially absent with a concomitant 
40% increase in levels of uracil misincorporation in mtDNA. These data support the 
importance of de novo dTMP biosynthesis in limiting uracil misincorporation in mtDNA.  
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    The availability of both dUTPase and de novo dTMP biosynthetic pathways to sites where 
DNA is synthesized show the importance of maintaining the dUTP/dTTP ratio in limiting 
uracil misincorporation.  
    Regardless of the multiple enzymes that exist to remove uracil from DNA, it seems that one 
of the most important factors in limiting the presence of uracil within DNA is folate. Previous 
work has observed that in humans deficient in folate, levels of uracil within blood and bone 
marrow DNA are increased 8 and 9 fold respectively as compared to patients with normal 
folate levels (27). Upon folate supplementation, levels of uracil within blood DNA decreased 
20 fold in patients with the lowest presupplementation folate levels. In normal human 
lymphocytes grown in medium with decreasing concentrations of folates, the presence of 
uracil increased as folate levels decreased (28). It has also been observed that in lymphocytes 
of hooded lister rats fed folate deficient diets that uracil levels increase in response (29). In a 
DNA repair deficient CHO cell line, CHO-UV5 cells, which are hemizygous at the aprt locus, 
it was observed that cells grown in media lacking folates, thymidine, and hypoxanthine had 
drastic increases in dUTP/dTTP ratios along with increases in the presence of uracil within 
DNA as compared to cells grown in replete media (30). Within our lab, we have seen that 
mice lacking Shmt1 exhibit increased uracil levels within liver and colon DNA (7,31) and that 
these increases double when mice are fed a folate and choline deficient diet. These data 
implicate folate status as a determining factor in regulating uracil content within DNA. 
Redundancy in uracil repair mechanisms 
    Although multiple repair enzymes exist for uracil within DNA, the focus of this review will 
be in enzymes that work to repair uracil misincorporation and not spontaneous or enzymatic 
deamination of cytidine within DNA leading to the presence of uracil. The major repair 
enzymes that work to remove uracil from U:A pairs derived from uracil misincorporation are 
the mitochondrial and nuclear isoforms of uracil DNA glycosylases, UNG1 and UNG2 
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respectively. The UNG gene is highly conserved across several species including mammals, 
bacteria, yeast, and herpes viruses (32). UNG1 and UNG2 have a high catalytic turnover rate, 
600-1000 uracils/min (33), consistent with the rapid movement of the replication fork (33-35). 
Both UNG1 and UNG2 do not have specificities for U:A or U:G pairings and work to repair 
uracil in DNA in both of those contexts in both single stranded and double stranded DNA 
(33).  In mammalian cells, both UNG1 and UNG2 are derived from the UNG gene through 
mRNA splicing and alternate promoter usage (36). The different N-termini encoded for on 
these transcripts are required for nuclear and mitochondrial sorting (2).  
UNG1 
     Mitochondrial DNA (mtDNA) is subject to increased mutation rates. The presence of an 
oxidative environment due to the process of respiration can lead to mtDNA mutagenesis. 
Respiration has been observed to function abnormally in cells depleted of mtDNA (37). 
Mutations in mtDNA can result in diseases such as cancer (38), neurodegeneration (39), and 
diabetes (40). Maintaining mtDNA integrity is essential for maintaining human health. Within 
mitochondria UNG1 is the only known uracil-DNA glycosylase (41). Like DUT-M and 
SHMT2 (42), UNG1 exhibits housekeeping-like expression. Highest levels of human UNG1 
expression occur in skeletal muscle, heart, and testis (43). UNG1 has been observed to remove 
uracil from mtDNA in short patch and long patch base excision repair (BER) in human 
mitochondrial extracts devoid of nuclear proteins (41). It must be noted that species specific 
differences exist between mice and men. While the Ung gene is organized similarly in both 
mice and men, murine Ung1 products sort to both mitochondria and nucleus (36,44) whereas 
in humans, UNG1 is only mitochondrial (43,44). This is due to a poor conservation of the 
mitochondrial localization signal in Ung1. A stronger promoter driving Ung1 in mice leads to 
a higher contribution of Ung1 to total Ung activity within mice compared to humans. In mice, 
the stronger promoter driving Ung1 and its localization to nuclei suggests that Ung1 acts as a 
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backup for Ung2 activity and works to ensure nuclear Ung activity. Understanding these 
species specific difference is important in interpreting data from mouse models. While these 
differences exist, mouse and rat models can be informative. During rat gestation, transcripts 
for both Ung1 and Ung2 exhibit high expression in embryos and yolk sacs between gestational 
days 10 and 12. Both Ung1 and Ung2 transcript levels are increased by 400% in gestational 
day 12 embryos and yolk sacs versus gestational day 10 embryos and yolk sacs (45). 
Treatment of embryo and yolk sac cells of rats in vitro with 0.5 µM methotrexate showed a 
30-40% increase in Ung1 levels in both embryos and yolk sacs while Ung2 levels were only 
increased in yolk sacs. Within mice, Ung1 is highly expressed in tissues rich in mitochondria 
similar to humans (43,44). An increase of Ung1 during embryo mid-gestation has been 
observed. These data may be indicative of important aspects of mitochondrial dUTP 
misincorporation during embryogenesis which are still unknown although the relative 
contributions of mouse Ung1 and Ung2 within the nucleus need further research. 
    Mice deficient in the Ung gene show a marked phenotype following ischemic insult and 
lower numbers of surviving neurons (46). Although the Ung
-/-
 mouse model does not 
discriminate between the mitochondrial and nuclear isoforms of Ung, disruption of mtDNA 
repair and mitochondrial damage has been shown to lead to cell death. Both mtDNA and 
mitochondrial damage are known to occur in response to ischemic brain injury and in Ung 
wild-type mice, the Ung1 transcript is specifically upregulated in response to stroke (46). The 
existence of mitochondrial and nuclear isoforms of dUTPase and UNG, as well as the 
presence of mitochondrial and nuclear de novo dTMP synthesis suggests that maintaining 
uracil levels in both compartments where DNA is synthesized is a critical process.    
UNG2 
    UNG2 is expressed most highly during S-phase in dividing cells and is undetectable in cells 
that are non-dividing (47) with highest UNG2 mRNA levels in late G1/early S phase (43). In 
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the nucleus, UNG2 accumulates at replication foci and binds to PCNA and replication factor 
A (RPA) suggesting a processive removal of uracils during replication which is consistent 
with its high catalytic rate (35,48). UNG2 has been observed to be in association with 
complexes containing APE1, POLD, XRCC1, and DNA ligase which are competent for both 
short-patch and long-patch BER (34). Interestingly, SHMT1 has been shown to interact with 
BER proteins suggesting a processive repair pathway in which UNG2 removes uracil and 
thymidylate is synthesized at those repair foci for incorporation in DNA (Unpublished results 
Anderson). More work must be done in order to understand the role of SHMT1 in repairing 
and limiting uracil in DNA.  
    Post-translational modification of UNG2 is an important mediator of degradation and 
activity. Phosphorylation of serines and threonines in the N-terminus of UNG2 has been 
observed (49) and UNG2 phosphorylation occurs at the initial start of S-phase (47). 
Furthermore, phosphorylation was observed to occur on Ser23 at late G1/early S-phase which 
increases its association with RPA and increases activity (50). Throughout S-phase, a 
sequential phosphorylation of Thr60 and Ser64 result in decreased affinity for RPA. S64A 
mutants of UNG2 accumulate in cells suggesting phosphorylation at that site is required for 
proteosomal degradation (47) via ubiquitination of UNG2 by late G2 phase (50). UNG2 is 
also phosphorylated at threonines 6 and 126 in response to UV damage. These phospho-forms 
of UNG2 have increased activity with subsequent dephosphorylation decreasing activity (51). 
Future work should be done to understand how the various phospho-forms of UNG2 affect 
protein-protein interactions and if differing partners exist in normal cycling cells versus UV 
treated cells.   
     Little phenotypic evidence is available from Ung-/- mice. These mice are viable and 
develop normally (52) whereas later in life these mice develop B cell lymphomas (53,54). As 
stated previously, species specific differences do exist between mice and men and 
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accumulating evidence in mammalian cell culture models shows UNG2 as playing a role in 
proliferation, cell death, and mitotic dysfunction.  Previous reports have indicated that 
treatment of human cells with uracil-DNA glycosylase inhibitor protein (UGi) results in 
reduced cellular proliferation (55). Knockdown of UNG2 using siRNA has also been observed 
to decrease cell proliferation and increased apoptosis as compared to controls (56). In rat 
hippocampal neurons grown in culture, knockdown of Ung induced apoptosis (57). Recent 
evidence supports a role for UNG2 in mediating kinetochore assembly for mitosis by acting as 
an assembly factor for the histone H3 variant, CENP-A (58,59). CENP-A is required for 
kinetochore assembly during mitosis and also binds to sites of DNA damage (60). UNG2 co-
localizes at centromeres and sites of double strand breaks (DSB) with CENP-A and phosph-
H2AX, a histone H2A variant that rapidly localizes to sites of DSB. Knockdown using siRNA 
specific to UNG2 results in the inability for CENP-A to assemble and results in cell death, 
reduced proliferation, and increased frequencies of mitotic dysfunction (59). Mutants of 
UNG2 lacking catalytic activity still rapidly form foci in cells at sites of laser induced damage 
suggesting the catalytic activity is not required for this function (59). Future work must be 
done in order to more fully understand whether all the defects seen in mammalian cell culture 
models are due to lack of UNG2 mediated CENP-A assembly. 
NEIL1 
    Some recent evidence implicates human NEIL1 as a mediator of increased sensitivity to de 
novo dTMP synthesis pathway inhibition with addition of dTTP rescuing the phenotype (6). 
Although this data may be indicative of human NEIL1 playing a role in removal of U:A pairs, 
mouse Neil1 is selective in removal of U:G mispairs (5). More work should be done in order 
to fully understand the selectivity and characteristics of human and mouse Neil1. 
Uracil in DNA as a controller of gene expression 
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    Evidence supports that uracil misincorporation leads to genomic instability (27,28,61-63). 
While this may be accurate and responsible for some pathologies, other possibilities exist 
namely: alterations in the transcriptome and/or nucleotide sensing mechanisms.  
    Maternal folate supplementation has reduced the numbers of neural tube defects in the 
population (64,65). Until recently though, no folate-dependent enzymes have been implicated 
in neural tube defects. Mice deficient in SHMT1 fed folate deficient diets exhibit increased 
risks of neural tube defects (66). These mice also exhibit increased uracil misincorporation in 
DNA (7) and decreased capacity for de novo dTMP synthesis (9). While uracil in DNA may 
be a marker of potential genomic instability, Ung-/- mice exhibit 100 fold increased uracil in 
genomic DNA, yet they develop normally with no evident macroscopic phenotypes (35). 
Because impaired dTMP synthesis, the presence of uracil in DNA, and folate status are 
associated with neural tube defects, it would stand to reason that Ung-/- mice on folate 
deficient diets would also exhibit neural tube defects if it were uracil misincorporation related, 
which is not the case. Lower folate status would be expected to increase the dUTP/dTTP ratio. 
It may be that uracil in DNA is simply a marker of increased dUTP/dTTP ratio and that this 
ratio in the cell signals some downstream event that acts as a master regulator. This has been 
observed in the bacterium E. coli, where the transcription factor RutR was found to be 
regulated by uracil and thymine levels (67). The RutR regulon contains a large number of 
genes involved in the degradation of purines and pyrimidines; the synthesis of pyrimidines, 
glutamine, and arginine; and the transport of glutamate. Future work should identify potential 
RutR homologues in mammalian cells to determine if similar regulatory processes occur. 
Master regulatory events may be important in understanding early developmental processes 
due to aberrant levels of uracil and thymine. 
     Another intriguing hypothesis of regulation of gene expression by uracil in DNA is 
supported by several lines of evidence. Pyrimidine C5 methyl groups exist in two forms: 
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methylation of cytosine by DNA methyltransferases and in thymine. Thymine bases have a 
methyl group at C5 whereas uracil does not. Interestingly, these methyl groups exist in the 
major groove of B-form DNA, with the major groove being the more accessible to regulatory 
proteins such as transcription factors (68). It is known that cytosine methylation plays an 
important part in epigenetic phenomenon and regulation of gene expression. An intriguing 
hypothesis emerges in that thymine methyls could be playing a role in regulation with the 
absence of a methyl group (uracil in place of thymine) also playing a role.  
    Protein-DNA interactions can be facilitated by the C-5 methyl group of thymine. This was 
originally identified for restriction enzymes containing thymine in their recognition motifs.  
The B. subtilis phage, PBS2, contains uracil in its DNA in place of thymine. When PBS2 
DNA was subjected to restriction enzymes that recognize thymine-containing sequences, such 
as HpaI and HindIII, DNA was digested inefficiently (69). The efficiency of enzymes 
containing only G-C base pairs within their recognition motifs was unaffected. Furthermore, 
site-directed mutagenesis of the EcoRI, EcoRII, and EcoRV recognition sites in which 
thymines were replaced with uracil lead to a 30%, 50%, and complete reduction of activity 
respectively (70,71).  
    The regulatory impact of uracil in place of thymine has been described in the E. coli lac 
operon, a 26 bp region containing 16 A-T base pairs (72). Several thymines within the 
sequence at positions 6,7,13,25, and 26 were required for normal lac repressor-lac operon 
(RO) complex formation. Replacing these thymines with uracil resulted in drastic reduction of 
RO complex stability and solidified a role for thymine methyls in making hydrophobic 
contacts with the lac repressor.  
    The promoter regions of E. coli also contain thymines. The consensus sequences -35 and -
10 upstream of transcription start sites are A-T rich. Replacement of thymines at -35 and -34 
with uracil resulted in the abolishment of promoter function showing how critical thymines at 
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those positions are for transcriptional activity (73). Although several studies have implicated 
roles for uracil misincorporation regulating protein-DNA interactions in bacteria, evidence 
exists within higher eukaryotes as well. The yeast transcription factor GCN4 is a transcription 
factor in the AP-1 family (74). The sequence that GCN4 binds to is ATGACTCAT (75) and 
contains 6 A-T pairs. Using uracil interference assays this sequence was probed for GCN4 
binding when T is replaced with U (76). It was observed that the 4 internal thymines within 
the sequence were required for the high affinity binding of GCN4 in vitro. These data support 
the importance of thymine methyls in protein-DNA interactions. A model of how uracil in 
DNA may play a role in protein-DNA interactions is shown in figure 1.3. It can be envisioned 
that in DNA, transcriptional activators or repressors that recognize thymine methyls could 
recognize and bind to their DNA binding motif when thymine is present. Upon replacement of 
thymines with uracil, transcriptional activators or repressors may have a lower or higher 
affinity for the DNA binding motif which would affect transcriptional processes. 
 
Figure 1.3. Models of Transcriptional Response to Uracil Misincorporation.  A) 
Transcriptional activators or repressors containing critical thymines in their binding sequence 
can recognize and bind to their motif.  B) Upon uracil misincorporation (as denoted by the 
asterisk) transcriptional activators or repressor DNA binding may be affected by changing 
binding constants for the cognate site or C) completely inhibiting binding and decreasing or 
increasing transcription.  D) Conversely, a transcriptional activator or repressor inhibited by 
thymine containing sequence may bind E) when the methyl group of thymine is missing in 
uracil containing sequence. 
 
In Drosophila, no UNG activity has been detected (77). Instead, a nuclease which acts upon 
uracil containing DNA has been isolated. Using uracil-containing DNA, pull-down 
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experiments were performed to isolate interactors that contained uracilated DNA nuclease 
activity. The enzyme that was purified was termed uracil-DNA-degrading factor protein 
(UDE) (78).  It has been determined that a drastic reduction of dUTPase in larval stages prior 
to pupation and lack of UNG activity could significantly increase uracil in DNA during those 
developmental stages (79). UDE expression is also under strict control during Drosophila 
development with upregulation just prior to pupation with little expression during the 
embryonic and larval stages (78). The significant increases in uracil-DNA during larval stages 
suggests some sort of uracil-mediated control of metamorphosis.      
    DNA replication, repair, recombination, and transcriptional processes all use DNA as 
substrate and these processes are inherently connected (80). Increased transcriptional 
activation occurs in association with genomic instability. In S. cerevisiae it has been 
determined that a link exists between transcription associated mutagenesis and the levels of 
transcription. The accumulation of abasic sites has been observed to be greatly increased in 
highly transcribed DNA. Using ung deficient mutants in yeast, it was identified that UNG was 
responsible for generating abasic sites that accumulate under high-transcriptional conditions 
(81). The authors went on to overexpress dUTPase in yeast and observed lower mutation rates 
showing that most uracil present in highly-transcribed DNA is derived from dUTP 
misincorporation versus cytosine deamination. These data provide a direct link between the 
presence of uracil in DNA and transcriptional response.  
    Although evidence of these types of regulatory events is lacking in mammalian cells, 
models of hypotheses that uracil misincorporation in DNA leads to transcriptional changes can 
be made. GATA-1 is a transcription factor that is required for erythroid and megakaryocyte 
differentiation. The DNA binding motif that GATA-1 recognizes is (A/T)GATA(A/G) (82). A 





Figure 1.4. GATA-1 as an example of thymine recognition transcription factors. PyMOL 
generated figures of the zinc-finger protein GATA-1 (PDB Entry:  1GAT).  A)  A cartoon of 
the co-crystal structure of the GATA-1 DNA binding region interacting with DNA. The 
GATA-1 DNA element is (A/T)GATA(A/G).   A GATA-1 α-helix and loop structure fit into 
the major groove of DNA where thymine methyl groups are always located. B) and C) The α-
helix and loop structures shown contain hydrophobic residues which are close enough for van 
der Waals contacts allowing for the recognition of thymine methyls.  
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The α-helix and loop structure shown are present within the major groove of DNA with 
potential van der Waals contacts between DNA thymine methyls and Leu33 and Leu37 in the 
α-helix (Figure 1.4B) and Thr16 and Leu17 on the loop structure (Figure 1.4C). Due to these 
interactions, it could be postulated that uracil in place of thymine in these sequences would 
decrease GATA-1 binding. 
    Another intriguing aspect of GATA-1 as a model is that multiple GATA-1 binding sites 
exist within the same promoters that drive both the mouse α-globin gene cluster and the mouse 
high affinity receptor for IgE (FcεRI) β-chain. The mouse FcεRI β-chain promoter is activated 
through binding to four different GATA motifs (Figure 1.5A) (84). 
 
Figure 1.5.Multiple GATA-1 motifs are required for transcription.  Two examples of GATA-
1 driven genes are shown. A) In the mouse FcεRI β-chain promoter, recruitment of GATA-1 
to four separate GATA-1 binding motifs is required for wild-type levels of FcεRI β-chain to 
be produced. B) The mouse α-globin locus requires the nucleation of multi-protein complexes 
by GATA-1.  GATA-1 recruits multiple transcription factors which allow for the recruitment 




At the mouse α-globin gene cluster, it has been reported that the binding of GATA-1 to 
multiple motifs recruits several different proteins including the pre-initiation complex and 
RNA polymerase II for transcription (85,86). Promoter sequence containing multiple GATA 
sites in several different genes have higher affinities for GATA-1 than promoter sequence 
containing only 1 GATA site (87). Uracil-misincorporation is driven by the dUTP/dTTP ratio 
and so incorporation of uracil is both dUTP concentration and DNA sequence dependent. 
Therefore, DNA regions that have higher numbers of thymines in the sequence are more likely 
to contain uracil in place of thymine than in regions where thymine is not prevalent within the 
sequence. If uracil is expected to cause changes in transcription through changes in 
transcription factor binding, then it would be a more likely event in regions where multiple 
thymine containing binding sites exist.  
    Another important hypothesis to consider is that a more general process controlling 
transcription is occurring. Approximately 24% of human genes contain TATA box elements 
(88). TATA-containing genes are generally non-housekeeping genes which are under tight 
control. Multiple transcription factors bind to the TATA box prior to recruitment of RNA 
polymerase II for transcription. More research is required to fully understand how uracil 
containing DNA may regulate transcription globally.  
Genomic instability 
    As previously stated, much evidence supports uracil misincorporation associated with 
genomic instability. Following the criteria for uracil misincorporation into regions enriched in 
thymine, several regions of the genome become of interest, such as telomeric sequence that is 
enriched in long TTAGGG repeats (89).  
    Telomeres are essential for maintaining genome stability. Because of the linear nature of 
human chromosomes, the progressive loss of DNA sequence at chromosome ends occurs with 
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every replication. Once chromosomes lose a critical amount of sequence, cells enter 
senescence and programmed cell death (90,91). Shortening of telomeres occurs with age (92), 
with loss of telomeres resulting in susceptibility to chromosome fusion and/or DSBs which 
can result in chromosomal rearrangements (93). Embryonic stem cells, germ cells, and some 
cancer cells exhibit telomerase activity, whereas somatic cells exhibit low levels of telomerase 
(94) . Telomerase is essential for the maintenance of chromosome ends during development 
and has been proposed to be a mechanism of transformation in cancer cells. Telomerase has 
reverse transcriptase activity and uses its own RNA molecule (TERC) as a template for 
addition of repeats (94). Following the addition of long repeats of the aforementioned 
sequence, DNA polymerase α uses the ssDNA sequence made by telomerase as a template to 
synthesize the complementary strand and form dsDNA. Although DNA polymerase does not 
differentiate between dUTP and dTTP, it is still unknown whether telomerase makes a choice 
between the two nucleotides. If dUTP is not as good a substrate for telomerase, telomerase 
stalling may occur. Because telomerase is highly active during embryogenesis, this may have 
extreme deleterious effects on cell differentiation and growth. Furthermore, if dUTP is 
misincorporated into telomeric DNA, DSBs may be induced because the repeated TTAGGG 
sequence would result in strings of thymine on both strands of DNA. Repair occurring on both 
strands simultaneously would likely produce DSB. Both of these mechanisms could lead to 
increased telomere loss and potentially induce programmed cell death. 
    DSB either within telomeric regions or in other DNA regions have to be repaired either by 
homologous recombination, or non-homologous end joining (NHEJ). Homologous 
recombination requires a significant amount of homology while NHEJ is a process that 
requires no homologous sequence and can occur at any time during the cell cycle (95). When 
the formation of DSB at telomeric or other DNA regions occurs, the potential for aneuploidy 
increases due to bridge fusion break cycles (96). Aneuploidy is associated with folate 
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deficiency although the molecular mechanisms are still poorly understood (97-99). 
Aneuploidy is a hallmark of cancer cells and is also one of the major contributors to 
spontaneous abortion (100). An interesting caveat is that although aneuploidy occurs in 
populations of cells undergoing uncontrolled proliferation, most aneuploidies reduce fitness of 
organisms. Only after enough aneuploidy tolerating mutations have been acquired do these 
cells proliferate unchecked (101). 
 Conclusions    
    Uracil misincorporation may reflect a new form of transcriptional regulation (Figure 1.6). 
Uracil in DNA may lead to altered gene expression through some unknown mechanism 
(Figure 1.6A). Uracil in DNA may also lead to chromosomal aberrations through increasing 
genome instability.  
 
Figure 1.6. Uracil: Friend or Foe? Models showing potential consequences of uracil 
misincorporation. A) Upon uracil misincorporation in folate depleted individuals, as uracil is 
removed from DNA and repaired, high dUTP/dTTP ratios could favor the continued 
incorporation of uracil into DNA. If this occurs in regulatory sequence, changes in 
transcription may be observed. B) If uracil misincorporation occurs on adjacent strands of 
DNA upon uracil removal, double strand breaks (DSBs) can occur. Upon homologous 
recombination or NHEJ it can be hypothesized that translocations could occur potentially 
leading to other chromosomal aberrations such as aneuploidy.  Aneuplody can lead to cell 
death or upon aneuploidy tolerating mutations, tumor progression can take place.  Human 
telomeres contain long TTAGGG repeats.  The high number of thymines in telomeric DNA in 
adjacent strands could lead to DSBs in telomeric DNA leading to telomere shortening, 
premature aging, and cell senescence. 
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This may occur in several ways (Figure 1.6B): decreased dTTP availability for telomerase 
causing stalling; increased dUTP incorporation into telomeres resulting in DSB; increases in 
telomere fusion, homologous recombination, or NHEJ in response to DSB leading to 
aneuploidy. Following aneuploidy tolerating mutations, tumor progression can occur. 
Telomeric shortening may lead to cell death. During embryogenesis telomere shortening could 
be catastrophic resulting in decreased cell proliferation. Telomeric fusion resulting from 
shortening could lead to aneuploidy. Aneuploidy is seen in many spontaneous abortions and 
could be partially due to maternal nutritional status. Future work will need to be done to 
understand if telomerase is affected by altered dTTP levels and if dU in telomeres is 
problematic.  
    We have seen that increased uracil in DNA and deficiencies in dTMP synthesis result in 
increased risk for neural tube defects and intestinal cancers. We have also seen that mice 
deficient in nuclear SHMT1 on folate deficient diets exhibit drastic increases in uracil levels 
within DNA and it is protective against cancer (Unpublished results, MacFarlane et al). Neural 
tube defects could be caused by aberrant uracil in DNA which leads to telomere shortening 
and/or an increase in aneuploidy leading to decreased cell proliferation. Aneuploidy does 
occur in NTDs (102,103). Neural tube closure could also be affected by global changes in 
gene expression during critically timed events due to uracil in DNA. Future work will need to 
determine if any of these hypotheses are valid.  
    Cancer could also be due to altered gene expression from uracil within DNA. Altered 
expression of oncogenes or tumor suppressors could lead to aberrant cell growth. For genomic 
instability to be causal in cancer progression, cells would have to overcome the programmed 
cell death induced by both telomere shortening and aneuploidy. If mutations arose that 
tolerated these genomic problems then those cells could progress. There may be a critical 
threshold of uracil in DNA which may be protective such that increasing uracil above that 
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point causes severe DNA damage and increased cell death. Because uracil misincorporation is 
not mutagenic, as is the case in cytosine deamination, the likelihood of tolerating mutations 
would be less.  
    Future work should identify which regions, if any, in DNA are enriched with uracil. 
Understanding how DNA acts as a sink for dUTP and what outcomes can arise will give 
insight into multiple biological processes. Another interesting question would be to determine 
if any RutR homologues exist within humans and to characterize it. The coordination of 
nucleotide pools and master regulatory processes could also lend insight to our understanding 
of these pathways. Finally, more work should be done to understand uracil misincorporation 
into mtDNA. It is intriguing that UNG1 is the only uracil dna glycosylase in mitochondria. 
Limiting levels of dUTP in mitochondria may therfore be more important. Little work has 
been done on UNG1, but what is known is that loss of SHMT2 results in increased uracil 
misincorporation into mtDNA. Future work should determine how folate deficiency affects 
uracil misincorporation in mtDNA and if critical levels of uracil in mtDNA cause metabolic 
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SHMT1 and SHMT2 Are Functionally Redundant in Nuclear De novo Thymidylate 
Biosynthesis 
Introduction 
Tetrahydrofolate (THF) is a metabolic cofactor that carries and activates single carbons for the 
synthesis of nucleotides and methionine (1). Folate-mediated one-carbon metabolism is 
compartmentalized in the mitochondria and cytoplasm of eukaryotic cells (Figure 1).  
 
Figure 2.1. Compartmentation of folate-mediated one-carbon metabolism in the cytoplasm, 
mitochondria and nucleus. One-carbon metabolism in the cytoplasm is required for the de 
novo synthesis of purines and thymidylate, and for the remethylation of homocysteine to 
methionine. One-carbon metabolism in mitochondria generates one-carbon units for 
cytoplasmic one-carbon metabolism by generating formate from serine and glycine. One-
carbon metabolism in the nucleus synthesizes dTMP from dUMP and serine. SHMT2, 
mitochondrial serine hydroxymethyltransferase; SHMT1, cytoplasmic serine 




In the cytoplasm, this metabolic network is required for the biosynthesis of purines, 
thymidylate, and the remethylation of homocysteine to form methionine. Serine is a major 
source of one-carbon units for this network through its reversible and tetrahydrofolate-
dependent conversion to glycine and methyleneTHF catalyzed by serine 
hydroxymethyltransferase (SHMT). There are cytoplasmic and mitochondrial SHMT 
isozymes. SHMT1 encodes the cytoplasmic isozyme (SHMT1) and SHMT2 encodes the 
mitochondrial isozyme (SHMT2) (2-4). Mitochondrial one-carbon metabolism generates one-
carbons from serine through the activity of SHMT2, and the one-carbon is oxidized and 
exported to the cytoplasm as formate, supporting cytoplasmic one-carbon metabolism (5). The 
SHMT1 enzyme generates methyleneTHF for thymidylate and methionine biosynthesis, but 
isotope tracer studies indicate that SHMT1 preferentially partitions methyleneTHF to 
thymidylate biosynthesis (6). The de novo thymidylate biosynthesis pathway requires three 
enzymes: thymidylate synthase (TYMS), dihydrofolate reductase (DHFR), and SHMT1. 
MethyleneTHF generated by SHMT is the one-carbon donor for the TYMS catalyzed 
conversion of dUMP to dTMP generating dihydrofolate (DHF). DHFR catalyzes the NADPH-
dependent reduction of DHF to regenerate THF for subsequent cycles of de novo thymidylate 
synthesis. Recently, the enzymes that constitute the thymidylate synthesis cycle were shown to 
undergo post-translational modification by the small ubiquitin-like modifier (SUMO) and 
nuclear translocation during S and G2/M phases (7,8). Although the synthesis of thymidylate 
in the nucleus has never been demonstrated, others have found folate cofactors present in liver 
nuclei (9), and multi-enzyme complexes containing ribonucleotide reductase and thymidylate 
synthase have been isolated from nuclear extracts (10). In this study, intact nuclei are shown to 
catalyze the formation of dTMP from dUMP, which accounts for the results of stable isotope 
studies that indicate SHMT preferentially partitions methyleneTHF to thymidylate 
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biosynthesis. Furthermore, both Shmt1 and Shmt2 are shown to contribute to nuclear de novo 
thymidylate biosynthesis. 
Results 
Shmt1 and Shmt2 contribute to nuclear dTMP biosynthesis. The ability of purified nuclei to 
catalyze the formation of tritiated dTMP from unlabeled dUMP, NADPH and [2,3-
3
H]-L-
serine in vitro was investigated (Figure 2.2).  
 










H]dTMP was determined in reactions that contained: 1) sonicated nuclei; 2) intact nuclei; 3) 
intact nuclei with 200 µM 5-CHOTHFGlu5; and 4) intact nuclei with 100 mM aminomethyl 
phosphonate (AMPA). De novo thymidylate biosynthesis activities were normalized to 
activity generated from SHMT1
+/+
 intact nuclei which was given an arbitrary value of 1.0. 
Reactions containing sonicated nuclei contained no activity. All reactions were performed in 
duplicate and the experiment repeated twice. Variation is expressed as the standard deviation. 
 
Intact nuclei isolated from the livers of wild type mice were capable of generating tritiated 
dTMP, demonstrating that folate-dependent nuclear dTMP synthesis occurs in liver. The 
addition of the SHMT inhibitor and amino acid analog, aminomethylphosphonate, to the 
reaction mixture inhibited dTMP synthesis by greater than 95%, demonstrating the essentiality 
of the SHMT reaction in generating folate-activated one-carbons from serine for dTMP 
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synthesis in nuclei. 5-formyltetrahydrofolate pentaglutamate, a natural inhibitor of SHMT 
(11), did not inhibit nuclear dTMP biosynthesis but may not have been able to traverse the 
nuclear membrane. Disruption of nuclei by sonication eliminated all dTMP synthesis activity, 
indicating that cytoplasmic contamination was not responsible for the observed dTMP 
synthesis activity in nuclei, and suggesting that maintenance of nuclear architecture is 
essential for nuclear dTMP synthesis. Surprisingly, intact nuclei isolated from the liver of 
Shmt1
−/−
 mice were capable of generating tritiated dTMP at approximately 25% of the level 
observed from nuclei isolated from Shmt1
+/+
 mice (Figure 2.2). Aminomethylphosphonate 
inhibited dTMP synthesis in nuclei generated from Shmt1
−/−
 mice, indicating that a second 
SHMT activity is present in nuclei which is not derived from Shmt1. PCR was used to confirm 
the genotype of the purified nuclei and immunoblotting was performed to verify that the 
nuclei lacked Shmt1 (Figure 2.3A).  
 
Figure 2.3. Identification of SHMT2 in purified nuclei. Panel A) PCR was used to confirm the 






 mice were 
generated through deletion of exon 7 which encodes the PLP binding site. SHMT1
+/+
 mice 
exhibit a 740-bp PCR product whereas the SHMT1
−/−
 mice exhibit a 460-bp PCR product. 
Western blotting confirmed the presence of TYMS and DHFR in nuclei of both genotypes. 
SHMT1 was present in purified liver nuclei from SHMT1
+/+
 mice, but absent in liver nuclei 
from SHMT1
−/−
 mice. SHMT2 was present in nuclei from both genotypes. Panel B) Western 
blots confirm the purity of the isolated liver nuclei. The control lane represents purified 
cytosol from NIH/3T3 cells for both the Lamin A (nuclear marker) and GAPDH (cytoplasmic 
marker). The control for the COX IV immunoblot represents a purified mitochondrial fraction 
from NIH/3T3 cells. The absence of GAPDH and COX IV in nuclear extracts indicated that 
no cytosolic or mitochondrial contamination was present in the nuclear dTMP assays. 
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Furthermore, the nuclei were shown to be free of cytosolic and mitochondrial contamination 
(Figure 2.3B). DHFR and TYMS protein were observed in purified nuclei isolated from the 
livers of wild type and Shmt1
−/−
 mice, and surprisingly, SHMT2 protein was also observed in 
nuclei isolated from the livers of wild type and Shmt1
−/−
 mice (Figure 2.3A). 
Previous evidence suggests that Shmt2 contains two translation initiation sites. Expression of a 
SHMT2 gene fragment lacking exon 1 in glyA CHO cells, which lack SHMT2 activity, 
rescued the glycine auxotrophy (4). Exon 1 encodes the first translation initiation start site and 
most of the peptide sequence required for efficient import into mitochondria. Shmt2 contains a 
potential second translation initiation codon within exon 2, and translation initiation from this 
site generated a protein capable of import into mitochondria, albeit at lower efficiency (Figure 
2.4) (4).  
 
Figure 2.4. The mouse Shmt2 encodes two transcripts and contains two translation initiation 
sites.The SHMT2 transcript is denoted by the color red. The first nucleotide of the translation 
initiation site contained in exon 1 is numbered as +1. The first translation initiation site in 
exon 1, which encodes for the mitochondrial leader sequence, is boxed in blue. The 
mitochondrial leader sequence is cleaved co-translationally in the mitochondria denoted by the 
scissors (2). The second translation initiation site, present in exon 2, is boxed in blue. A 
transcription start site in intron 1 deduced from a mouse liver EST (AA793217) is denoted by 
the arrow and starts at −166 from the second ORF. 
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To determine if two transcripts were generated from Shmt2, one containing exon 1 and one 
lacking exon 1, the mouse EST database was probed for Shmt2 cDNA sequences that 
contained nucleotide sequence from the Shmt2 intron 1/exon 2 boundary. An EST 
(AA793217) that lacked exon 1 but contained 166 nucleotides from the 3′ end of intron 1 at its 
5′ end was identified. Similarly, the human EST database was probed and two SHMT2 
transcripts containing 131 nucleotides from the 3′ end of intron 1 were identified (DB184899 
and DA597551). These data indicate that SHMT2 encodes two transcripts and an alternative 
promoter within intron 1.  
Subcellular localization of SHMT2 gene products 
The cellular localization of the two SHMT2 isoforms was determined by expression of 
SHMT-yellow fluorescent protein (YFP) and red fluorescent protein (RFP) fusion proteins. 
Cyan fluorescent protein fused to a mitochondrial leader sequence (CFP-mito) at its amino 
terminus and Draq5 DNA binding dye were used as mitochondrial and nuclear markers 
respectively. Confocal microscopy revealed that the SHMT protein expressed from the 
SHMT2 transcript containing exon 1 (referred to as SHMT2-YFP) and CFP-mito protein co-
localized to mitochondria. However, SHMT protein expressed from the SHMT2 transcript 
lacking exon 1 (referred to as SHMT2α-RFP) localized predominantly to the cytoplasm and 
nucleus (Figure 2.5A). The nuclear localization of the SHMT2α-RFP fusion protein exhibited 
similar cell cycle dependence as observed for SHMT1 (8). The SHMT2α-RFP fusion protein 
localized exclusively to the cytoplasm in G1 phase whereas in S and G2/M phases it localized 







Figure 2.5. SHMT2α localizes to the cytoplasm and nucleus. HeLa cells were transfected with 
cDNAs encoding SHMT2-YFP, mito-CFP, and SHMT2α-RFP. A) The SHMT2-YFP fusion 
protein expressed in HeLa cells localizes to mitochondria. The mitochondrial marker, mito-
CFP has a similar localization pattern as that of SHMT2. The SHMT2α-RFP fusion protein 
expressed in HeLa cells localizes to both the cytoplasm and the nucleus. B) SHMT2α-RFP 
localizes to the nucleus in a cell cycle dependent manner during S-phase and G2/M, whereas it 
is absent from the nucleus in G1 phase. 
 
Both SHMT2 and SHMT2α rescue the glycine auxotrophy in GlyA Chinese Hamster Ovary 
cells 
Previously, transfection of a human SHMT2 gene fragment that lacked exon 1 into CHO GlyA 
cells, which lack SHMT2 activity in mitochondria and exhibit a glycine auxotrophy, resulted 
in very low levels of SHMT2 activity in mitochondria which was sufficient to rescue the 
glycine auxotrophy (4). In this study, the ability of SHMT2α to rescue the glycine auxotrophy 
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in GlyA cells was determined. Twelve to fifteen stable transfectants were selected for G418 
resistance from GlyA cells electroporated with either an empty TagRFP-N plasmid, a plasmid 
expressing the cDNA encoding SHMT2, or a plasmid expressing the cDNA encoding 
SHMT2α. All plasmids were driven by the immediate early promoter of cytomegalovirus. 
Stable transfectants containing the RFP empty vector did not rescue glycine auxotrophy and 
no revertants were observed in the 12 colonies screened. However, the glycine auxotrophy 
was rescued in all selected cell lines expressing either the SHMT2-RFP or the SHMT2α-RFP 
fusion protein (Figure 2.6). This data confirms that SHMT2α localizes to mitochondria and 
can rescue mitochondrial one-carbon metabolism.  
 
Figure 2.6. SHMT2 and SHMT2α rescue the glycine auxotrophy in CHO glyA cells.CHO 
glyA cells were transfected with cDNAs encoding human SHMT2-RFP, SHMT2α−RFP, and a 
RFP-empty vector control. Stable cells lines were selected for G418 resistance in the presence 
of 200 mM glycine. For growth assays, cells were cultured with and without glycine and MTT 
assays were used to quantify growth. Twelve independent lines were assayed per transfection 
and experiments were done in triplicate. All values are normalized to RFP-empty vector 
transfectants. There was no significant difference in growth among the cells transfected with 
SHMT2 and SHMT2α with or without glycine. RFP-empty vector transfectants with and 
without glycine are shown as a circle and open box respectively. SHMT2-RFP transfectants 
with and without glycine are shown as a closed box and triangle respectively. SHMT2α−RFP 
transfectants with and without glycine are shown as an inverted triangle and diamond 
respectively. 
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Expression of SHMT2 and SHMT2α in mouse tissues 
The relative levels of each SHMT2 isoform was determined in mouse liver and kidney by 
western blot analyses (Figure 2.7).  
 
Figure 2.7. SHMT2 and SHMT2α are present in mouse tissues. Immunoblots using a sheep-
anti-human SHMT2 antibody revealed the presence of three immunoreactive bands. Protein 
masses were determined by the migration distance and relative mobility of standards. Purified 
liver nuclei, whole liver and whole kidney extracts contained an immunoreactive band at ~53 
kDa, the predicted mass of SHMT2α. Purified liver mitochondria, whole liver and whole 
kidney extracts contained a band at ~56 kDa, the predicted mass of the SHMT2 pre-processed 
protein. Purified liver mitochondria and whole liver, but not whole kidney extracts contained a 
band at ~50 kDa, the predicted mass of the SHMT2 processed protein. The nuclear fraction 
was free of cytosolic and mitochondrial contamination as shown by the GAPDH and COX IV 
immunoblots. 
 
A single immunoreactive band that migrated at 53 kD was present in nuclear extracts isolated 
from mouse liver when probed with an antibody against SHMT2. This molecular mass 
corresponds to the predicted size of the SHMT2α protein expressed from the Shmt2 transcript 
lacking exon 1. Purified liver mitochondrial extracts exhibited three immunoreactive bands. 
The upper band, which migrated with a molecular mass of approximately 56 kDa, is consistent 
with the predicted mass of the full length SHMT2 pre-processed protein. A lower band, which 
migrated with a molecular mass of approximately 50 kDa, corresponds to the processed 
SHMT2 protein lacking its leader sequence as present in mitochondria. These 3 bands were 
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also observed in whole liver extract, and the blot indicates that the predominant SHMT2 
isoform is the processed mitochondrial form. However, a substantial amount of the SHMT2α 
protein was also present in liver. In kidney, only the pre-processed SHMT2 and SHMT2α 
form of the enzyme were observed. 
A single nucleotide polymorphism in SHMT1 impairs nuclear localization 
Previously, we demonstrated that a common polymorphism in SHMT1, L474F impairs SUMO 
modification of the SHMT1 protein (8). To determine if this polymorphism impairs nuclear 
localization and to explore the potential for the redundancy between SHMT1 and SHMT2α, 
MEFS derived from Shmt1
−/−
 mice were electroporated with plasmids that express the wild- 
type human SHMT1-YFP fusion protein, the human L474F SHMT1-YFP fusion protein or a 
mutated K38R/K39R SHMT1-YFP fusion protein, which lacks a SUMO-modification site (8). 
MEFs isolated from Shmt1
−/−
 mice were used to eliminate the possibility that endogenous 
mouse SHMT1 protein could oligomerize with the human SHMT1 fusion proteins thereby 
allowing nuclear import. The SHMT1-YFP fusion protein localized to both the cytoplasm and 
nucleus in S-phase, whereas the K38R/K39R SHMT1-YFP fusion protein localized 
exclusively to the cytoplasm in S-phase (Figure 2.8).  
 
Figure 2.8. The L474F polymorphism in SHMT1 impairs nuclear localization. SHMT1
−/−
 
MEF cells were transfected with cDNAs encoding the YFP-empty vector, YFP-SHMT1 wild-
type, YFP-SHMT1-K38R/K39R, and YFP-SHMT1-L474F. S-phase blocked transfectants 
showed that YFP-SHMT1 is greatly increased in the nucleus in S-phase. Empty vector control 
and K38R/K39R mutation eliminated nuclear localization, and the L474F polymorphism 
inhibited nuclear localization. 
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The L474F SHMT1-YFP fusion protein was found in both the cytoplasm and nucleus at S-
phase, but in contrast to the SHMT1-YFP protein, its localization was primarily cytoplasmic. 
These data demonstrate that the SHMT1 L474 polymorphism impairs nuclear localization. The 
potential for functional redundancy between SHMT1 and SHMT2α in nuclear folate 
metabolism may have been the permissive factor that allowed this mutation to expand in 
human populations. 
Discussion 
The results from this study demonstrate directly the existence of nuclear thymidylate 
biosynthesis. Pardee and co-workers (10,12,13) first proposed the concept of nuclear 
nucleotide biosynthesis and put forward the concept of a nuclear multi-enzyme complex 
termed the replitase, which synthesized nucleotides at the replication fork during DNA 
synthesis. Both DHFR and TYMS activities were found in these purified complexes isolated 
from nuclei, but no direct evidence for nuclear nucleotide biosynthesis was reported. The 
concept of nuclear folate metabolism is also supported by early studies that demonstrated 10% 
of the total cellular hepatic folate was present within the nucleus (9). Previous studies have 
shown that TYMS localizes to the nucleus at S-phase (8), (14), and recently SHMT1, DHFR, 
and TYMS proteins have all been shown to be SUMOylated, providing a mechanism by 
which all the enzymes required for de novo thymidylate biosynthesis can be localized to the 
nucleus (7,8). Recent evidence indicates that nuclear folate-dependent nucleotide biosynthesis 
is limited to thymidylate biosynthesis, as the multi-enzyme complex responsible for de novo 
purine biosynthesis, the purineosome, localizes to the cytoplasm (15). 
In this study, we demonstrated that one-carbon units generated from serine are used for 
nuclear de novo thymidylate biosynthesis, and that the three enzymes that participate in de 
novo thymidylate pathway are present in nuclei. Compartmentalization of these enzymes to 
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the nucleus accounts for previous isotope tracer studies that demonstrate SHMT1 
preferentially shuttles one-carbon units towards thymidylate biosynthesis (6). 
The data also demonstrate functional redundancy between Shmt1 and Shmt2 in nuclear folate 
metabolism. The observation that Shmt2 (and human SHMT2) encodes a nuclear/cytoplasmic 
isozyme, SHMT2α, may account for the unexpected viability of Shmt1
−/−
 mice, and 
potentially the emergence in human populations of the L474F SHMT1 polymorphism, which 
impairs nuclear SHMT1 import. However, SHMT2α cannot fully replace SHMT1 function as 
Shmt1
−/−
 mice exhibit elevated uracil content in DNA (16). The S-phase and G2/M phase 
dependence of SHMT2α nuclear localization suggests that it is available for de novo 
thymidylate biosynthesis during DNA synthesis and repair as observed for SHMT1 (8). The 
mechanism by which SHMT2α localizes to the nucleus is currently under investigation. 
To our knowledge, SHMT2 is the only gene identified that encodes proteins that can localize 
to the cytoplasm, nucleus and mitochondria. Previously, zebrafish SHMT2 protein was shown 
to localize exclusively to mitochondria (17). The zebrafish Shmt2 gene lacks the second 
translation initiation site in exon 2 and thus can only encode a mitochondrial isozyme. 
Mammalian SHMT2 genes, with the exception of the lagomorph gene, encode a translation 
initiation codon in exon 2 and therefore likely encode the cytoplasmic/nuclear SHMT2α 
isozyme. These data also provide evidence for tissue-specific expression of the SHMT2 
isoforms. The SHMT2/SHMT2α ratio differs between liver and kidney, with SHMT2 being 
the predominant form in liver, whereas only the SHMT2α and the SHMT2 unprocessed 
protein precursor were observed in kidney. Mitochondria are a primary source of one-carbon 
units for cytoplasmic one-carbon metabolism through the activity of SHMT2, and the 
SHMT2α protein lacks most of the mitochondrial targeting sequence and may not be imported 
into mitochondria efficiently (4). Therefore, the lack of processed SHMT2 protein in kidney 
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mitochondria may account for previous findings that glycine catabolism through the 
mitochondrial glycine cleavage system is a major source of one-carbon units in kidney (18). 
The molecular mechanisms underlying the differential promoter usage in SHMT2 that results 
in the synthesis of the SHMT2 isoforms is currently under investigation. 
Compartmentation of SHMT2α and the other de novo thymidylate biosynthetic pathway 
enzymes in the nucleus may allow for folate dependent dTTP biosynthesis directly at the 
replication fork. It is likely that nuclear thymidylate synthesis requires the formation of an 
enzyme complex, as sonicated nuclei were not capable of dTMP biosynthesis. It has been 
shown that the processivity factor PCNA interacts with SHMT1 in both C. elegans and HeLa 
cDNA yeast two hybrids (8), (19). Additional studies are required to determine why 
thymidylate biosynthesis, unlike purine nucleotide biosynthesis (15), occurs in the nucleus and 
if a thymidylate-specific replitase-like complex exists that enables the de novo dTMP 
synthesis pathway to function at the replication fork and prevent uracil misincorporation into 
DNA. 
Materials and Methods 
Nuclear Biosynthesis Assay  
The generation and characterization of SHMT1
−/−
 mice has been described previously (16). 
All study protocols were approved by the Institutional Animal Care and Use Committee of 
Cornell University and conform to the NIH Guide for the Care and Use of Laboratory 




 mice on a 129SvEv 
background and placed immediately in cold phosphate buffered saline at 5°C. Liver extracts 
from six age-matched males and females were combined and used for each genotype group. 
Nuclei were prepared using an iodixanol gradient as previously described (20). Purified nuclei 
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were suspended in 500 µL of nuclear assay buffer containing 5 mM NADPH (Sigma), 100 
mM β-mercaptoethanol, 25 mM HEPES, pH 7.5, 50 mM Sucrose, 5 mM MgCl2, 25 mM KCl, 
and 1 mM dUMP (Sigma) and quantified using a hemocytometer. 125 µL of assay buffer 
containing suspended nuclei were aliquoted into four 1.5 ml plastic tubes and 8 µCi of [2,3-
3
H]-L-Serine (Moravek Biochemicals) was added to each tube. The assay was conducted 
under 4 different experimental conditions: Experiment 1, nuclei that were lysed with 
sonication (Branson Sonifier 150) at 5°C using two 10 sec pulses at 10 watts separated by a 10 
sec resting interval; experiment 2, intact nuclei; experiment 3, intact nuclei with 5-
formyltetrahydrofolate pentaglutamate (Schirks Laboratory) added to at a final concentration 
of 200 µM; experiment 4, intact nuclei with aminomethylphosphonate added to a final 
concentration of 100 mM (Sigma). Reactions were incubated for 12 h at 37°C with shaking at 
300 rpm. Nuclei were pelleted by centrifugation at 2000 rpm for 5 min and the supernatant 
was collected and analyzed for radiolabeled thymidylate by high performance liquid 
chromatography (HPLC). Sample preparation and HPLC was performed as previously 
described (21,22). Fractions were collected and tritium quantified with a scintillation counter. 
The retention times of [2,3-
3
H]-L-serine (9 min) and 
3
H-thymidine (17 min) (Moravek 
Biochemicals) were verified prior to separation of the reaction mixtures. All experiments were 
performed in duplicate. 
Genotyping and immunoblotting 
After completion of the nuclear thymidylate biosynthesis reactions, pelleted nuclei were 
genotyped and analyzed by western blots. DNA was isolated using the DNeasy Blood and 
Tissue Kit (Qiagen) per manufacturer's protocol and genotyping as previously described to 
confirm the Shmt1 genotype (16). For western blots, nuclei were disrupted by boiling in SDS-
PAGE loading buffer for 10 min and protein concentrations quantified by the Lowry-
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Bensadoun assay (23). 20 µg of protein were loaded into each lane of a 10% SDS-PAGE gel 
(23). Protein transfers, western blotting and DHFR and TYMS detection were performed as 
previously described (7). SHMT1 and SHMT2 detection were completed as previously 
described (24,25). Equal loading and/or purity of nuclear fractions was confirmed through the 
detection of GAPDH using α-GAPDH (Novus Biologicals, 1:20000 dilution), Lamin A using 
α-Lamin A (Santa Cruz Biotechnology, 1:500 dilution), and COX IV using α-COX IV 
(Abcam, 1:5000 dilution). For Lamin A detection, goat anti-rabbit IgG-horseradish 
peroxidase-conjugated secondary (Pierce) was used at a1:20000 dilution. For COX IV and 
GAPDH detection, a 1:10000 dilution of goat anti-mouse IgG-horseradish peroxidase-
conjugated secondary (Pierce) was used. 
The sizes of the SHMT2α isoforms were determined using the Precision Plus Protein All Blue 
(BIORAD) and Kaleidoscope Prestained Standard (BIORAD). Processed mitochondrial 
SHMT2 migrated with the Precision Plus Protein All Blue 50 kDa marker. To determine the 
size of the bands corresponding to preprocessed SHMT2 and SHMT2α proteins, a standard 
curve was generated by measuring the migration distances of the protein standards. These 
distances were plotted as a function of log10 of the molecular mass standards, and the 
molecular mass of preprocessed SHMT2 and SHMT2α were determined using the equation 
MM = −1.4D+137.9; R
2
 = 0.98, where MM is molecular mass in kDa and D is migration 
distance in mm. The migration distance of the largest molecular mass band corresponding to 
preprocessed SHMT2 migrated 58 mm and SHMT2α migrated 61 mm, corresponding to 
approximately 56 kDa and 53 kDa respectively.  
Identification of Shmt2α expression 
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The nucleotide sequences of the human SHMT2 and mouse shmt2 intron 1/exon 2 boundaries 
were BLASTED against both the human and mouse EST databases to identify alternative 
SHMT2 and Shmt2 transcripts lacking sequence encoded by exon 1 but containing intron 1 
sequence within the 5′-untranslated region. To identify shmt2 protein products expressed from 
alternative shmt2 transcripts, liver and kidney were isolated from SHMT1
+/+
 mice on a 
C57Bl/6 background. The tissues were washed with phosphate-buffered saline and proteins 
solubilized using the Mammalian Protein Extraction Reagent (Pierce) containing 10 mM β-
mercaptoethanol and a 1:100 dilution of mammalian protease inhibitor (Sigma). 
Immunoblotting was performed as described above. 
Cell lines and culture 
HeLa cells (CCL2) and NIH/3T3 cells (CRL-1658) were obtained from ATCC. Mouse 
embryonic fibroblasts were isolated and maintained as previously described (8). GlyA, a CHO 
cell mutant lacking SHMT2 activity, was obtained from Dr. Larry Thompson, Lawrence 
Livermore Labs. All cells were cultured at 37°C in a 5% CO2 atmosphere. HeLa cells were 
maintained in minimal essential medium (α-MEM) (Hyclone) with 10% fetal bovine serum 
(Hyclone) and penicillin/streptomycin (Gibco). NIH/3T3 cells were cultured in DMEM 
(Gibco) supplemented with 10% fetal bovine serum and penicillin/streptomycin. GlyA cells 
were cultured in DMEM supplemented with 10% dialyzed and charcoal treated fetal bovine 
serum (dDMEM), 20 nM leucovorin (Sigma), 200 µM glycine (Sigma), and 
penicillin/streptomycin. 
Subcellular localization of SHMT2 and SHMT2α 
The human SHMT2 full length open reading frame was purchased from Open Biosystems. The 
cDNAs for the full length transcript (encoding SHMT2), and the transcript lacking exon 1 but 
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containing 131 nucleotides of intron 1 in the 5′UTR (encoding SHMT2α) were amplified by 
PCR amplified and cloned into PhiYFP-N (Evrogen) and TagRFP-N (Evrogen) vectors 
respectively. The forward primer used to amplify the SHMT2 transcript was 5′-
ATATCTCGAGATGCTGTACTTCTCTTTGTT-3′. The forward primer to amplify the 
SHMT2α transcript was 5′-ATATCTCGAGGTATGGCCATTCGGGCTCAGCAC-3′. The 
underlined sequence signifies a XhoI (Promega) restriction site. The same reverse primer was 
used for both amplifications: 5′-ATATAAGCTTCTAATGCTCATCAAAACCAG-3′. The 
underlined sequence denotes a HindIII (Promega) restriction site. The PCR conditions for 
amplification of both the SHMT2 and SHMT2α transcripts were as follows: 95°C for 45 s, 
52°C for 45 s, and 72°C for 2 min. A vector containing a mitochondrial marker, pTagCFP-
mito (Evrogen) was used for control transfections to identify mitochondria. Plasmids were 
transfected into HeLa cells using Lipofectamine 2000 (Invitrogen) per manufacturer's 
protocol. The DNA binding dye, Draq5 (Biostatus Limited) was used to visualize nuclei. For 
cell cycle analysis, HeLa cells were treated with 1 mM hydroxyurea, 30 µM Lovastatin or 60 
ng/ml nocodazole to block at S, G1 and G2/M phase respectively as previously described (8). 
Confocal fluorescence microscopy (Leica TCS SP2 system) was used to image all cells at the 
Cornell Microscope and Imaging Facility. 
Rescue of the glycine auxotrophy in GlyA cells 
GlyA cells were cultured in dDMEM supplemented with 200 µM glycine and 20 nM 
leucovorin. TagRFP-N-SHMT2 and TagRFP-N-SHMT2α and TagRFP-N vectors were 
linearized using NheI (Promega) and electroporated into GlyA cells as previously described 
(26). Following electroporation, cells were plated on BD Primaria 100×20 mm culture dishes 
(BD Bioscience) containing 10 ml of dDMEM medium, supplemented with 20 nM leucovorin, 
200 µM glycine and 200 µg/ml Geneticin (Gibco). 12–15 colonies from each transfection 
47 
were isolated and plated in 6-well plates (Corning) containing 3 ml dDMEM medium 
supplemented with glycine, leucovorin, and Geneticin. Cell growth assays were completed in 
media with and without glycine as previously reported (27). 
Site-directed mutagenesis and subcellular localization of SHMT1 
The SHMT1 cDNA (28) was used as a template to generate SHMT1-YFP fusion proteins. The 
SHMT1 cDNA was amplified for cloning into PhiYFP-N by PCR. The forward and reverse 
primers used were 5′- ATATCTCGAGATGACGATGCCAGTCAAC-3′ and 5′-
ATATAAGCTTTTAGAAGTCAGGCAGGCC-3′ respectively. The PCR conditions were as 
follows: 95°C for 45 s, 55°C for 45 s, and 72°C for 2 min. The underlined regions depict XhoI 
and HindIII restriction sites respectively. Coding mutations K38R/K39R and L474F mutations 
were made as previously described (8). PhiYFP-N vectors containing the SHMT1 cDNA, the 
SHMT1 cDNA containing a K38R/K39R mutation, and a SHMT1 cDNA containing the 
L474F mutation were transfected into Shmt1
−/−
 MEFs using electroporation protocols 
described above. Cells were blocked at S-phase by exposure to 1 mM hydroxyurea (Sigma) 
for 24 h. Confocal fluorescence microscopy (Leica TCS SP2 system) was used to image the 
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    Regulation of cellular dTTP pools is essential for faithful replication of nuclear and 
mitochondrial DNA (mtDNA), with both depletion and expansion of the pool affecting DNA 
integrity and human health (1). Depletion of de novo dTMP synthesis results in deoxyuridine 
misincorporation into nuclear DNA leading to genome instability (2), whereas depletion of 
mitochondrial dTTP pools, due to mitochondrial deoxyribonucleoside kinases, 
deoxyguanosine kinase, or thymidine kinase 2 (TK2) mutations are associated with mtDNA-
depletion syndromes and severe mitochondrial dysfunction in humans (3). Elevations in dTTP 
pools, as observed in mitochondrial neurogastrointestinal encephalomyopathy (4), an 
autosomal recessive disease resulting from decreased levels of cytoplasmic thymidine 
phosphorylase, results in mtDNA depletion (5), deletions (6), and site-specific point 
mutations (6). 
    There are two distinct pathways for thymidine nucleotide synthesis (Figure 3.1).  
 
Figure 3.1. De novo and salvage pathway synthesis of dTTP. There are two distinct pathways 
for dTTP synthesis. In the de novo pathway, SHMT catalyzes the conversion of serine and 
tetrahydrofolate (THF) to methyleneTHF and glycine. TYMS converts methyleneTHF and 
dUMP to dihydrofolate (DHF) and dTMP. DHF is converted to THF for subsequent rounds of 
dTMP synthesis in an NADPH-dependent reaction catalyzed by DHFR. In the salvage 
pathway, thymidine is phosphorylated by TK to form dTMP. 
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The salvage pathway involves the conversion of thymidine to thymidylate, and occurs in the 
mitochondria and cytoplasm catalyzed by TK2 and thymidine kinase 1 (TK1), respectively 
(7). Salvage pathway synthesis of dTTP is not sufficient to sustain mtDNA replication (3) and 
therefore requires de novo dTMP synthesis, which involves the conversion of dUMP to 
dTMP, catalyzed by the tetrahydrofolate (THF)-dependent enzymes serine 
hydroxymethyltransferase (SHMT), thymidylate synthase (TYMS), and dihydrofolate 
reductase (DHFR) (8). In this pathway, 5,10-methyleneTHF, a one-carbon donor, is generated 
from serine by SHMT and used for the conversion of dUMP to dTMP in a reaction catalyzed 
by TYMS. The TYMS catalyzed reaction generates dihydrofolate, which is converted to THF 
in an NADPH-dependent manner by DHFR. The regenerated THF can then be used for 
subsequent rounds of thymidylate biosynthesis. 
    Both de novo and salvage dTMP synthesis have been assumed to occur in the cytoplasm to 
support both nuclear and mtDNA replication, but recent studies have demonstrated nuclear 
localization of TK1 (9) and the de novo dTMP biosynthesis pathway during S-phase and as a 
result of DNA damage (10, 11). The inability of the mitochondrial dTMP salvage pathway to 
support mtDNA synthesis, and recent studies indicating that de novo 
dTMP synthesis occurs in the nucleus, raised the possibility for a requirement for de novo 
thymidylate biosynthesis in mitochondria.  
    De novo thymidylate synthesis has been shown to occur in plant mitochondria through the 
activities of an SHMT isozyme [mitochondrial serine hydroxymethyltransferase (SHMT2)] 
and a bifunctional enzyme containing both TYMS and DHFR (12). Interestingly, previous 
studies have localized TYMS to the mitochondria in mammalian cells (1, 13) and in 
neurospora crassa (14). In mammalian cells, mitochondria contain SHMT2, which is required 
for formate and glycine synthesis (15), but the third enzyme in the pathway, DHFR, does not 
localize to the mitochondria (16). 
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    In this study, a de novo dTMP biosynthesis pathway was identified in mammalian 
mitochondria that includes a unique mitochondrial isozyme of DHFR called DHFRL1, which 
was previously thought to be a pseudogene (17). De novo dTMP synthesis is shown to be 
necessary to prevent uracil accumulation in mtDNA. 
Results 
Mammalian Mitochondria Contain a De Novo dTMP Synthesis Pathway 
    Purified intact mitochondria from Chinese hamster ovary (CHO) cells and HepG2 cells 
(Table 3.1 and Figure 3.2) were capable of catalyzing the formation of 3H-dTMP from 
unlabeled dUMP, NADPH, and [2,3-3H]-L-serine in vitro.  
 
Table 3.1 Mitochondrial de novo thymidylate biosynthesis. Mitochondria were isolated from 
HepG2, wild-type CHO, and glyACHOcells which lack SHMT2 activity. The capacity to 




H-dTMP was determined in reactions that contained: 
(i) sonicated mitochondria, (ii) intact mitochondria for both the HepG2 and CHO cell 
reactions; and (iii) intact mitochondria with 100 µM methotrexate (MTX), a dihydrofolate 
reductase inhibitor for CHO cell reactions. The reactions were all normalized to the activity 
obtained from intact mitochondria isolated from wild-type CHO or HepG2 cells and given an 
arbitrary value of 1.0. Thymidylate synthesis was inhibited in MTX treated reactions (p < 
0.001, n=3) and in CHO glyA cells (p< 0.001, n=3) compared to the activity obtained in intact 
mitochondria isolated from wild-type CHO cells. Data were analyzed by two-way ANOVA 
with Tukey’s post hoc test for treatment. For HepG2, thymidylate synthesis was inhibited in 







Figure 3.2. Purity of Chinese hamster ovary (CHO) mitochondria. Mitochondria that were 
purified from CHO cells for the experiment described in Table 1 exhibited no nuclear or 
cytosolic contamination using immunoblots against GAPDH and Lamin A. 
 
This activity is a unique demonstration of folate-dependent de novo dTMP biosynthesis in 
mammalian mitochondria. Methotrexate inhibited dTMP production in mitochondria isolated 
from wild-type CHO cells. Mitochondria isolated from glyA CHO cell mutants, which lack 
SHMT2, exhibited a 94% reduction in dTMP synthesis capacity, indicating the essentiality of 
SHMT2 within mitochondria for mitochondrial de novo dTMP synthesis. Disruption of 
mitochondria by sonication-reduced de novo dTMP synthesis activity, indicating that 
compartmentalization within mitochondria, or the formation of complexes within 
mitochondria, may be important for de novo dTMP synthesis. Alternatively, the reduced 
activity may reflect dilution or loss of the endogenous folate cofactor pool following 
sonication. 
Identification of DHFRL1 as an Expressed Gene.  
    To determine if alternative human DHFR transcripts are expressed that encode a 
mitochondrial leader sequence, 5’ rapid amplification of cDNA ends (RACE) was conducted 
using total mRNA isolated from HepG2 cells. Two prominent bands were observed from the 
5’ RACE experiment. Upon sequencing the two bands, both DHFR and DHFRL1 were 
identified (Fig. 3.3A). DHFRL1 is annotated as a mammalian pseudo gene in Entrez Gene, 
and expressed sequence tags are present (GenBank accession no. DN994912).  
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Figure 3.3. Identification of DHFRL1 and alignment to DHFR. (A) 5’RACE was performed 
to identify DHFR transcripts that encoded a mitochondrial DHFR isozyme. Using a primer 
complementary to DHFR sequence, two bands were obtained following electrophoresis. The 
bands were isolated, cloned, and sequenced revealing DHFRL1 as an expressed transcript. (B) 
The sequence of DHFR and DHFRL1 were aligned using ClustalW in Lasergene Megalign 
software. The sequences are 92% identical. 
 
The DHFR and DHFRL1 primary sequences are 92% identical (Fig. 3.3B). An energy 
minimized three-dimensional model of DHFRL1 was constructed using the crystal structure of 
human DHFR [Protein Data Bank (PDB) ID code 3GHW] as a template. The model of 






Figure 3.4. Model of dihydrofolate reductase-like protein 1 (DHFRL1) protein. The protein 
sequence of DHFRL1 was modeled using the structure of human dihydrofolate reductase 
(DHFR) [Protein Data Bank (PDB) ID code 3GHW] as a template. The energy minimized 
model of DHFRL1 was produced in SWISS-PDB viewer and the model alignment and images 
were made in PyMOL. The rms between DHFR and the DHFRL1 model was determined to be 
0.0034 indicating high similarity in structure. 
 
Localization of DHFRL1 and TYMS to Mitochondria 
The subcellular localization of DHFRL1 and TYMS were determined by confocal microscopy 
following the  transfection of pCMV6-ACDHFRL1-GFP and pCMV6-AC-TYMS-GFP 
constructs into HeLa cells. The mitochondrial control vector pTagCFP-mito was also 
transfected to visualize mitochondria, and DRAQ5 nuclear stain was used to visualize nuclei. 
Colocalization of the mitochondrial control protein, and both TYMS-GFP and DHFRL1-GFP 
fusion proteins, was observed. TYMS-GFP localized to the cytoplasm, mitochondria, and 
nuclei (Figure 3.5A), whereas DHFRL1-GFP was present exclusively within mitochondria 
(Figure 3.5B). DHFRL1, SHMT2, and TYMS endogenous to HepG2 mitochondria were 
localized to the mitochondrial matrix and inner membrane in fractionated mitochondria 
(Figure 3.5C), consistent with previous localization studies of SHMT2 (18, 19). Using 
MITOPRED (20, 21), a bioinformatics program for prediction of mitochondrial proteins, no 
canonical mitochondrial leader sequence was identified for DHFRL1. The primary sequence 
of DHFRL1 shown in Figure 3.3 was sufficient for mitochondrial import.  
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Figure 3.5. TYMS and DHFRL1 localize to mitochondria. TYMS-GFP fusion proteins (A) 
and DHFRL1-GFP fusion proteins (B) were expressed in HeLa cells, as well as a 
mitochondrial marker mito-CFP. (A) TYMS-GFP localizes to the nucleus, cytoplasm, and 
colocalizes with the mito-CFP mitochondrial marker. (B) DHFRL1-GFP localizes exclusively 
to mitochondria. (C) TYMS, DHFRL1, and SHMT2 proteins localize to the matrix and inner 
membrane of fractionated HepG2 cells. Lane 1, mitochondrial extract; lane 2, outer membrane 
fraction; lane 3, innermembrane space; lane 4, matrix; lane 5, inner membrane. Hsp60 is the 
inner membrane/matrix marker, Cox I is an inner membrane marker, and Bcl-xS⁄L is an outer 
membrane marker. 
 
These data demonstrate that both TYMS and DHFRL1 are present in human mitochondria, 




DHFRL1 is a Functional Enzyme in Mitochondria 
The presence of DHFR activity in mitochondria was investigated in human HepG2 cells 
treated with scrambled control siRNA, and siRNA specific to the DHFRL1 5’ untranslated 
region and not present in the DHFR transcript. The DHFR activity in extracts from 
mitochondria isolated from the control siRNA (32.4 ±4.0 nmol⁄min ⁄mg protein) and 
DHFRL1-specific siRNA treatments (0.17 ±0.008 nmol⁄ min ⁄mg protein) were significantly 
different with a p value of 0.0002 (n=3) where error is expressed as SEM. The mitochondria 
isolated for these assays exhibited no nuclear or cytosolic contamination as determined by 
immuno-blotting against Lamin A and GAPDH, respectively (Figure 3.6A).  
 
Figure 3.6. Knockdown of DHFRL1 inhibits DHFR activity in mitochondrial extracts. 
Scrambled siRNA and siRNA against DHFRL1 were  transfected into HepG2 cells and 
DHFRL1 protein and activity was measured. (A)Mitochondria from HepG2 cells that were 
purified for de novo dTMP synthesis assays (Table 3.2), and DHFRL1 activity experiments 
exhibited no nuclear or cytosolic contamination using immunoblots against GAPDH and 
Lamin A. (B) No DHFRL1 was present in mitochondria of HepG2 cells transfected with 








Table 3.2. Uracil content in mtDNA from wild-type CHO and glyA CHO cells. MtDNA was 
isolated from wild-type CHO and glyA CHO cells and levels of uracil were determined using 
GC/MS. Uracil levels were higher in mtDNA isolated from glyA CHO cells compared to 
wild-type CHO cells using a t-test (p= 0.01, n=3). Variation is expressed as SD. 
 
In the samples in which DHFRL1 was knocked down, no DHFRL1 protein was present in the 
mitochondrial extracts. COX-IV immunoblotting was used as a positive mitochondrial control. 
DHFR activity in the cytosolic extracts was unaffected by both scrambled and DHFRL1-
specific siRNA treatment with specific activities of 4.5 ±2.6 and 4.5 ±2.8 nmol⁄ min ⁄mg 
protein, respectively, indicating that DHFRL1 knockdown did not affect DHFR expression. 
For comparison, DHFR activity in purified nuclei from HepG2 cells exhibited a specific 
activity of 14.3±1.0 nmol⁄ min ⁄mg protein. 
De Novo Thymidylate Biosynthesis is Required to Prevent Uracil Accumulation in mtDNA 
mtDNA was isolated from both wild-type and glyA CHO cells and uracil content in mtDNA 
was quantified. GlyA CHO cells lack SHMT2 activity and are auxotrophic for glycine (22, 
23). mtDNA isolated from wild-type cells contained 40% less uracil than mtDNA from glyA 
CHO cells (Table 3.2). These data confirm the importance of SHMT2 activity within 
mitochondria for the production of dTMP, and demonstrate the importance of mitochondrial 
dTMP de novo biosynthesis in protecting mtDNA from uracil misincorporation.  
DHFRL1 Expression Rescues the Glycine Auxotrophy in glyC CHO Cells 
To verify the function of DHFRL1 in mitochondrial folate metabolism, the ability of DHFRL1 
to rescue the glycine auxotrophy caused by disrupted mitochondrial folate-metabolism in a 





Figure 3.7. DHFRL1 cDNA rescues glycine auxotrophy in glyC CHO cells. CHO glyC cells 
were transfected with cDNAs encoding  human DHFRL1-GFP, or a GFP-empty vector 
control. Stable cells lines were selected for G418 resistance in the presence of 200 µM glycine 
and 10 mg⁄L thymidine. For growth assays, cells were cultured with and without glycine and 
trypan blue exclusion was used to quantify viable cells. Four independent lines were assayed 
per transfection and experiments were done in triplicate. There was no significant difference 
in growth among the cells transfected with DHFRL1-GFP with or without glycine. CHO glyC 
cells transfected with GFP-empty vector and cultured without glycine failed to proliferate over 
the 72 h time period. 
 
Four stable transfectants were selected for G418 resistance from glyC cells electroporated 
with either an empty pCMV6-AC-GFP plasmid, or a plasmid containing the DHFRL1 cDNA 
with a 5’ CMV promoter. Stable transfectants containing the pCMV6-AC-GFP empty vector 
did not rescue the glycine auxotrophy. However, the glycine auxotrophy was rescued in all 
selected cell lines transfected with the vector that contained the DHFRL1 cDNA. These results 
confirm that DHFRL1 localizes to mitochondria and can rescue mitochondrial one-carbon 
metabolism. 
Discussion 
This study demonstrates that human mitochondria contain an active de novo thymidylate 
biosynthesis pathway, composed of SHMT2, TYMS and DHFRL1. This study supports two 
previous studies that have observed TYMS protein localized within mammalian mitochondria, 
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although the functional significance of these observations was never established (1, 13). 
Folate-activated one-carbon units for mammalian mitochondrial thymidylate biosynthesis 
are derived from serine through the catalytic activity of SHMT2; mitochondria lacking 
functional SHMT2, isolated from glyA CHO cells, exhibited impaired de novo thymidylate 
synthesis. The discovery of DHFRL1 as the functional mitochondrial enzyme completes the 
de novo thymidylate synthesis cycle. Inhibition of DHFRL1 expression by siRNA 
significantly reduced DHFR activity in mitochondria isolated from HepG2 cells. DHFRL1 
was previously thought to be a pseudogene and was mapped to chromosome 3q11.2 (17). The 
mechanism whereby TYMS and DHFRL1 are localized to mitochondria remains to be 
established as neither protein contains a canonical mitochondrial leader sequence at its amino 
terminus. Disruption of mitochondrial folate metabolism results in a glycine auxotrophy due 
to loss of SHMT2 function (22). In this study, we show that DHFRL1 complements the 
previously uncharacterized CHO glycine auxotrophic mutant, glyC. Previous reports have 
observed that glyC mutants have normal SHMT levels in both the cytosol and mitochondria 
(15, 24). Because the mitochondrial and cytoplasmic folate pools are not in equilibrium, loss 
of DHFR activity in mitochondria is expected to result in an accumulation of mitochondrial 
folate as dihydrofolate, thereby depleting THF pools for the SHMT2-catalyzed conversion of 
serine to glycine. 
    De novo thymidylate synthesis appears to be required to maintain mtDNA integrity, as glyA 
cells were observed to have elevated levels of uracil in DNA. During nuclear DNA 
replication, dTTP is the only deoxyribonucleotide that is not essential for DNA synthesis as 
dUTP can be incorporated into DNA when dTTP levels fall (2). Results from these studies 
indicate that impaired de novo thymidylate synthesis in mitochondria also results in 
deoxyuridylate incorporation in mtDNA. A recent report observed increases in mtDNA 
deletions in mice lacking the Ung gene undergoing folate deprivation compared to wild-type 
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controls (25). Other studies support a role for de novo thymidylate biosynthesis in maintaining 
DNA integrity. Patients with the mitochondrial disorder, Friedrich’s ataxia, which leads to 
large increases in mtDNA damage, exhibited elevated DHFRL1 mRNA (26). Elevated 
DHFRL1 expression may help limit some deleterious changes in mtDNA. Other studies have 
demonstrated that TYMS inhibition leads to caspase-dependent apoptosis and changes in 
mitochondrial membrane potential (27, 28). mtDNA damage has been shown to initiate 
apoptosis rapidly, independent of deleterious mutations (29).  Mitochondrial DNA damage 
due to inhibition of mitochondrial dTMP synthesis could explain the increases in apoptosis 
observed (27). Further investigation should be undertaken to determine if TYMS inhibition-
dependent apoptosis is due to uracil misincorporation within mtDNA and/or reduced 
mitochondrial thymidylate biosynthesis.  
    Unlike the synthesis of purine and cytosine deoxyribonucleotides, dTMP synthesis is 
compartmentalized to the nucleus and mitochondria, both sites of DNA replication. Elevated 
uracil content in DNA results from both nutritional deficiency of folate (2) and impaired 
expression of the thymidylate biosynthesis pathway genes (30); genetic disruption of SHMT1 
in mice increases uracil levels in nuclear DNA (31). To our knowledge, impairment of de 
novo thymidylate biosynthesis has not been shown previously to elevate uracil in mtDNA. 
These data also indicate that a high level of organization within the mitochondria may be 
required for efficient dTMP biosynthesis, such as the proposed complex in nuclei for dTMP 
biosynthesis (11, 32, 33). As observed previously in nuclei, disruption of mitochondria by 
sonication inhibited thymidylate biosynthesis (11). Others have observed that SHMT2 cross-
links to mtDNA in HeLa cells upon formaldehyde treatment (34, 35). Collectively, these data 
suggest that a multienzyme complex may exist within mitochondria at mtDNA replication 
forks. Ongoing studies will address the biological necessity for thymidylate biosynthesis 
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within both the nuclei and mitochondria, whereas purine biosynthesis occurs in the cytosol 
(11, 36). 
Methods 
Cell Lines and Culture 
HeLa and HepG2 cells were acquired from American Type Culture Collection (ATCC). GlyA, 
a CHO cell mutant lacking SHMT2 activity, was obtained from Larry Thompson, Lawrence 
Livermore Labs, Livermore, CA. GlyC, an uncharacterized CHO cell mutant which is 
auxotrophic for glycine was obtained from Barry Shane, University of California, Berkeley, 
CA. All cells were cultured at 37 °C in a 5% CO2 atmosphere. HeLa and HepG2 cells were 
maintained in minimal essential medium (α-MEM) (Hyclone) with 10% fetal bovine serum 
(Hyclone) and penicillin/streptomycin (Gibco). GlyA and GlyC cells were cultured in defined 
minimal essential medium which lacks glycine and supplemented with 10% dialyzed and 
charcoal treated fetal bovine serum (dDMEM), pencillin/streptomycin, and 20 nM leucovorin 
(Sigma). For the complementation assays, positive growth controls included 200 µM glycine. 
5′ Rapid Amplification of cDNA Ends (5′ RACE) Identifies DHFRL1 Transcript.  
Polyadenylated mRNA was isolated from HepG2 cells using the Dynabeads mRNA 
purification kit (Invitrogen) as per manufacturer’s instructions. The isolated mRNA was then 
used for 5′ RACE using the FirstChoice RNA Ligase Mediated-RACE kit (Ambion, Inc.) as 
per manufacturer’s instructions. For the outer and inner amplifications the primers used were 
5′-TGG AGG TTC CTT GAG TTC TCTGCT-3′ and 5′- AGG TCG ATT CTT CTC AGG 
AAT GGA GA-3′, respectively. The primers were made to detect DHFR but also identified 
DHFRL1. The outer and inner primers are made to nucleotides 229–252 and 176–201 of both 
DHFR and DHFRL1 coding sequence. The outer primer has a sequence identity of 96% to 
DHFRL1. The inner primer has 100% sequence identity to DHFRL1. 
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The nested PCR products were run on a 2% agarose gel. Bands were cut from the gel and 
purified using the QIAquick gel extraction kit (Qiagen). The isolated cDNA was then Topo 
cloned using the pCR-Blunt II-Topo vector (Invitrogen) as per manufacturer’s instructions. 
Topo clones were picked and grown overnight at 37 °C for DNA isolation. Plasmid DNA was 
isolated using a Miniprep kit from Qiagen as per manufacturer’s instructions. The isolated 
plasmid DNA was sent to sequencing at the Biotech Resource Center at Cornell University. 
Primers against the T7 promoter priming site present in the pCR-Blunt II-Topo vector was 
used for sequencing. 
Homology Modeling and Alignment of DHFRL1.  
The primary protein sequence of DHFRL1 (GenBank accession no. AAH63379.1) was 
modeled against the structure of human DHFR (PDB ID code 3GHW) using 
DeepView/Swiss-PDB viewer 3.7. The Iterative Magic Fit of all atoms tool was used to 
generate a structural alignment. The structure model was then energy minimized using 
GROMOS96 energy minimization tool. PyMOL was used to generate three-dimensional 
structures and the RMS was determined using the align action within PyMOL. Primary protein 
sequences alignments between DHFR (GenBank accession no. AAH71996.1) and DHFRL1 
were generated using the ClustalW tool in Lasergene Megalign software.  
Localization of TYMS and DHFRL1 by Confocal Microscopy in HeLa Cells. 
 TYMS and DHFRL1 cDNAs were fused to the N terminus of GFP within the pCMV6-AC-
GFP vector (Origene). A vector expressing a mitochondrial marker, pTagCFP-mito (Evrogen) 
was used for control transfections to identify mitochondria. Plasmids were transfected into 
HeLa cells using the Nucleofector II and the nucleofection kit R (Lonza) as per 
manufacturer’s protocol. The DNA binding dye, Draq5 (Biostatus Limited) was used to 
visualize nuclei. Confocal fluorescence microscopy (Zeiss 710 Confocal system) was used to 
image all cells at the Cornell Microscope and Imaging Facility. 
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Rescue of the Glycine Auxotrophy in CHO GlyC Cells.  
GlyC CHO cells were cultured in dDMEM supplemented with 200 µM glycine and 20 nM 
leucovorin. pCMV6-DHFRL1-GFP and pCMV6-GFP vectors were linearized using ScaI 
(New England Biolabs), electroporated into CHO GlyC cells, and selected as previously 
described (11). Trypan blue exclusion assays were completed in media with and without 
glycine as previously reported (37). 
Knockdown of DHFRL1 and Dihydrofolate Reductase Activity in Mitochondria.  
DHFRL1-specific siRNA and control scrambled siRNA (Qiagen) were transfected into 
HepG2 cells using Nucleofection (Lonza) as per manufacturer’s instructions. After a 24 h 
incubation, mitochondria were isolated using the same protocol described below for the 
mitochondrial dTMP biosynthesis assays. Mitochondria were lysed using mammalian protein 
extraction reagent (Pierce) supplemented with 1 mMEDTA, 10 mM PMSF (Alexis 
Biochemicals), and 11;000 dilution of protease inhibitor (Sigma). DHFR enzyme activity 
was determined in isolated mitochondria from both control siRNA treated and DHFRL1 
siRNA-treated HepG2 cells using the DHFR activity kit (Sigma) as per manufacturer’s 
instructions. To control for cytoplasmic and nuclear contamination, immunoblotting was 
performed as previously reported (11). To determine if DHFRL1 was present in mitochondria 
and knocked down in the siRNA-treated samples, immunoblots were performed using a 
mouse polyclonal antibody toward DHFRL1 (Abnova) at a concentration of 1:5;000. Goat 
anti-mouse HRP (Pierce) conjugated secondary was used at a concentration of 1:10;000. Cox 
IV antibody was used as a mitochondrial control as previously described (11). 
Mitochondrial Thymidylate Biosynthesis Assay.  
Mitochondria were isolated from 109 cells of each HepG2, wild-type CHO and glyA CHO 
cells. Cells were grown in Hyperflasks (Corning) in DMEM (Gibco) supplemented with 10% 
fetal bovine serum (Hyclone) and penicillin/streptomycin (Gibco). Cells were 
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trypsinized and collected in 50 mL conical tubes and centrifuged at 2,000 rpm for 5 min. The 
cell pellets were washed twice with phosphate buffered saline with centrifugation at 2,000 rpm 
between washes. Isolation of mitochondrial fractions were completed as previously reported 
(38). The mitochondrial pellets were resuspended in buffer containing 0.3 M sucrose, 1.0 mM 
EGTA, 5.0 mM MOPS, 5.0 mM K2PO4, and 0.1% BSA, and adjusted to pH 7.4 with KOH. 
The mitochondria were then distributed equally into 1.5 mL tubes, nine fractions for each of 
wild-type CHO cells and glyA CHO cells and six fractions for HepG2 cells. These tubes were 
centrifuged at 5;000 × g for 10 min at 4 °C. The pelleted mitochondria were then resuspended 
in 600 µL of thymidylate reaction buffer containing 5 mM NADPH (Sigma), 100 mM β-
mercaptoethanol (Sigma), 50 mM Hepes, pH 7.4, 2 mM MgCl2, 50 mMKCl, 25  mM 
K2HPO4, 1 mM dUMP, and 0.3 M sucrose. The mitochondria used for the sonicated reactions 
were then subjected to five 10 s pulses with 10 s rests between pulses on ice. The small probe 
on a Branson sonifier was used at 20% power. O2 gas was bubbled into each reaction vessel 
for 3 min. prior to addition of 8 µL [2,3-3H]-L-serine (Moravek). The reactions were put in a 
shaking incubator at 300 rpm and 37 °C for 12 h. The samples were then centrifuged at 5;000 
× g for 10 min to pellet mitochondria and the supernatant was collected. The mitochondria 
were then lysed using 500 µL 1% SDS and sonication as previously stated. The lysate was 
then analyzed using HPLC as previously reported (11). 
mtDNA Purification and Determination of Uracil Misincorporation in glyA and Wild-Type 
CHO Cells. 
Mitochondria were isolated from both CHO wild-type and CHO glyA cells. The 
mitochondrial pellet was resuspended in 50 mM glucose (Sigma), 20 mM Tris·HCl pH 8.0 
(Fisher), and 10 mM EDTA (Fisher) at 1 mL buffer per 500 µg mitochondria. Lysozyme 
(Sigma) was added at a concentration of 2 mg⁄mL and incubated on ice for 20 min. Two 
milliliters of 0.2 M NaOH (Fisher) containing 1% SDS (Fisher) were added and incubated on 
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ice for 5 min. One and a half milliliters of 3 M potassium acetate dissolved in 2 M acetic acid 
was used to neutralize the sample to pH 7.0. The samples were incubated on ice for 1 h. The 
samples were then centrifuged at 11;000 × g for 30 min. The supernatant was decanted and 
then treated with 1⁄10 the volume of 3 M sodium acetate and two volumes of ethanol. The 
mtDNA was precipitated for 2 h at −20 °C. The samples were centrifuged at 10;000 × g for 20 
min at 4 °C. The pellet was resuspended in 0.6 mL of 10 mM Tris/1 mM EDTA, pH 8.0 
containing 0.1 mg⁄mL RNaseA. The mtDNA was purified using 1 mL of the Wizard Plus 
Resin from the Wizard Plus Miniprep kit (Promega) as per manufacturer’s instructions. 
Analysis of uracil levels was performed as previously reported with modifications; a 
Shimadzu QP2010 Plus GC/MS was used for analysis (31).  
Mitochondrial Subfractionation.  
Purified mitochondria from HepG2 cells were subfractionated into matrix, outer membrane, 
and inner membrane fractions as previously reported (39) and immunoblots were performed 
on each fraction to determine submitochondrial localization of DHFRL1, TYMS, and 
SHMT2. DHFRL1 immunoblots were performed as mentioned above. TYMS and SHMT2 
immunoblots were performed as previously reported (11). Mouse anti-hsp60 (inner 
membrane/matrix marker), mouse anti-Cox I (inner membrane marker), and mouse anti-Bcl-
xS⁄L (outer membrane marker) were purchased from Santa Cruz Biotechnology and were used 
at a dilution of 1:200. HRP conjugated goat anti-mouse (Pierce) secondary antibodies were 
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Folate-mediated one-carbon metabolism is compartmentalized in the mitochondria, nucleus  
and cytoplasm of eukaryotic cells (1) (Figure 4.1).   
 
Figure 4.1. Folate-mediated one carbon metabolism.   Schematic of folate-mediated one-
carbon metabolism in the cytoplasm and nucleus.  One-carbon metabolism in the cytoplasm is 
required for the de novo synthesis of purines and thymidylate, and for the remethylation of 
homocysteine to methionine.  One-carbon metabolism in the nucleus synthesizes dTMP from 
dUMP and serine.  MTHFD1, Methylenetetrahydrofolate Dehydrogenase; MTR, Methionine 
Syntase;  MTHFR, Methylenetetrahydrofolate Reductase; SHMT1, Cytoplasmic Serine 




This metabolic network is required for the de novo biosynthesis of purines and thymidylate, 
and for the remethylation of homocysteine to methionine. Nuclear de novo thymidylate 
biosynthesis requires three enzymes: thymidylate synthase (TYMS), dihydrofolate reductase 
(DHFR), and serine hydroxymethyltransferase (SHMT1 and SHMT2α). SHMT generates an 
activated single carbon from serine and tetrahydrofolate (THF) in the form of 
methylenetetrahydrofolate (methyleneTHF), which serves as the one-carbon and two-electron 
donor for the TYMS catalyzed conversion of dUMP to dTMP generating dihydrofolate (DHF). 
DHFR catalyzes the NADPH-dependent reduction of DHF to regenerate THF for subsequent 
rounds of de novo thymidylate synthesis. The enzymes that constitute the de novo dTMP 
synthesis pathway are post-translationally modified by Ubc9 with the small ubiquitin-like 
modifier 1 (SUMO-1) and undergo nuclear translocation during S and G2/M phases (2-4), and 
in response to UV (5) for nuclear dTMP synthesis (4).  Studies in cell cultures and mice have 
shown that SHMT1 expression determined capacity for de novo dTMP synthesis (Anderson et 
al Unpublished) (6).   Regulation of cellular dTTP pools is essential for maintaining both 
nuclear and mitochondrial DNA integrity and previous studies have indicated the importance of 
maintaining dNTP pool size throughout the cell cycle to avoid genome instability (7,8).   
      We have previously observed that SHMT1 interacts with Ubc13, an E2 conjugase for 
ubiquitination (2), although the functional significance of this interaction has yet to be 
determined.  Previous studies have indicated that SUMO and ubiquitin (Ub) can modify the 
same consensus motif, ΨKXE/D, on target proteins, and in some cases have antagonistic 
effects and allow pathway choice (9). Whereas SUMO-1 modification is essential for nuclear 
translocation of the de novo dTMP pathway, the role of ubiquitination in the regulation of 
SHMT1 and de novo thymidylate biosynthesis is unknown. In this study we demonstrate that 
Ubc13-mediated modification of SHMT1 leads to nuclear export and acts as a mediator of 
SHMT1 stability within the nucleus. Furthermore, we demonstrate that SHMT1 is degraded in 
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the cytoplasm via the proteasome through K48 linkage specific poly-ubiquitination. The study 
indicates competition between SHMT1 SUMOylation and Ubiquitination to regulate SHMT1 
nuclear localization and levels by competing for the same consensus motif on SHMT1. 
EXPERIMENTAL PROCEDURES 
Cell Lines, Media, and Transfection conditions― HeLa cells were obtained and maintained 
as previously reported (4). Cells were grown in α-MEM (Hyclone) supplemented with 10% 
fetal bovine serum (Hyclone) and penicillin/streptomycin (Mediatech) at 37° C and 5% CO2. 
All transfections were performed using the Nucleofector II and kitR for HeLa cells per 
manufacturer’s instructions (Lonza). 
Vectors and vector construction- A construct encoding a V5-SHMT1 fusion protein, 
pcDNA3.1-SHMT1-V5-HisA, was generated to differentiate between endogenous SHMT1 
and SUMO site mutants. pcDNA3.1/V5-HisA was purchased from Invitrogen. The human 
SHMT1 cDNA from phiYFP-SHMT1 (4) was amplified by PCR using the forward primer 5’-
ATATAAGCTTATGACGATGCCAGTCAAC-3’ where the bold text indicates a HindIII 
restriction site (New England Biolabs Inc.). The reverse primer was 5’-
ATATCTCGAGGAAGTCAGGCAGGCCAGG-3’ where the bold text indicates a XhoI 
restriction site. PCR reactions were conducted as follows: 95°C for 45 s, 55°C for 45 s, and 
72°C for 2 min. PCR products were gel purified using the QIAquick Gel extraction kit 
(Qiagen). Vectors and PCR products were restriction digested with their respective restriction 
enzymes as per manufacturer’s protocol. Ligation was completed using T4 DNA ligase 
(Invitrogen) as per manufacturer’s protocol. Ligations were transformed into Top10 cells 
(Invitrogen) and selected for ampicillin (Fisher) resistance. Following plasmid purification and 
isolation using plasmid mini-preps (Qiagen), vectors were sequenced at the Cornell University 
Life Sciences Core Laboratories Center. Mutations within the conserved SUMO motif were 
performed as previously reported (2). The pCMV-HA-Ub vector was generously provided by 
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Dr. Shu-Bing Qian, Cornell University, Ithaca, NY. The K48R and K63R Ub mutants were 
made using the primers 5’-ATCTTTGCAGGCAGGCAGCTGGAAGA -3’ and 5’-
CTACAATATTCAAAGGGAGTCTACTC-3’ respectively and reverse complements 
(mutation is bold) using the QuikChange II Site-directed mutagenesis kit (Stratagene) per 
manufacturer’s instruction. All siRNA was purchased from Qiagen.                                             
Preparation of cDNA and real-time PCR – HeLa cells were cell cycle arrested as described 
below and total RNA was isolated using a RNeasy kit (Qiagen) per manufacturer’s protocol 
after 1 h. treatment of samples with DNase I (Qiagen) at 37° C to remove residual DNA. Total 
RNA was converted to cDNA using Superscript III first-strand cDNA synthesis kit 
(Invitrogen) using oligo-dT primers per manufacturer’s protocol.  Real-time PCR was 
completed using Quantifast SYBR green PCR kit (Qiagen) and SHMT1 primers (Qiagen).  
PCR products were quantified using Applied Biosystems 7500 real-time PCR system. 
Immunoblotting―Cellular proteins were quantified, separated, transferred, and detected as 
previously described (2). GAPDH, Lamin-A, and Ubc13 immunoblotting were performed as 
previously described (2,4). All antibodies were diluted in 5% non-fat dry milk (Carnation) 
containing 1% NP40 (US Biologicals). For Ub detection, mouse anti-Ub antibody (BIOMOL) 
was diluted 1:1000. For V5-tag detection, mouse anti-V5 antibody (Invitrogen) was diluted 
1:5000. Mouse anti-β-Actin antibody (Abcam) was used at a 1:5000 dilution. For detection of 
HA tagged Ub, Mouse anti-HA antibody (Santa Cruz Biotechnology, Inc.) was used. For 
detection of Ub, V5, HA, and β-Actin, goat anti-mouse IgG-horse radish peroxidase (HRP) 
(Thermo Scientific) was diluted 1:10,000. For detection of SUMO-2/3 conjugates, Rabbit anti-
SUMO-2/3 (Cell Signaling) was used at a dilution of 1:1000. Goat anti-rabbit-HRP secondary 
was used at a dilution of 1:20,000 (Thermo Scientific). 
Immunoprecipitation―Immunoprecipitation was conducted using the Dynabeads Protein G 
Immunoprecipitation Kit (Invitrogen). For whole cell immunoprecipitation, HeLa cells were 
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lysed using mammalian protein extraction reagent (Pierce) supplemented with 1 mM N-
ethylmaleimide (Sigma), 100 µM ALLN (Sigma), 2 mM β-mercaptoethanol (Calbiochem), 0.1 
mM EDTA (Fisher Scientific), 1 mM PMSF (Alexis Biochemicals), and 1:1000 Protease 
Inhibitor Cocktail (Sigma). For immunoprecipitations of nuclear and cytosolic extracts, nuclei 
were purified using the Active Motif Nuclear extract kit per manufacturer’s protocol. 1 mg of 
total protein per sample was incubated with 5 µg of either anti-K63-linkage Ub (Millipore), 
anti-Ub (BIOMOL) or anti-V5 tag (Invitrogen) antibody overnight at 4
o
C. For the nuclear 
immunoprecipitations, anti-SHMT1 antibody was used with the same parameters. The beads 
were collected and washed four times with 1 mL PBS. 40 µLs SDS-PAGE sample buffer were 
added to the beads to elute with heating at 100°C.           
Cell Cycle Synchronization and Analysis―HeLa cells at 60% confluence were arrested at 
various cell cycle stages using 30 µM lovastatin for G1 (Sigma), 2 mM hydroxyurea for S-
phase (Sigma), or 100 ng/mL nocodazole for G2/M phase (Sigma). Preparation for 
fluorescence activated cell sorting (FACS) was performed as previously described (2). FACS 
analysis was performed by Biomedical Sciences Flow Cytometry Core Laboratory at Cornell 
University.     
Proteasomal Inhibition and Half-life Analysis―HeLa cells were treated with 50 µg/mL 
cycloheximide (Sigma) to stabilize cellular protein levels and 100 µM ALLN (Sigma) to 
stabilize Ub linkages. Proteasome inhibition was achieved using 20 µM MG132 (Sigma). 
Cells were isolated at either 0, 1, 2, 4, and 8 hrs or 0, 2, 4, 8 hrs as described in the figure 
legends. For determination of SHMT1 nuclear versus cytoplasmic half-life, nuclei and cytosol 
were isolated from cells using a nuclear extraction kit (Active Motif) at the appropriate time 
points as per manufacturer’s protocol.  
Immunofluorescence – SHMT1 antibody was labeled with Cy3 dye using the Amersham Cy3 
bis-reactive labeling kit (GE Lifesciences) per manufacturer’s protocol. HeLa cells were 
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grown on cover slips in 6-well plates. Cells were treated with DMSO (Fisher) or 50 µM 
Mg132 (Sigma) for 3 h. Cells were washed and medium added back and cells were incubated 
for 12 h for recovery. Cells were then fixed using 4% formaldehyde solution at room 
temperature for 10 min. Fixation was quenched in 100 mM glycine in PBS for 5 min. Cells 
were permeabilized in 0.1% Triton X-100 (Fisher) in PBS for 5 min at room temperature. 
Immunohistochemistry was performed using antibodies against SHMT1, 20S α + β subunits 
(Abcam), and the 19S S7 subunit (Abcam) diluted in 1% BSA (Sigma) in PBS at 1 µg/mL, 
1:500 and 1:1000 respectively. Primary antibodies were incubated on the fixed and 
permeabilized cells for 1 h at room temperature. Following 4 washes of each coverslip with 3 
mL of PBS, secondary antibodies were incubated on coverslips for 1 h at room temperature.  
Alexa Fluor 555 Donkey anti-rabbit secondary was used for detection of 20S α + β subunits 
and the 19S S7 subunit diluted in 1% BSA in PBS at 1:1000.  Coverslips were washed as 
previously stated. DRAQ5 (Alexis Biochemicals) was used for nuclear staining as per 
manufacturer’s protocol. Cells were mounted to slides using Mowiol mounting solution 
(Calbiochem) and allowed to harden overnight at 4° then visualized using confocal 
microscopy.                          
Leptomycin B treatment – HeLa cells were treated with or without 20 µM Mg132 and either 
0, 2.5, or 5 ng/mL of the nuclear export inhibitor leptomycin B (LMB) (Sigma) for 24 h. 
Nuclei were isolated as stated above from cells and lysed using SDS-PAGE loading buffer for 
immunoblotting.            
Nuclear localization of SHMT1 as a function of Ubc13 expression - cDNAs encoding 
SHMT1- YFP (4), Ubc13 (Open Biosystems), or siRNA against Ubc13 (Qiagen) were 
transfected into HeLa cells. Cells were visualized using confocal microscopy with DRAQ5 as 
the nuclear control. Cells with nuclear SHMT1 versus cytosolic were counted (n = 200) for 
each of the following treatments:  YFP-SHMT1 with endogenous Ubc13 levels; YFP-SHMT1 
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and Ubc13 siRNA; YFP-SHMT1 and Ubc13 overexpression; and YFP-SHMT1 with Ubc13 
overexpression and 2.5 ng/mL LMB treatment. 
RESULTS                                                    
SHMT1 protein levels and ubiquitination change with the cell cycle – The levels of cellular 
SHMT1 protein and Ub-modified SHMT1 (Ub-SHMT1) were quantified as a function of cell 
cycle in HeLa cells (Figure 4.2).    
 
Figure 4.2. SHMT1 protein levels change with the cell cycle. HeLa cells were cell cycle 
blocked by 24 h treatment with Lovastatin (30 µM) for G1 phase, Hydroxyurea (1 mM) for S 
phase, and Nocodazole (100 ng/mL) for G2/M phase.  Panel A:  SHMT1 protein levels were 
determined by immumoblotting of 20 µg protein extract.  Panel  B:  SHMT1 mRNA levels 
were quantified from whole cell extract. Panel C: Ub-SHMT1 levels were quantified by 
immunoprecipitation of ubiquitinated substrates from whole cell extracts (20 µg) followed by 




SHMT1 protein levels were elevated during S-phase (Figure 4.2A) whereas SHMT1 mRNA 
levels did not change as a function of cell cycle (Figure 4.2B). Ub-SHMT1 was detected in 
whole-cell extracts at all phases of the cell cycle, but was diminished at S-phase. These data 
demonstrate that SHMT1 is a cell-cycle regulated protein, and that Ub-SHMT1 levels are 
lowest at S-phase when SHMT1 undergoes SUMO modification and nuclear transport. 
Proteasome inhibition stabilizes SHMT1 and increases ubiquitinated SHMT1 levels. – HeLa 
cells were treated with the translation inhibitor cycloheximide (CHX) and proteasome 
inhibitors Mg132 and ALLN to determine if Ub-modification mediates SHMT1 half-life. 
SHMT1 exhibited a half-life of approximately 2 hours in HeLa cells treated with CHX, 
whereas SHMT1 levels increased over an 8 h in HeLa cells treated with CHX and proteosome 
inhibitors (Figure 4.3A),  indicating that SHMT1 is subject to Ub-dependent proteasomal 
processing.  
 
Figure 4.3. Proteasome inhibition stabilizes SHMT1 and increases ubiquitinated SHMT1 
levels.  HeLa cells were treated with DMSO (control), cycloheximide (CHX), or CHX and 20 
µM Mg132 + 100 µM ALLN proteasome inhibitors (PI) for 8 h. SHMT1 immunoblots were 
performed as described in materials and Methods.  Panel A: Total cellular protein extracts (20 
µg) were separated by electrophoresis and SHMT1 protein levels determined by 
immunoblotting.  The half-life of endogenous SHMT1 when CHX treated is approximately 2 
hours.  DMSO control and CHX + PI treatments were stable over 8 hours.  Panel B: SHMT1 
was visualized in cell extracts by immunoblotting as described above.  Accumulation of 
higher molecular weight bands was observed in CHX + PI treatment over 8 h.  Panel C:  Ub-
SHMT1 was visualized in total cell protein extracts (20 µg) by immunoprecipitation of Ub-
conjugated proteins followed by SHMT1 immunoblotting. 
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Cells treated with CHX and proteosome inhibitors accumulated higher molecular weight 
SHMT1 immunoreactive bands over time (Figure 4.3B), indicating that Ub-SHMT1 is an 
intermediated in SHMT1 degradation by the proteosome. These higher molecular weight 
bands were identified as SHMT1 polyUb conjugates through Ub immunoprecipitation and 
SHMT1 immunoblotting (Figure 4.3C).  
SHMT1 K39 is the ubiquitin modification site – We previously observed that SHMT1 
SUMO-1 modification  occurs at either K38 or K39 (Figure 4.4C) and that mutation of either 
lysine to arginine resulted in the ablation of SUMOylation (2,4).  
 
Figure 4.4. SHMT1 K39 is the Ub modification site. HeLa cells were transfected with 
expression vectors encoding V5 tagged wild type SHMT1, K38R SHMT1, K38R/K39R 
SHMT1, or K39R SHMT1. Panel A:  Total cellular protein extracts (20 µg) were separated by 
electrophoresis and V5-SHMT1 protein levels determined by immunoblots against V5. V5-
wild type SHMT1 and V5-K38R SHMT1 both exhibited a half-life of approximately 4 h. 
Mutation of both K38R and K39R results in SHMT1 stability. Actin was used as a loading 
control.  Panel B: Ub-V5-SHMT1 was visualized in total cell protein extracts (20 µg) by V5 
immunoprecipitation followed by Ub immunoblots.  Ub-V5-SHMT1 is reduced in K39R 
mutants compared to wild type SHMT1 and K38R mutants. Panel C: The conserved SUMO 
motif (IKKE) is also a site for ubiquitination. 
 
 81 
To determine if ubiquitination occurs at this site, expression vectors encoding V5-SHMT1, 
V5-K38R SHMT1, and V5-K38R/K39R were transfected into HeLa cells. The cells were 
treated with CHX to determine the role of K38 and K39 in SHMT1 turnover and half-life. V5-
SHMT1 and V5-K38R SHMT1 exhibited similar half-lives, whereas V5-K38R/K39R SHMT1 
was stable over time (Figure 4.4A). Immunoprecipitation of the V5 tag followed by 
immunobloting with anti-Ub antibody indicated that mutation of K39 results in a marked 
reduction of Ub-SHMT (Figure 4.4B). These data demonstrate that K39 is a modification site 
for ubiquitination and that K39 ubiquitination leads to proteasomal processing.  
SHMT1 co-localizes with the 19S cap and 20S core of the proteasome in the nucleus and 
the cytosol – Immunolocalization and biochemical studies have shown that proteasomes are 
localized to nuclei and cytosol (10,11). To determine if degradation of SHMT1 occurs within 
the nucleus and cytoplasm, immunochemistry was performed using HeLa cells treated with 
either DMSO or Mg132. SHMT1 and the proteosome 20S catalytic core and 19S cap 
colocalized in both the cytosol and nucleus with discrete puncta formation following Mg132 
treatment as compared to control DMSO treatments, indicating that SHMT1 associates with 
the proteosome in both compartments (Figure 4.5).  
Inhibition of nuclear export leads to accumulation of SHMT1 in the nucleus – To determine 
if SHMT1 is degraded within the nucleus or if it is shuttled to the cytoplasm prior to 
degradation, HeLa cells were treated with the nuclear export inhibitor leptomycin B (LMB) 
for 24 h with or without Mg132. Nuclei were isolated and SHMT1 protein levels were 
quantified by western blot.  Nuclear SHMT1 levels increased following LMB treatment, with 
an accumulation of higher molecular weight immunoreactive bands in both the Mg132 treated 
and untreated cells (Figure 4.6A and B). Nuclear extracts from Mg132 treated cells exhibited a 
prominent 75 kDa band that was identified to be a SUMO-2/3 conjugate of SHMT1 (Figure 
4.6B, C and D). 
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Figure 4.5. SHMT1 co-localizes with the 19S cap and 20S core of the proteasome in the 
nucleus and the cytosol. Cells were treated with DMSO (A and C) or 50 µM Mg132 (B and D) 
for 3 hours. Cells were washed and medium was added back and cells were incubated for a 12 
h recovery.  Immunohistochemistry was performed using antibodies against SHMT1, 20S α + 
β subunits, and the 19S S7 subunit. DRAQ5 was used for nuclear staining. Cells were then 
visualized using confocal microscopy. Colocalization of SHMT1 with 19S and 20S are seen in 
controls most prevalently within the cytosol. Upon treatment with Mg132 and recovery, 














Figure 4.6. Inhibition of nuclear export leads to accumulation of SHMT1 in the nucleus.  
Panel A: HeLa cells were treated with or without 20 µM Mg132 and varying levels of the 
nuclear export inhibitor, leptomycin b (LMB) for 24 hours. Nuclei were isolated from cells 
and lysed using SDS-PAGE loading buffer. SHMT1 immunoblots were completed as 
described in figure legend 4.2. Lamin A immunoblots were performed to control for loading. 
Panel B: Nuclear purity was assessed by GAPDH immunoblotting.  Panel C: SHMT1 
immunoprecipitations were performed using nuclear extracts from cells treated with 2.5 
ng/mL LMB (lane 2) or 2.5 ng/mL LMB and 20 µM Mg132 (lane 3) as described in figure 3. 
Non-immune IgG was used as a negative control for samples treated as in lane 3. Panel D: 
SHMT1 immunoprecipitations were performed using nuclear extracts from cells treated with 
2.5 ng/mL LMB (lane 3) or 2.5 ng/mL LMB and 20 µM Mg132 (lane 2). Non-immune IgG 
was used as a negative control for samples treated as in lane 2. A darker exposure shows the 
presence of multiple higher molecular weight SHMT1-SUMO-2/3 conjugates in samples 
treated with Mg132. 
 
In the LMB treated cells without Mg132, nuclear extracts accumulated higher molecular 
weight SHMT1 immunoreactive bands consistent with canonical ubiquitination ladders 
(Figure 4.6A). These were identified as Ub-SHMT1 through immunoprecipitation (Figure 
4.6C).  An increase in nuclear SUMO-2/3-SHMT1 conjugates and Ub conjugates were 
observed in the samples treated with LMB and Mg132 (Figure 4.6C and 4.6D). These data 
demonstrate that nuclear Ub-SHMT1 conjugates accumulate when SHMT1 nuclear export is 
inhibited, and that mixed SUMO-2/3 and Ub SHMT1 conjugates accumulate when both 
SHMT1 nuclear export and degradation are impaired, indicating a role for Ub modification in 
nuclear export, and SUMO-2/3 modification in SHMT1 degradation.    
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K63 polyubiquitination of SHMT1 is cell cycle and compartment specific – Ubc13 has been 
reported to interact with SHMT1 (2),  which catalyzes the formation of K63 linked polyUb 
chains and is important for exporting p53 out of the nucleus (12). The cell cycle dependency 
and compartment specificity of SHMT1 K63 Ub linkages was determined in nuclear and 
cytosolic fractions of HeLa cells. K63 ubiquitination was present in S and G2/M while absent 
from G1 in both nuclear and cytosolic fractions. SHMT1 K63 polyubiquitination was 
extensive in the nuclear fraction (Figure 4.7B) while only bands consistent with di-
ubiquitination were observed in the cytosolic fraction (Figure 4.7A). K63 ubiquitination of 
SHMT1 exhibited a distinct cell cycle profile in both the cytosolic and nuclear fractions 
compared to ubiquitination in general (Figures 4.7 & 4.1C). 
 
Figure 4.7. K63 polyubiquitination of SHMT1 is cell cycle and compartment specific. HeLa 
cells were treated with cell cycle blocking agents as reported above. Nuclear and cytosolic 
fractions were isolated and immunoprecipitation against K63-linkage specific Ub were 
performed.  Antibody protein complexes were isolated from 20 µg of extract protein using 
protein g conjugated dynabeads. Immunoblots were performed against SHMT1 as described in 
figure legend 4.2.  In the cytosolic fraction, K63 linked diUb was the most prevalent band and 
was diminished in G1 phase compared to S and G2/M phases. In the nuclear fraction, 
extensive K63 polyubiquitination was observed in S and G2/M phases. K63 ubiquitination 
was diminished in G1 phase in the nuclear fraction. 
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Ubc13 affects SHMT1 nuclear accumulation – To determine if Ubc13 mediates nuclear 
accumulation and/or SHMT1 half-life within the nucleus, a SHMT1-YFP expressing vector, 
and either an Ubc13-expressing vector or Ubc13 siRNA were co-expressed in the presence 
and absence of LMB (Figure 4.8). 
 
Figure 4.8. Ubc13 affects nuclear accumulation of SHMT1. Expression vectors encoding 
SHMT1-YFP, Ubc13, or siRNA against Ubc13 were transfected into HeLa cells. Cells were 
visualized using confocal microscopy with DRAQ5 as the nuclear control. Cells with nuclear 
SHMT1 (Panel A) versus cytosolic (Panel B) were counted (n = 100) for each of the following 
treatments:  YFP-SHMT1 with endogenous Ubc13 levels; YFP-SHMT1 and Ubc13 siRNA; 
YFP-SHMT1 and Ubc13 overexpression; and YFP-SHMT1 with Ubc13 overexpression and 
leptomycin b treatment (LMB). (Panel C) YFP-SHMT1 samples with endogenous Ubc13 
levels exhibited highest number of cells exhibiting nuclear SHMT1 (43%). Overexpression of 
Ubc13 with LMB treatment had intermediate levels (31%) between endogenous Ubc13 and 
Ubc13 overexpression alone (23%). Treatment with siRNA directed against Ubc13 exhibited 
the lowest number of cells with nuclear SHMT1 (6%). (Panel D) Immunoblotting was 
performed on 20 µg of total cell extract to ensure Ubc13 knockdown and over-expression in 
cells with GAPDH as a loading control.  
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43% of cells expressing YFP-SHMT1 with endogenous levels of Ubc13 accumulated SHMT1 
in the nucleus. Ubc13 over-expression led to fewer cells with nuclear SHMT1 (23%), 
indicating a role for Ubc13 in nuclear SHMT1 accumulation. Ubc13 overexpression with 
LMB treatment restored nuclear SHMT1 levels to 31%, which is statistically greater than 
observed for non-LMB treated samples (t-test, p<0.0001, n=100) indicating a role for Ubc13 
in facilitating SHMT1 nuclear export. Alternatively, overexpression of Ubc13 may have 
antagonistic affects on Ubc9 in the cytosol, although LMB would not be expected to restore 
nuclear SHMT1 if that were the case.  Depletion of Ubc13 by siRNA treatment strongly 
inhibited SHMT1 accumulation in the nucleus with only 6% of cells exhibiting nuclear 
SHMT1.  This may reflect competition between Ubc9 and Ubc13 in the nucleus leading to 
Sumo2/3 mediated SHMT1 degradation.   The effects were not due to cell cycle differences as 
determined by cell sorting (unpublished data). These data suggest that Ubc13 may be playing 
a role in both stabilization of SHMT1 within nuclei and export of SHMT1 out of nuclei.   
Ubc13 affects cytosolic but not nuclear turnover of SHMT1 – To determine if Ubc13 
stabilizes SHMT1 in the nucleus and the cytosol, the effect of Ubc13 expression on SHMT1 
half-life was determined (Figure 4.9).  
 
Figure 4.9. Ubc13 effects cytosolic turnover but not nuclear turnover of SHMT1. HeLa cells 
were subjected to mock, cDNA encoding Ubc13, or Ubc13 siRNA transfections and subjected 
to 50 µg/mL CHX for the times indicated. Nuclei and cytosol were isolated. A)SHMT1 was 
stable within the nucleus in all samples except for Ubc13 siRNA treated. B) Cytosolic 
SHMT1 was less stable within the cytosol. Ubc13 overexpression and knockdown increased 
half-life of SHMT1 C) To ensure that Ubc13 over-expressed and was knocked down, 
immunoblotting against Ubc13 on samples treated with cycloheximide for 8 hours was 
performed. GAPDH was used as a loading control. 
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SHMT1 was stable in nuclear extracts from cells treated with cycloheximide except for cells 
treated with Ubc13 siRNA, supporting the hypothesis that Ubc9 and Ubc13 compete for 
SHMT1 modification leading to either degradation in the nucleus or nuclear export 
respectively.  In cytoplasmic extracts, cells over-expressing Ubc13 exhibited elevated SHMT1 
levels and increased SHMT1 stability, indicating that UBC9 mediated SHMT1 K63 
modification protects SHMT1 from degradation in the cytoplasm.  Ubc13 knockdown led to a 
decrease in SHMT1 stability in the cytosolic fraction again supporting a role for K63 
ubiquitination in stabilizing SHMT1 in the cytoplasm and nucleus.  
K48R and K63R ubiquitin mutants affect cytosolic and nuclear SHMT1 turnover. Ubc13 
functions in K63 Ub linkages, whereas the major Ub linkage implicated in degradation are 
K48 modifications.  To determine the role of K63 and K48 Ub modifications on SHMT1 
stability, K48 and K63 mutant Ub proteins were expressed in cells and their effect on SHMT1 
stability determined in the cytoplasmic and nuclear compartments.  SHMT1 levels were stable 
in nuclear extracts from cells transfected with either K48R or wild-type Ub, indicating that 
K48 linked Ub is not involved in nuclear SHMT1 stability (Figure 4.10A).  However, SHMT1 
was stable in cytosolic extracts from cells expressing K48R Ub compared to extracts from 
cells expressing wild type Ub, indicating a role for K48 Ub linkages in SHMT1 turnover in 
the cytoplasm (Figure 4.10A).  In contrast, SHMT1 stability was unaffected in cytoplasmic 
extracts expressing K63R Ub relative to cytosolic extracts from cells expressing wild type Ub, 
indicating that SHMT1 K63 Ub modification does not play a role in SHMT1 stability in the 
cytoplasm.  However, SHMT1 stability was decreased in nuclear extracts from cells 
expressing K63R Ub relative to cytosolic extracts from cells expressing wild type Ub, 
indicating a protective role for K63 Ub modification of SHMT1 in the nucleus. These data 
indicate that SHMT1 is degraded via K48 polyubiquitination only in the cytoplasm, whereas 
K63 Ub modification is necessary for SHMT1 stability in the nucleus. 
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Figure 4.10. Ub K63 modifications enhance SHMT1 stability in the nucleus, whereas Ub K48 
modifications decrease SHMT1 stability in the cytoplasm.   HeLa cells were transfected with 
expression vectors encoding HA-Ub, HA-K48R Ub, or HA-K63R Ub. Following transfection, 
the cells were subjected to 50 µg/mL CHX for the times indicated, and SHMT1 
immunoblotting performed on  nuclear and cytosolic fractions as described in figure legend 2.  
Panel A: SHMT1 was stable in nuclear extracts from cells transfected with HA-WT Ub and 
HA-K48R Ub whereas in HA-K63R Ub transfections decreased SHMT1 stability.  In 
cytosolic fractions, SHMT1 stability was enhanced by transfection of HA-K48R Ub as 
compared to HA-WT Ub and HA-K63R Ub. Lamin A/C and GAPDH immunoblots were 
performed to control for nuclear and cytosolic purity and loading.  Panel B:  A representative 
figure of HA immunoblotting is shown here to validate expression. 
 
DISCUSSION                                             
Thymidine nucleotide  synthesis and pool size is highly regulated, with expansion of the pool 
occuring during S-phase (13,14). As the need for dTTP diminishes towards mitotic entry; 
depletion of dTTP pools is a necessity to avoid growth retardation and genetic instability (7). 
SHMT1 expression has been shown to be  rate-limiting de novo dTMP synthesis in both cell 
culture  (15) and animal models (16). Previous studies have observed that DHFR is mono-
ubiquitinated by MDM2 and that mono-ubiquitination lowers DHFR activity (17). However, 
ubiquitination of DHFR is not involved in DHFR degradation (17). TYMS degradation has 
also been studied and has been found to be proteasomal dependent but Ub independent (18-
20). Regulation of SHMT1 levels appears to be central to determining de novo dTMP 
synthesis capacity for DNA replication and repair. Here we report that SHMT1 levels are  
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regulated in an Ub dependent proteasomal manner in both the cytoplasm and in the nucleus. 
The ubiquitination observed is cell cycle dependent with greater SHMT1 ubiquitination 
occurring during G1 and G2/M phases.  
    In this study we demonstrate the interplay of SUMOylation and ubiquitination for the 
control of SHMT1 levels within the nucleus and cytoplasm. We have previously shown that 
mutation of the conserved SHMT1 SUMO motif prevents SHMT1 translocation to the nucleus 
(4). Here we show that mutation of the conserved SUMO site leads to the stabilization of 
SHMT1 in cycloheximide treated samples and that there is a requirement for K39 for SHMT1 
degradation. Co-localization of SHMT1 with the 20S catalytic core and 19S cap of the 
proteasome within the cytoplasm and nucleus indicates that SHMT1 degradation occurs in 
both compartments. In the cytoplasm, SHMT1 degradation is facilitated by K48 Ub linkages, 
whereas in the nucleus K63-linked ubiquitination prevents degradation, potentially by 
blocking Ubc9-mediated Sumo2/3 modification (Figure 4.11) This finding suggests that K63-
linked ubiquitination may occur within the nucleus once SUMO1 modification that is required 
for nuclear import is removed and leads to the export of SHMT1 from the nucleus to the 
cytoplasm.  
     Our proposed model for the interplay between ubiquitination and SUMOylation is as 
follows: following the SUMO-1 dependent import of SHMT1 within the nucleus, the SUMO-
1 moiety can be removed from the SUMO consensus motif of SHMT1 by the action of SUMO 
proteases (SENPs) (Figure 4.11). Following removal, ubiquitination can occur via Ubc13 
creating K63 Ub linkages. Although some K63 linked Ub modifications have been observed 
to be signals for proteasomal degradation (21), our data does not support that hypothesis for 
SHMT1. Total cellular SHMT1 protein levels decline during G1 and G2/M phases with a  
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Figure 4.11. Interactions among SHMT1 ubiquitination and SUMOylation.  In this model, 
SUMO-1 is conjugated to SHMT1 by Ubc9 during S, G2/M phases and in response to UV 
damage which leads to nuclear import.  The Ub E2 conjugase Ubc13 acts to A) stabilize 
SHMT1 within the nucleus and B) signals nuclear export of SHMT1 through K63 specific Ub 
linkage. Following nuclear export, SHMT1 is degraded via the proteasome in a K48 Ub 
linkage specific manner by unknown Ub pathway E2s and E3s in the cytoplasm. C) Ubc9 
catalyzes the formation of SUMO-2/3 conjugates which may be involved in nuclear SHMT1 
degradation as SHMT1 accumulates in the nucleus when nuclear export is blocked and 
proteasomal degradation is inhibited. Ubiquitination of SHMT1 also increases in the nucleus 
following proteasome inhibition. Following SUMO-2/3 addition to SHMT1, ubiquitination 
may occur in mixed SUMO/Ub chains mediating SHMT1 degradation. Degradation of 
SHMT1 may occur in both nuclear and cytosolic compartments. 
 
concomitant increase in ubiquitination, which reflects predominately K48 linkages in the 
cytoplasm (Fig 4.2). K63 ubiquitination occurs most during S and G2/M phases but is absent 
in G1 phase. K63 linked ubiquitination seems to serve a role as a mediator of SHMT1 export, 
as is the case for p53 protein (22) and also as an important factor in maintaining SHMT1 
stability within the nucleus. Alternatively, K63 ubiquitination may act as a way to retain 
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SHMT1 in the nucleus. More research must be done in order to more fully understand these 
processes. 
    SHMT1 is also a substrate for UBC-9 mediated SUMOylation with SUMO-2/3. Here we 
propose that mixed SUMO-2/3-Ub chains may be acting to mediate the proteasomal 
degradation of SHMT1 within the nucleus which has been observed previously for other 
proteins (23). The role of mixed SUMO-2/3-Ub chains seem to be compartment specific to the 
nucleus. Future work must be done in order to understand what other Ub pathway enzymes are 
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SHMT1 and SHMT2 anchor the nuclear de novo thymidylate synthesis pathway to the nuclear 
lamina for DNA replication and repair 
 
Introduction 
Regulation of cellular dTTP synthesis is essential for DNA replication and genome stability in 
the nucleus (1) and mitochondria (2). Depressed de novo thymidylate synthesis, resulting from 
folate deficiency or anti-folates results in deoxyuridine misincorporation into nuclear DNA 
leading to genome instability (3). Tetrahydrofolate (THF) is a metabolic cofactor that carries 
and activates single carbons for the synthesis of purine and thymidine nucleotides, and for 
homocysteine remethylation to methionine (4). Folate-mediated one-carbon metabolism is 
compartmentalized in the mitochondria, nucleus, and cytoplasm of eukaryotic cells (5).  The 
enzymes that constitute the de novo thymidylate pathway include SHMT1, SHMT2α, 
thymidylate synthase (TYMS), and dihydrofolate reductase (DHFR).  MethyleneTHF 
generated by SHMT is the one-carbon donor for the TYMS catalyzed conversion of dUMP to 
thymidylate generating dihydrofolate (DHF). DHFR catalyzes the NADPH-dependent 
reduction of DHF to regenerate THF for subsequent cycles of de novo thymidylate synthesis 
(Figure 1). SHMT1, TYMS, and DHFR have been localized to the nucleus, and their 
translocation is mediated by a post-translational modification by the small ubiquitin-like 
modifier (SUMO) (6,7).   SHMT1 nuclear translocation is cell cycle dependent and occurs 
during the S and G2/M phases and in response to UV damage (7-9). Intact purified nuclei 
from mouse liver exhibit de novo thymidylate synthesis activity, whereas nuclei disrupted by 
sonication lack this activity indicating that multienzyme complex formation may be required 
for the pathway to function (6).  
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Figure 5.1. Folate Mediated One-carbon metabolism.    Schematic of folate-mediated one-
carbon metabolism in the cytoplasm and nucleus.  One-carbon metabolism is required for the 
de novo synthesis of purines and thymidylate, and for the remethylation of homocysteine to 
methionine.  The de novo thymidylate pathway is sumoylated and translocates to the nucleus 
during S-phase.  MTHFD1, Methylenetetrahydrofolate Dehydrogenase; MTR, Methionine 
Syntase;  MTHFR, Methylenetetrahydrofolate Reductase; SHMT1, Cytoplasmic Serine 
Hydroxymethyltransferase; SHMT2α, Serine Hydroxymethyltransferase 2α; TYMS, 
Thymidylate Synthase; DHFR, Dihydrofolate Reductase. 
 
Previous studies in cell culture and mouse models have shown that SHMT1 expression 
determines de novo thymidylate synthesis activity, indicating that this enzyme is limiting for 
de novo thymidylate synthesis in vivo (10,11). In mammals, there are two SHMT isozymes 
encoded by distinct genes (12-14).  SHMT1 encodes the cytoplasmic/nuclear isozyme 
(SHMT1) and SHMT2 encodes  mitochondrial (SHMT2) and cytoplasmic/nuclear (SHMT2α)  
isoform through alternative promoter use (6,12-14). The primary SHMT2 transcript encodes a 
mitochondrial leader sequence derived from exon 1 of the SHMT2 gene. The SHMT2 gene 
contains a second promoter within intron 1 that generates a second transcript that lacks exon 1 
but contains a conserved initiator methionine within Exon 2 (6).   This second transcript 
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encodes SHMT2α, a cytoplasmic/nuclear SHMT isozyme that provides functional redundancy 
within the de novo thymidylate synthesis pathway.   SHMT2α accounts for 25% of de novo 
thymidylate biosynthesis activity in purified mouse liver (6).  
         Recent evidence indicates that the formation of a multi-enzyme metabolic complex is 
required for de novo purine nucleotide biosynthesis in the cytoplasm, referred to as a 
purinosome.  The complex includes the folate utilizing enzymes aminoimidazolecarboximide 
ribonucleotide formyltransferase (AICARFT), glycinamide ribonucleotide formyltransferase 
(GARFT), and 5,10-methenylTHF synthetase (MTHFS) (15,16).  Formation of the 
purinosome is regulated by cell cycle, purine levels, protein kinases (17),  by microtubule 
networks (18) and by sumoylation (16), with disruption of microtubule networks resulting in 
the suppression of the rate of de novo purine biosynthesis. Multi-enzyme complexes 
containing some components of the de novo thymidylate cycle, including ribonucleotide 
reductase, TYMS, and DHFR, have been identified in nuclear extracts (19,20).  
    Previous studies have identified SHMT1 as an interacting partner with proliferating cell 
nuclear antigen (PCNA), indicating that SHMT1 and the de novo thymidylate pathway may 
localize to sites of DNA synthesis (8,21). PCNA is a DNA replication and repair processivity 
factor which acts as a “sliding clamp” and crucial factor to localize proteins to replication 
forks and repair foci (22,23). Shmt1
+/-
 mice accumulate uracil within nuclear DNA (11) and 
increased sensitivity to neural tube defects (24) and intestinal cancer (25).  This study 
investigated the presence of a nuclear multi-enzyme complex that included the de novo 
thymidylate pathway, and its association with the DNA replication machinery.  The results of 
this study demonstrate that the de novo thymidylate synthesis pathway is associated with 
nuclear lamina, and that SHMT1 or SHMT2α serve essential roles as scaffold proteins for 
complex formation.  Furthermore, this metabolic complex is enriched at sites of DNA 
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replication initiation, indicating that de novo thymidine nucleotide synthesis occurs at the sites 
of DNA synthesis. 
Results 
SHMT1, SHMT2α, DHFR and TYMS are present in nuclei during S and G2/M phases. 
SHMT1, SHMT2α, TYMS and DHFR have been localized previously to the nucleus and 
cytoplasm of human and mouse cell lines (2,6,8,16).  Nuclear localization of SHMT1 and 
SHMT2α in mouse embryonic fibroblasts (MEFS) and human cell lines (6,8) is restricted to 
the S and G2/M phases of the cell cycle and in response to UV damage (9).  In this study, the 
nuclear localization of TYMS and DHFR was determined as a function of cell cycle. As seen 
previously for SHMT1, DHFR (Figure 5.2) and TYMS (Figure 5.3) localized to the nucleus 
during S and G2/M phases, but not in G1 phase. These data confirm all the enzymes necessary 
for de novo thymidylate biosynthesis are present within the nucleus during S and G2/M 
phases. When DNA replication and repair are occurring respectively. 
 
Figure 5.2. DHFR nuclear localization is cell cycle dependent. cDNAs encoding GFP-DHFR 
were transfected into cells and blocked in G1 (30 uM lovastatin), S phase (1 mM 
hydroxyurea), and G2/M (100 ng/mL nocodazole) phases of the cell cycle. DRAQ5 was used 
as the nuclear stain and cells were visualized with confocal microscopy. DHFR is present in 




Figure 5.3. TYMS nuclear localization is cell cycle dependent. cDNAs encoding GFP-TYMS 
were transfected into cells and blocked in G1 (30 uM lovastatin), S phase (1 mM 
hydroxyurea), and G2/M (100 ng/mL nocodazole) phases of the cell cycle. DRAQ5 was used 
as the nuclear stain and cells were visualized with confocal microscopy. TYMS is present in 
nuclei during S and G2/M phases of the cell cycle. 
 
Identification of SHMT1-interacting proteins in nuclear extracts.  
Intact purified nuclei from mouse liver can convert tritium-labeled serine and dUMP to 
tritium-labeled thymidylate (Figure 1), but this activity is lost in sonicated nuclei, indicating 
that nuclear integrity and multi-enzyme complex formation may be necessary for de novo 
thymidylate synthesis (6).  To determine if the de novo thymidylate biosynthesis pathway is 
present in nuclei within a multi-enzyme complex, SHMT1 tandem affinity purification and 
SHMT1 co-precipitation experiments were performed on benzonase-treated nuclear extracts 
isolated from S-phase cells and cells treated with UV (Figure 5.4). Over 833 proteins were 
identified as SHMT1-interacting proteins. The list was refined by excluding proteins with less 
than 3 peptides identified, and the remaining proteins were grouped by gene ontology term 
enrichment using the bioinformatics tool DAVID (Table 5.1). Multiple proteins involved in 
nucleotide metabolism, DNA replication, and repair were identified, as well as 80 lamin 
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interacting proteins. The majority of the identified proteins known to be involved in DNA 
replication and repair, as well as lamin interacting proteins, were found in both S-phase and 
UV treated samples, although some of these interactions were identified only in one of those 
two exposures (Table 5.1). 
 
Figure 5.4. Tandem affinity purification of SHMT1.  pCMV-FLAG-SHMT1-MAT-Tag-1 (S-
phase and UV) and pCMV-FLAG-MAT-Tag-1 empty vector (control) were transfected into 
HeLa cells. Cells were treated with hydroxyurea (1 mM) for S-phase or exposed to 10 mJ/cm
2
 
UV. Following treatment, cells were incubated for 24 hours.   Nuclei were isolated, treated 
with benzonase and tandem affinity purified using FLAG and Nickel resins. The lanes were 
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Validation of SHMT1 interacting partners. 
DNA replication occurs on nucleoskeletal structures (26) and disruption of the nuclear lamina 
results in DNA replication arrests (27,28).  Several proteins involved in DNA replication are 
lamin-binding proteins including PCNA, which acts as a processivity factor for DNA 
replication (29).  SHMT1 has been identified previously as a PCNA interacting partner (8), 
and this interaction was confirmed in this tandem affinity purification experiment (Figure 5.4, 
Table 5.1). To validate SHMT1 as a lamin interacting partner, co-immunoprecipitation 
experiments using benzonase-treated nuclear extracts were performed with antibodies against 
either Lamin A/C or Lamin B1. SHMT1 co-precipitated with Lamin A/C and Lamin B1 
antibodies under stringent (650 mM NaCl) and less stringent conditions (150 mM NaCl) 
(Figure 5.5A). Neither TYMS or DHFR co-precipitated with lamin proteins under these 
conditions.   
Other SHMT1 interacting partners identified in table 1 were validated by co-
immunoprecipitation followed by immunoblotting against the interacting protein. SHMT1, 
TYMS, and DHFR all co-precipitated with PCNA in nuclear extracts (Figure S4A, B, C), but 
not in cytoplasmic extracts (Figure 5.6A, and B). Lysine demethylase 1 (KDM1), which has 
been recently identified as a folate binding protein (30), immunoprecipitated with anti-
SHMT1 antibodies (Figure 5.6D). Other proteins involved in DNA replication and repair 
including DNA polymerases δ and ε (POLD and POLE respectively), replication factor C 
activator 1 (RFC1), and uracil DNA glycosylase 2 (UNG2) (Figure 5.6E) all co-
immunoprecipitated with SHMT1.  In total, 8 validations were performed and no false 




Figure 5.5. SHMT1 is a nuclear lamin associated protein.  A) Both Lamin A/C and Lamin B1 
co-immunoprecipitations from benzonase-treated nuclar extracts contained SHMT1 even in 
high salt conditions (650 mM NaCl), whereas neither TYMS or DHFR immumoprecipitated 
even under low salt conditions (150 mM NaCl). B) pNTAPb-SHMT1 and pNTAPb empty 
vectors were transfected into HeLa cells and tandem affinity purification was performed using 
streptavidin and calmodulin resins.  SHMT1, TYMS, and DHFR were detected in pNTAPb-
SHMT1 transfections in samples that were not treated with nucleases.  C) The DNA 
dependence of SHMT1, TYMS, and DHFR interactions were determined by SHMT1 
immunoprecipitation in purified nuclear extracts treated with or without benzonase. TYMS 
and DHFR only immunoprecipitated with SHMT1 in samples lacking benzonase treatment. D) 
The interaction of SHMT1, laminB1 and DHFR was investigated by confocal microscopy 
following transfection of cDNAs encoding GFP-DHFR, SHMT1-YFP, and mKate-LaminB1 
fusion proteins in cells blocked in G1 (30 uM lovastatin), S phase (1 mM hydroxyurea), and 
G2/M (100 ng/mL nocodazole) phases of the cell cycle. Co-localization of DHFR and SHMT1 
with LaminB1 is concomitant with nuclear localization of DHFR and SHMT1 during S and 







Figure 5.6. Further validation of SHMT1 interacting partners. Nuclear (A,B, C, and D) and 
cytosolic fractions (A and B) of HeLa cells were isolated and subjected to 
immunoprecipitations. A) TYMS and B) SHMT1 co-precipitated with PCNA only in nuclear 
fractions. C) Nuclear fractions were subjected to PCNA, control, or DHFR 
immunoprecipitations. PCNA co-precipitates with DHFR, but not in control IgG. D) SHMT1 
co-immunoprecipitates with KDM1 but not in IgG controls. E) SHMT1 co-
immunoprecipitates with DNA polymerases δ and ε, RFC1, and UNG2, but not in IgG 
controls. 
 
SHMT1 interaction with TYMS and DHFR is DNA dependent. 
Neither TYMS nor DHFR were identified as SHMT1- or lamin-interacting proteins by tandem 
affinity purification.  The ability of nuclear SHMT1 to interact with TYMS and DHFR in the 
absence of DNA digestion was determined by co-precipitation with SHMT1 in small scale 
tandem affinity purification (Figure 5.5B) and SHMT1 immunoprecipitation (Figure 5.5C).  In 
the tandem affinity purification, both TYMS and DHFR co-precipitated with SHMT1 in the 
absence of benzonase treatment (Figure 5.5B).  However, neither TYMS nor DHFR co-
precipitated with SHMT1 in nuclear extracts treated with benzonase, whereas in the absence 
of benzonase treatment, co-immunoprecipitates contained TYMS and DHFR (Figure 5.5C). 
Co-localization of the de novo thymidylate biosynthesis pathway with Lamin B1. 
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The co-localization of the de novo thymidylate biosynthesis pathway with the nuclear lamina 
was investigated by confocal microscopy.  HeLa cells transfected with pCMV6-AC-DHFR-
GFP, phiYFP-N-SHMT1, and mKate2-LaminB1 expression plasmids exhibited co-
localization of Lamin B1, SHMT1, and DHFR fusion proteins in filament-like linear 
structures and clusters in S and G2/M phases of the cell cycle (Figure 5.5D).  To control for 
potential artifacts resulting from Lamin B1 fusion protein expression, confocal microscopy 
was performed on HeLa cells following transfection of pCMV6-AC-DHFR-GFP (Figure 
5.7A), pCMV6-AC-TYMS-GFP (Figure 5.7B and 5.7C), or phiYFP-N-SHMT1 (Figure 5.7C) 
plasmids.   
 
Figure 5.7. TYMS, DHFR, and SHMT1 localize to linear structures within nuclei regardless 
of LaminB1 over-expression. cDNAs encoding A) GFP-DHFR, B) and C) GFP-TYMS, and 
C) YFP-SHMT1 were transfected into HeLa cells. DRAQ5 was used as the nuclear stain to 
control for LaminB1 over-expression causing aggregation. Cells were visualized with confocal 
microscopy. Over-expression of LaminB1 in cells is not a requirement for visualization of 
linear structures within nuclei. DHFR, TYMS, and SHMT1 all form linear structures (white 
arrows) within nuclei.  
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All three fusion proteins, which constitute the de novo thymidylate biosynthesis cycle, co-
localized as linear structures within nuclei demonstrating that the formation of these structures 
was not of the result of Lamin B1 over expression. 
Formation of the thymidylate biosynthesis complex is nucleotide independent. 
Previous studies have demonstrated that the assembly of the purinosome, a cytoplasmic multi-
enzyme complex comprised of the de novo purine biosynthesis enzymes, is regulated by levels 
of purines within the cell (16,31).  The effect of nucleotides on multi-enzyme complex 
formation of the de novo thymidylate biosynthesis pathway in nuclei was determined in HeLa 
cells grown in media lacking all nucleotides (DMEM), lacking deoxyuridine (dU), lacking 
thymidine (dT), or media replete with nucleotides (αMEM) following transfection with the 
plasmids pCMV6-AC-TYMS-GFP, phiYFP-N-SHMT1, and mKate2-LaminB1 (Figure 5.8).   
The presence or absence of nucleosides in the culture media did not affect the co-localization 
of SHMT1, TYMS, and Lamin B1 as determined by confocal microscopy, demonstrating that 
formation of the observed linear structures is independent of nucleoside availability. 
SHMT1 and SHMT2α are required for DHFR, TYMS and Lamin B1 co-localization.  
The lamin-binding property of SHMT1 and the lack of interaction among TYMS and DHFR 
and lamins suggested that SHMT1 and/or SHMT2α may function as scaffold proteins required 
for DHFR and TYMS localization to the lamina and assembly of the de novo thymidylate 
synthesis pathway complex. Therefore, the co-localization of TYMS and DHFR with nuclear 
lamins was investigated in the absence of SHMT. DHFR-GFP and mKate-LaminB1 (Figure 
5.9A) or TYMS-GFP and mKate-LaminB1 (Figure 5.10A) co-localized in HeLa cells 
transfected with scrambled siRNA in 95% of the observed cells, but was reduced to 50% and 
75% respectively of cells treated with SHMT2 siRNA.  Lamin B1 and DHFR or TYMS co-
localizing structures were observed in only 5% and 14% respectively of cells treated with 
SHMT1 siRNA, and were absent in SHMT1 and SHMT2 siRNA treated samples.  
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Figure 5.8. SHMT1 and TYMS form linear lamin B1 co-localizing structures in a non-
substrate specific manner. The cDNAs encoding YFP-SHMT1, TYMS-GFP, and mKate-
LaminB1 fusion proteins were transfected into cells grown in media containing nucleotides (α-
MEM), no nucleotides (DMEM), and α-mem lacking either deoxyuridine (dU) or thymidine 
(dT) and visualized with confocal microscopy. The co-localization of SHMT1 and TYMS 












Figure 5.9. SHMT1 and SHMT2 are required for DHFR and Lamin B1 co-localization. A) 
cDNAs encoding  GFP-DHFR, mKate-Lamin B1, and siRNAs including scrambled (mock) 
SHMT1, SHMT2, or both SHMT1 and SHMT2  were transfected into HeLa cells.  Cells were 
blocked in S-phase using hydroxyurea (2 mM) and visualized with confocal microscopy.  For 
each siRNA treatment, 100 cells were counted. The presence of DHFR and Lamin B1 co-
localizing structures occurred in 95%, 5%, 50%, and 0% of cells transfected with scrambled, 
SHMT1, SHMT2, and both SHMT1 and SHMT2 siRNAs respectively. B) Immunoblotting 
was performed on siRNA treated samples to ensure knockdown of SHMT1 and SHMT2. 




Figure 5.10. SHMT1 and SHMT2 are required for TYMS and Lamin B1 co-localization. A) 
cDNAs encoding  GFP-TYMS, mKate-Lamin B1 fusion proteins and siRNAs including 
scrambled (mock) SHMT1, SHMT2, or both SHMT1 and SHMT2  were transfected into 
HeLa cells.  Cells were blocked in S-phase using hydroxyurea (2 mM) and visualized with 
confocal microscopy.  For each siRNA treatment, 100 cells were counted. The presence of 
DHFR and Lamin B1 co-localizing structures occurred in 95%, 14%, 75%, and 0% of cells 
transfected with scrambled, SHMT1, SHMT2, and both SHMT1 and SHMT2 siRNAs 
respectively. B) Immunoblotting was performed on siRNA treated samples to ensure 




Immunoblotting was performed against SHMT1 and SHMT2 to ensure that the knockdown of 
those enzymes had occurred (Figures 5.9B and 5.10B). These data demonstrate that SHMT1 
or SHMT2α function as scaffolds that are required for TYMS and DHFR co-localization with 
Lamin B1. 
 TYMS, DHFR, and SHMT2 do not affect SHMT1 and Lamin B1 co-localization.   
The effect of TYMS, DHFR, and SHMT2 on SHMT1 co-localization with Lamin B1 was 
investigated in HeLa cells expressing SHMT1-YFP and mKate-LaminB1 (Figure 5.11A).    
Lamin B1 and SHMT1 co-localized independent of TYMS, DHFR or SHMT2 expression 
which was reduced by siRNA treatment. Immunoblotting was performed against TYMS, 
DHFR, and SHMT2 to ensure that the knockdown of those enzymes had occurred (Figure 
5.11B). These data demonstrate that SHMT1 is essential for the de novo thymidylate synthesis 
pathway complex formation, and that SHMT1 anchors the de novo thymidylate pathway to 
Lamin B1. 
SHMT2α functions as a scaffold protein independent of SHMT1  
Previous studies have demonstrated that SHMT1 and SHMT2α are functionally redundant in 
de novo thymidylate synthesis (6).  The dependency of the SHMT2α-lamin interaction on 
SHMT1, TYMS and DHFR was investigated in HeLa cells expressing SHMT2α-RFP and 
mKate-LaminB1 fision proteins (Figure 5.12A).   SHMT2α and Lamin B1 co-localized 
independent of TYMS, DHFR and SHMT1 expression which was reduced by siRNA 
treatment. Immunoblotting was performed against TYMS, DHFR, and SHMT1 to ensure that 
the knockdown of those enzymes had occurred (Figure 5.12B). These data demonstrate that 
SHMT2α co-localizes with Lamin B1 even in the absence of SHMT1, further supporting the 





Figure 5.11. TYMS, DHFR, and SHMT2 are not requirements for SHMT1 and Lamin B1 co-
localization.  A) cDNAs encoding  SHMT1-YFP, mKate-Lamin B1, and siRNAs including 
scrambled, DHFR,TYMS, or SHMT2 were transfected into HeLa cells.  The formation of 
Lamin B1 and SHMT1 co-localizing structures was not inhibited by knockdown of DHFR, 
TYMS, or SHMT2. B) Immunoblotting was performed on siRNA treated samples to ensure 





Figure 5.12. TYMS, DHFR, and SHMT1 are not requirements for SHMT2α and Lamin B1 
co-localization.  cDNAs encoding  SHMT2α-RFP, mKate-Lamin B1, and siRNAs including 
scrambled, DHFR,TYMS, or SHMT1 were transfected into HeLa cells.  DHFR, TYMS, and 
SHMT1 were not required for SHMT2α and Lamin B1 co-localization. B) Immunoblotting 
was performed on siRNA treated samples to ensure knockdown of DHFR, TYMS and 





The SHMT1 scaffold function can determine de novo thymidylate synthesis capacity. 
Previous studies in SHMT1-deficient mice (11) and cell culture models (10,32) have 
demonstrated strong correlations between SHMT expression and de novo thymidylate 
synthesis capacity, although enzyme kinetic studies do not support that SHMT is catalytically 
rate-limiting in the de novo thymidylate biosynthesis pathway (33).  To distinguish between 
the catalytic and scaffold contributions by SHMT1 to nuclear de novo thymidylate 
biosynthesis, a dominant negative SHMT1 protein (DN2-SHMT1) was expressed in SH-
SY5Y cells that express endogenous SHMT1, and its effect on de novo thymidylate synthesis 
determined.  SHMT is a tetramer, best described as a dimer of obligate dimers, in which 
amino acid residues from each monomer in the obligate dimer contribute to both active sites in 
the dimer (34,35).  Previously, we have described the generation of a DN2-SHMT1 protein 
(Y82A/Y83F/K257Q ) that dimerizes with wild type SHMT1 creating a stable protein that 
lacks catalytic activity in both active sites of the dimer (35).  Y82 is required for hydrophobic 
stacking with the p-aminobenzoylglutamate moiety of tetrahydrofolate, and the Y82A 
mutation eliminates folate binding.  The hydroxyl group of Y83 and K257 are required for 
SHMT1 catalytic activity.  Transfection of dominant negative mutants into cells containing 
endogenous SHMT1 would result in a statistical mixture of active and inactive SHMT1 
tetramers, while decreasing the specific activity of SHMT1 in the cell.  Co-expression of YFP-
DN2-SHMT1 and mKate-LaminB fusion proteins resulted in the formation of linear structures 
SHMT1-laminB structures that were indistinguishable from structures resulting from 
coexpression of wild-type YFP-SHMT1 and mKATE-LaminB1 coexpression (Figure 5.13A), 
indicating that the mutations required to generate DN2-SHMT1 did not impair its lamin 
binding activity. To determine the effect of DN2-SHMT1 expression on SHMT1 activity with 
respect to de novo thymidine biosynthesis and homocysteine remethylation, metabolic isotope 
tracer experiments were performed using [L-
2
H3]-serine and SH-SY5Y cells that express  
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Figure 5.13. Dominant negative SHMT1 (DN2-SHMT1) localizes with Lamin B1 and 
enhances SHMT1 activity in de novo thymidylate biosynthesis.  A) cDNAs encoding  mKate-
Lamin B1 and either YFP-SHMT1 or YFP-DN2-SHMT1 fusion proteins were expressed in 
HeLa cells and co-localization  of the proteins determined by confocal microscopy.  Both 
SHMT and DN2-SHMT1 colocalize with Lamin B1.  B) The effect of tetracycline (tet)-
inducible expression of DN2-SHMT1 on SHMT1 activity in de novo thymidylate biosynthesis 
was determined in SH-SY5Y cells.  Cellular protein and DNA were isolated from cells 
cultured for 8 days in defined medium containing L-[2,3,3-
2
H3]serine. Isotopic enrichment of 
l-[2,3,3-
2
H3]serine into cellular protein pools was determined by the detection of labeled 
methionine (Met) and dehydroalanine (DHA). DHA is formed from serine during the assay.  
Enrichment of [2,3,3-
2
H3]serine in thymidine (dT) was determined by analysis of nuclear 
DNA. All values are expressed as the percent of L-[2,3,3-
2
H3]serine-derived carbons that 
contain two deuterium atoms (CD2) in the target compound (or the ratio of carbons containing 
two deuterium atoms in the target compound divided by the total number of carbons that 
contain one or two deuterium atoms × 100). Two independent experiments were performed 
with duplicate measurements for each sample, and identical values were obtained within each 
experiment. The results from one experiment are shown. The data demonstrate that tet-
inducible expression of DN2-SHMT1 decreased SHMT1 specific activity in homocysteine 
remethylation to methionine in the cytoplasm by 60%, whereas DN2-SHMT1 expression 
enhances SHMT1 specific activity in de novo thymidylate biosynthesis by 45% C) 
Immunoblotting was performed on SH-SY5Y-DN2-SHMT1 cells in a tet inducible system. 
The SH-SY5Y-DN2-SHMT1 cells exhibited increased levels of total SHMT1 in response to 




DN2-SHMT1 from a tet-inducible promoter (36).  In this assay, methylene-THF generated 
from [L-
2
H3]-serine by SHMT1 is incorporated into methionine or thymidine and retains the 
two deuterium atoms (CD2) present on the hydroxymethyl group of serine.  Alternatively, if 
[L-
2
H3]-serine enters the mitochondria, the hydroxymethyl group will be released from 
mitochondria as formate containing a single deuterium atom (CD1) and enters the methylene-
THF pool with one deuterium atom (CD1). CD2 -methyleneTHF can also be converted to 
CD1 methylene-THF through its reversible conversion to methenyl-THF through the activity 
of MTHFD1, which was identified to interact with SHMT1 in the nucleus both during S-phase 
and in response to UV.  The effect of DN2-SHMT1 expression on CD2 enrichment in 
thymidine in DNA, and serine and methionine in cellular protein, was determined following 
culture of SH-SY5Y with [L-
2
H3]-serine for 8 days.  Figure 5.13B shows that 81.3–86.6% of 
the isotopically labeled serine used for protein synthesis was unmetabolized as it retained both 
deuteriums on the C3 carbon in SY-SY5Y cells, and SH-SY5Y-DN2-SHMT1 cells in the 
presence and absence of tetracycline (Figure 1).   If the methionine and thymidylate one-
carbon units were only derived from SHMT1, the mass +2 species of these metabolites should 
be ∼80% of the labeled species.  Expression of DN2-SHMT1 suppressed CD2 incorporation 
into methionine by 60%, consistent with a loss of SHMT1 specific activity in the cytoplasm.  
Interestingly, CD2 incorporation into thymidine within nuclear DNA was increased by 45%, 
indicating that DN2-SHMT1 expression increased the flux of SHMT1-derived one-carbons 
into thymidylate.  These results demonstrate that the lamin-binding activity and scaffold 
function of SHMT1 contributes more than its catalytic activity to de novo thymidylate 
biosynthesis in this cell line (Figure 5.13B).  
De novo thymidylate pathway is associated with episomal DNA. 
The interaction of SHMT1 and the de novo thymidylate cycle with proteins involved in DNA 
replication and repair including UNG2, RFC1, PCNA, and DNA polymerases δ and ε (Table 
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1, Figure 5.6E) indicates that the thymidylate biosynthesis pathway may function at the 
replication fork.  During DNA replication initiation, RFC interacts with DNA at the primer-
template junction and loads PCNA onto the DNA template which allows for the processive 
replication of DNA by DNA polymerases δ and ε (22). Mammalian origins of replication are 
not well characterized; therefore a model system of episomally replicating DNA was 
employed to determine if the de novo thymidylate biosynthesis pathway is present at the 
replication fork.   HeLa cells were transfected with the pBABE-Puro SV40 LT plasmid which 
contains both the SV40 LT antigen cDNA as well as the SV40 origin of replication. The SV40 
LT antigen is sufficient for replication initiation at the SV40 origin of replication (37) and  has 
also been shown to induce S-phase (38). Tandem ChIP experiments using antibodies directed 
against PCNA followed by IgG, SHMT1, TYMS, or DHFR showed that all three enzymes 
required for de novo thymidylate synthesis are present on DNA, with the greatest occupancy 
observed at the SV40 origin of replication (Figure 5.14C). Because of the bi-directional nature 
of DNA replication, regions either upstream or downstream of the SV40 origin of replication 
were also probed. The required enzymes for de novo thymidylate biosynthesis were present 
within the SV40 LT antigen coding region (Figure 5.14A) and also within a randomly chosen 
area of the vector referred to as pBABE-Puro vector (Figure 5.14B). These data demonstrate 
that de novo thymidylate biosynthesis localizes to replication forks and suggests the 






Figure 5.14. The de novo dTMP synthesis pathway is associated with episomal DNA in 
tandem chromatin immunoprecipitations. HeLa cells were transfected with pBABE-Puro-
SV40 LT vector and selected for using puromycin.  Clones were isolated and immunoblots 
performed against SV40 large T antigen (SV40 LT) to ensure clones were expressing SV40 
LT (D).  Tandem ChIP assays were performed as described in experimental procedures using 
antibodies directed against PCNA and then antibodies directed against non-immune IgG, 
SHMT1, TYMS, or DHFR.  Regions of the pBABE-Puro-SV40 LT vector were probed for 
using real-time PCR (A,B, and C). All three enzymes precipitated regions of the vector 
including the A) LT antigen coding region , B) SV40 origin of replication, and C) downstream 












    Previous studies of cell culture and mouse models has indicated that SHMT1 expression is 
limiting for de novo thymidylate synthesis. Reduced SHMT1 expression in MCF-7 cells 
revealed a decrease in cellular de novo thymidylate synthesis whereas increases in SHMT1 
expression in MCF-7 and SH-SY5Y cells increases cellular thymidylate synthesis (10). Uracil 
accumulation in DNA is a proxy for thymidylate synthesis capacity, and  Shmt1
+/-
 mice exhibit 
elevated uracil levels in liver DNA compared to wild-type littermates (11), demonstrating a 
key role of this enzyme in determining cellular thymidylate synthesis capacity.  De novo 
thymidylate synthesis occurs in isolated intact nuclei, and SHMT1 and SHMT2α are present in 
the nucleus during S and G2/M phases (6). Here we show the localization of TYMS and 
DHFR to the nucleus during S and G2/M phases, supporting a role for nuclear de novo 
thymidylate synthesis during DNA replication and repair.  
   Previous studies have shown that de novo thymidylate synthesis activity in isolated nuclei is 
impaired following sonication, indicating a role for nuclear architecture in thymidylate 
synthesis (6).  The results of this study provide a mechanism for this observation, by 
demonstrating that SHMT1 and SHMT2α are lamin binding proteins that serve as scaffold 
proteins required for assembly of the de novo thymidylate synthesis pathway into a multi-
enzyme complex in the nucleus. Metabolic tracer studies in cells expressing a dominant 
negative form of SHMT1 demonstrate that the SHMT1 scaffold function can make a greater 
contribution to SHMT1 activity for de novo thymidylate synthesis than its catalytic activity. 
Increased uracil misincorporation in DNA along with increased risk of intestinal cancer (25) 
and neural tube defects (24) in Shmt1
+/-
 mice show although there is redundancy within the de 
novo thymidylate synthesis pathway due to both SHMT2α activity and scaffold function 
within nuclei, the pathway is sensitive to lack of SHMT1.  Furthermore, the dominant 
negative SHMT1 cell lines reduced methionine synthesis which is indicative of cytoplasmic 
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folate-mediated one-carbon metabolism but enhanced thymidylate synthesis. If de novo 
thymidylate synthesis was cytoplasmic, it would be expected to also be reduced in dominant 
negative SHMT1 cell lines, which was not the case. These data support that de novo 
thymidylate synthesis occurs in the compartments in which DNA is synthesized (2,6) and not 
in the cytosol.  
    The nuclear lamina has been observed to play an important role in tethering DNA to the 
nuclear periphery during replication and repair. The formation of de novo thymidylate multi-
enzyme complexes and lamin associated structures demonstrated in this study is dependent on 
cell cycle, occurring during the S and G2/M phases when DNA replication occurs, and is 
independent of nucleotide availability. These data support a role for SHMT1 in anchoring de 
novo thymidylate synthesis to the nuclear lamina and this scaffold function likely accounts for 
its role as a limiting factor for de novo thymidylate biosynthesis in cell culture and mouse 
models (10,11,32). The results of this study also indicate that de novo thymidylate 
biosynthesis occurs at the sites of DNA synthesis and is associated with the DNA replication 
machinery.  SHMT1 was shown to interact with PCNA, RFC1 and the DNA polymerases δ 
and ε, and PCNA interacts with SHMT1, TYMS, and DHFR, and has previously been 
identified as a lamin binding protein (29). SHMT1, TYMS and DHFR proteins are associated 
with replicating DNA, and enriched at sites of DNA replication initiation. These data indicate 
that de novo thymidylate biosynthesis is occurring at replication forks. De novo thymidylate 
biosynthesis is unique from the biosynthesis of other deoxyribonucleotides in its 
compartmentation to the nucleus at replication forks.  Thymidine deoxyribonucleotides are 
also unique in that they are not essential during DNA replication, as dUTP can be incorporated 
into DNA in lieu of dTTP.  The presence of the de novo thymidylate biosynthesis at the 
replication fork may permit regulation of dUTP incorporation into DNA, which may function 
to regulate transcriptional networks and biological pathways, as has been demonstrated in 
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Drosophila (39,40), and may account for the sensitivity of SHMT
+/-
 mice to neural tube 
closure defects (24) and intestinal cancers (25). 
Materials and Methods 
Cell Lines and Media― HeLa cells were obtained and cultured as previously reported (6). 
Cells were grown in α-MEM or DMEM (Hyclone) supplemented with 10% fetal bovine serum 
(Hyclone) and penicillin/streptomycin (Mediatech) at 37° C and 5% CO2. For all experiments, 
α-MEM (Hyclone) lacking nucleotides was used and supplemented with 10% dialyzed and 
charcoal treated fetal bovine serum and penicillin/streptomycin (Mediatech) with and without 
deoxyribonucleosides (10 mg/L). Cells were maintained in these medias at 37° C and 5% CO2 
for 2 passages over 1 week prior to transfection. The SH-SY5Y human neuroblastoma cell line 
has been described previously (41). Cells were cultured in αMEM with 10% dialyzed fetal 
bovine serum for all experiments. DN2-SHMT1 expression was induced in cell lines by the 
addition of 1 µg/ml tetracycline for a minimum of 4 days prior to experimentation as 
previously described for SH-SY5Y-FDH cells lines (36).  
Generation of Human DN2-SHMT1-expressing Cell Lines—Generation of the pet28a-DN2-
SHMT1 cDNA was described previously (35). This vector was treated with Kpn1 and BamHI 
(New England Biolabs) to isolated DN2-SHMT1 cDNA as was the pcDNA4/TO/myc-His C 
vector (Invitrogen). Following isolation of the restriction fragments through gel purification 
using the QIAquick Gel Extraction Kit (Qiagen), DN2-SHMT1 cDNA was ligated into the 
pcDNA4/TO/myc-His C vector using T4 DNA ligase (Invitrogen) generating pcDNA4-DN2-
SHMT1. Stable SH-SY5Y cell lines expressing pcDNA6/TR vector (Invitrogen) and 
pcDNA4-DN2-SHMT1 were generated. SH-SY5Y cells were electroporated with 20 µg of 
plasmid DNA (pcDNA4-DN2-SHMT1 and pcDNA6/TR vector) at 0.22 kV and 950 
microfarads (Bio-Rad Gene-Pulser), then cultured with αMEM for 48 h. The medium was 
replaced with αMEM containing blasticidin (10 µg/ml) and Zeocin (100 µg/ml, Invitrogen) to 
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select for stable integrants. Individual colonies resistant to Zeocin treatment were selected and 
expanded using αMEM containing blasticidin and Zeocin, and clonal lines expressing human 
DN2-SHMT1 protein were screened by Western blot analyses.  
Vectors and transfection procedures –  pCMV6-AC-DHFR-GFP, pCMV6-AC-TYMS-GFP, 
phiYFP-SHMT1, and TagRFP-N-SHMT2α were previously described (6). PmKate2-LaminB1 
was purchased from Evrogen. The pBABE-puro SV40 LT vector was deposited in Addgene 
by Dr. Thomas Roberts and purchased from Addgene (Addgene plasmid 13970). pNTAPB and 
pCMV-FLAG-MAT-Tag-1 were obtained from Stratagene and Sigma respectively. PCR was 
used to create adapters on SHMT1 cDNA for ligation. The forward primers for both pNTAPB-
SHMT1 and pCMV-FLAG-SHMT1-MAT-Tag-1 was 5’-
ATATAAGCTTATGACGATGCCAGTCAAC-3’ where the bold text indicates a HindIII 
(New England Biolabs Inc.) site. The reverse primer for pNTAPB-SHMT1 was 5’-
ATATCTCGAGGAAGTCAGGCAGGCCAGG-3’ where the bold text indicates a XhoI 
(New England Biolabs Inc.) site. The reverse primer for pCMV-FLAG-SHMT1-MAT-Tag-1 
was 5’-ATATAGATCTGAAGTCAGGCAGGCCAGG-3’ where the bold text indicates a 
BglII (New England Biolabs Inc.) restriction site. PCR reactions were completed as follows: 
95°C for 45 s, 55°C for 45 s, and 72°C for 2 min. Following PCR, products were gel purified 
using the QIAquick Gel extraction kit (Qiagen). Vectors and PCR products were restriction 
digested with their respective restriction enzymes as per manufacturer’s protocol. Ligation 
was completed using T4 DNA ligase (Invitrogen) as per manufacturer’s protocol. All 
transfection procedures were completed using Kit R (Lonza) for a Nucleofector II (Lonza) as 
per manufacturer’s instructions.  
Confocal microscopy – Following nucleofection, cells were incubated at 37° under 5% CO2 
for 24 hours. For visualization of nuclei in cells not transfected with pmKate2-Lamin B1, 
DRAQ5 (Alexis Biochemicals) was used per manufacturer’s instruction. Confocal 
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fluorescence microscopy (Leica TCS SP2 system) was used to image all cells at the Cornell 
Microscope and Imaging Facility. 
Cell Cycle Synchronization and Analysis―HeLa cells at 60% confluence were arrested at 
various cell cycle stages using 30 µM lovastatin (Sigma) (for G1 phase), 2 mM hydroxyurea 
(Sigma) (for S phase), or 100 ng/mL nocodazole (Sigma) (for G2/M phase) following 
transfection. Preparation for fluorescence activated cell sorting (FACS) was performed as 
previously described (8). FACS analysis was performed by Biomedical Sciences Flow 
Cytometry Core Laboratory at Cornell University. 
Immunoblotting – SHMT1, SHMT2, TYMS, DHFR, and GAPDH immunoblots were 
performed as described previously (6,7). Antibodies directed towards PCNA and the SV40 LT 
antigen were purchased from Abcam. Mouse anti-PCNA and Mouse anti-SV40 Large T 
antigen were diluted in 5% non-fat dry milk (Carnation) containing 1% NP40 (US 
Biologicals) at a concentration of 1 µg/mL and 1:1000 respectively. Goat anti-mouse HRP 
(Pierce) secondary antibodies were used at a dilution of 1:10,000. SuperSignal West Pico 
Chemiluminescent substrate was used for visualization (Pierce). 
Immunoprecipitation – Immunoprecipitation was conducted using the Dynabeads Protein G 
Immunoprecipitation Kit (Invitrogen). For whole cell immunoprecipitation, HeLa cells were 
lysed using mammalian protein extraction reagent (Pierce) supplemented with 2 mM β-
mercaptoethanol (Calbiochem), 0.1 mM EDTA (Fisher Scientific), 1 mM PMSF (Alexis 
Biochemicals), and 1:1000 Protease Inhibitor Cocktail (Sigma). For immunoprecipitations 
from nuclear and cytosolic extracts, nuclei were purified using the Active Motif Nuclear 
extract kit per manufacturer’s protocol. Antibodies directed toward the following proteins 
were purchased from Abcam: DNA polymerase δ, UNG2, PCNA, and DHFR. Lamin A/C, 
Lamin B1, DNA polymerase ε, KDM1 and RFC1 antibodies were purchased from Santa Cruz 
Biotechnology. Non-immune IgG was purchased from Pierce. SHMT1 antibody was obtained 
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as previously described (8).  1 mg of total protein per sample was incubated with 5 µg of 
antibody overnight at 4
o
C. The beads were collected and washed four times with PBS/0.1% 
Tween 20 (Fisher). For Lamin A/C and Lamin B1 immunoprecipitations, washes contained 
either 150 mM NaCl or 650 mM NaCl in PBS/0.1% Tween 20. For all immunoprecipitations, 
40 µls of SDS-PAGE sample buffer were added to the beads to elute with heating at 100°C. 
SHMT1 tandem affinity purification – pNTAPB-SHMT1 was transfected into HeLa cells as 
described above. For the isolation of TAP tagged SHMT1 and co-eluting proteins, the 
Interplay mammalian TAP system kit (Stratagene) was used according to manufacturer’s 
protocol. For isolation of FLAG-SHMT1-MAT and co-eluting proteins for peptide 
sequencing, pCMV-FLAG-SHMT1-MAT-Tag-1 was transfected as described above. 
Approximately 4 x 10
8
 HeLa cells were used per group. The groups were: empty pCMV-
FLAG-MAT-Tag-1 control, and pCMV-FLAG-SHMT1-MAT-Tag-1 S-phase synchronized 
cells and UV treated cells. UV treatment was accomplished as previously reported (9).  24 h 
following treatments, cells were washed with 20 mLs PBS/1 mM PMSF three times. Cells 
were scraped into 5 mLs of PBS/1 mM PMSF and collected in 50 mL conical tubes (Corning). 
Cells were pelleted at 1000 rpm for 5 min and  resuspended in 15 mLs swelling buffer (25mM 
HEPES (Fisher) pH 7.8, 1.5mM MgCl2 (Fisher), 10mM KCl (Fisher), 0.1% NP40 (US 
Biologicals),  1.0mM PMSF (Alexis Biochemicals), 1:100 Protease inhibitor (Sigma)) and 
incubated on ice for 10 min.  Cells were homogenized with 25 strokes of a B-type dounce 
homogenizer and checked for cell lysis using trypan blue (Fisher) exclusion. The homogenate 
was then filtered through a 70um mesh (BD Bioscience) and centrifuged at 4000 rpm for 5 
min to collect nuclei. Nuclei were washed with swelling buffer 2X followed by centrifugation. 
Nuclei were then resuspended in 1 mL ice-cold sodium phosphate (Fisher) pH 8.0/ 75 mM 
NaCl/ 1mM PMSF/ 1:100 protease inhibitor for histidine tag isolation (Sigma). MgCl2 was 
added to a concentration of 2 mM.  Benzonase (Sigma) was added at a concentration of 250 
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U/mL sample for removal of DNA and incubated for 30 minutes on ice. Following benzonase 
treatment, samples were centrifuged at 14,000 rpm for 15 minutes. The supernatant was 
collected and FLAG-SHMT1-MAT and co-eluting proteins were purified using Invitrogen 
His-TALON magnetic beads per manufacturer’s instructions. Following elution, the eluates 
were combined and diluted with 1 volume 100 mM Tris pH 7.4 and 2 mM EDTA and 1:100 
protease inhibitor cocktail for FLAG immunoprecipitation using FLAG affinity gel (Sigma) 
per manufacturer’s instruction. The eluate from the FLAG immunoprecipitation was then 
subjected to protein precipitation using the ND Protein Precipitation Kit (National 
Diagnostics) per manufacturer’s protocol. The protein pellet was resuspended in 20 uL of 20 
mM Tris pH 7.5 and 20 uL 2X SDS-PAGE loading buffer (Biorad) and heated at 95° for 10 
minutes.  
Mass Spectrometry – Tandem affinity purified samples from S-phase blocked and UV treated 
cells were run on a 12% polyacrylamide gel and was stained with Novex colloidal blue 
staining reagent (Invitrogen). The lanes were excised and great care was taken to avoid sample 
contamination. Excised lanes were cut into 9 fractions of approximately 7 mm by 5 mm areas 
and sent to the Harvard Microchemistry Facility for peptide digestion, purification, and 
sequencing. Each excised fraction was reduced, carboxyamidomethylated and digested with 
trypsin. Peptide identification of each digestion mixture was performed by microcapillary 
reversed-phase HPLC nanoelectrospray tandem mass spectrometry (µLC-MS/MS) on an 
LTQ-Orbitrap Velos or XL mass spectrometer (ThermoFisher Scientific, San Jose, MA). The 
Orbitrap repetitively surveyed an m/z range from 395 to 1600, while data-dependent MS/MS 
spectra on the twenty (Velos) or ten (XL) most abundant ions in each survey scan were 
acquired in the linear ion trap. MS/MS spectra were acquired with relative collision energy of 
30%, 2.5-Da isolation width, and recurring ions dynamically excluded for 60 s. Preliminary 
sequencing of peptides was facilitated with the SEQUEST algorithm with a 30 ppm mass 
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tolerance against a species specific (human) subset of the UniProt Knowledgebase. With a 
custom version of the Harvard Proteomics Browser Suite (ThermoFisher Scientific, San Jose 
CA), peptide spectrum matches (PSMs) were accepted with mass error < 2.5ppm and score 
thresholds to attain an estimated false discovery rate (FDR) of 1% using a reverse decoy 
database strategy.  Gene ontology term enrichment was performed using DAVID with the 
total set of proteins with a peptide count > 3 and greater than 1 ratio of experimental group 
peptide counts to control group peptide counts (42,43).  
Metabolic isotope tracer studies- Metabolic isotope tracer studies were completed as 
previously described (32). Cells were plated in 100-mm plates at 50% confluence in treatment 
media (10 g/liter HyQ αMEM-modified (HyClone), 2.5 g/liter NaHCO3, 11.2% (v/v) dialyzed 
fetal bovine serum, 0.05 µm 5-formyl-THF, 10 µm methionine, 1 mg/liter pyridoxine, glycine 
at 0.2 mM, 26 mg/liter L-[5,5,5-
2
H3]leucine, but lacking ribo- and deoxyribonucleosides, 
hypoxanthine, thymidine and serine]. Media were supplemented with L-[2,3,3-
2
H3]serine (250 
µm) and were refreshed every 2-3 days. Cells were cultured for 8 days with 2-4 doublings. 
Media were removed and cells washed in 2 ml of ice-cold phosphate-buffered saline. Cells 
were pelleted and whole cell pellets were lysed with 600 µl of 5% trichloroacetic acid for 
protein isolation. Total cellular protein was pelleted by centrifugation at 4000 × g for 30 min 
at 4 °C.  Protein pellets were suspended in 6 N HCl (100 µl) in vacuum hydrolysis tubes and 
heated at 100 °C for 20 h. The amino acids were purified by cation exchange chromatography 
(44-46). Amino acids were converted to heptafluorobutyryl n-propyl ester derivatives (45) and 
were separated on an HP-5MS column (30 m × 0.25 mm). Isotopic enrichment was 
determined in electron capture negative ionization mode by gas chromatography-mass 
spectrometry using a model 6890 gas chromatograph and model 5973 mass spectrometer 
(Hewlett-Packard Corp., Palo Alto, CA). Selected ion monitoring was conducted at a mass-to-
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charge ratio m/z 519–523 for serine, m/z 305–308 for dehydroalanine (DHA), m/z 349–353 for 
leucine, and m/z 367–370 for methionine. 
    Total genomic DNA was isolated using a QIAamp DNA Blood Mini kit (Qiagen). DNA 
samples were dried under nitrogen and suspended in formic acid (1 ml) and hydrolyzed at 
150 °C for 45 min in vacuum hydrolysis tubes. After drying at 55 °C under nitrogen, 
derivitization was performed by dissolving the bases in 0.2 ml of a 1:1 mixture of N,O-bis-
[trimethylsilyl]trifluoroacetamide/1% trimethylchlorosilane (Pierce) and acetonitrile, and 
heated at 140 °C for 30 min. The trimethylsilane-base derivatives were separated on a HP-
5MS column. Isotopic enrichment was determined in positive ionization mode by gas 
chromatography-mass spectrometry using a model 6890 gas chromatograph and model 5973 
mass spectrometer (Hewlett-Packard Corp., Palo Alto, CA). Selected ion monitoring was 
conducted at a mass-to-charge ratio m/z 255–257 for thymine. 
Tandem Chromatin Immunoprecipitation – Clones 1,2, and 3 of pBABE-Puro SV40 LT 
expressing HeLa cells that were selected using puromycin were used for this experiment. 
Approximately 2 x 10
8
 cells were used per clone. Each plate was washed 3 times with ice-cold 
PBS. The bifunctional cross-linker Dimethyl 3,3´-dithiobispropionimidate (DTBP) (Pierce) 
was resuspended at a concentration of 5 mM in PBS pH 8.0. 20 mL per plate was added and 
cells were incubated at 4° for 30 minutes. Cells were then washed 2 X with PBS. 20 mLs ice-
cold quenching buffer (100 mM Tris pH 8.0, 150 mM NaCl) was added per plate and 
incubated for 10 minutes at 4°.  Each plate was washed 3 X with room temperature PBS. A 
1% formaldehyde (Fisher) solution in PBS was added to each plate and incubated at room 
temperature for 10 minutes. To quench formaldehyde crosslinking, 3 mLs of 1.375 M glycine 
(Fisher) were added. Plates were washed 3 times with ice-cold PBS supplemented with 0.5 
mM PMSF. Cells were scraped into 5 mL ice cold PBS containing 0.5 mM PMSF and 
centrifuged at 1000 rpm for 5 minutes at 4°. The pelleted cells were resuspended in 10 
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volumes of swelling buffer and then subjected to dounce homogenization and centrifugation 
as reported above. Pelleted nuclei were resuspended in 5 mL sonication buffer (50mM Hepes 
pH 7.9, 140 mM NaCl, 1 mM EDTA, 1% Triton X-100, 0.1% Na-deoxycholate, 0.1% SDS, 
0.5 mM PMSF, and 1:1000 protease inhibitor cocktail). Nuclei were sonicated using a 3mm 
microtip probe on a Branson Sonifier 150 at 80% with 10 second pulses 10 times with 1 
minute rests on ice between pulses. Sonicated nuclei were centrifuged at 14,000 rpm for 15 
minutes at 4° and the supernatant supplemented with 1µg/mL sonicated salmon sperm DNA 
(Invitrogen) and bovine serum albumin (Sigma) at 1 mg/mL. The lysate was precleared using 
50 µL Invitrogen Protein G Dynabeads for 2 hours at 4° and beads collected on a magnet and 
the supernatant removed. Samples were divided into 1 mL aliquots for immunoprecipitation. 5 
µg PCNA (Abcam) antibody was incubated 12 hours per 1 mL aliquot at 4°. 50 µL Invitrogen 
Protein G Dynabeads were added and incubated for 1 hour at 4°. The beads were collected on 
a magnet and washed twice with 1 mL sonication buffer. The beads were washed twice with 1 
mL sonication buffer containing 500 mM NaCl and then twice with 1 mL 20mM Tris, pH 8.0, 
1mM EDTA, 250mM LiCl, 0.5% NP-40, 0.5% Na-deoxycholate, 0.5 mM PMSF, and 
Protease inhibitor cocktail. Two more washes were performed with 1 mL TE buffer. 50 µLs of 
10 mM DTT was then added to the beads and incubated at 37° for 30 min. The eluate was 
removed and that step was repeated. The eluates were then combined and diluted 40 times 
with sonication buffer. 10% of the sample was kept for input. The sample was then aliquoted 
into 1 mL fractions for TYMS, DHFR, SHMT1, and IgG control immunoprecipitations. 5 µg 
of each antibody was used and samples were incubated 12 hours at 4°. 50 µL of  Invitrogen 
Protein G Dynabeads were then added and incubated for 1 hour at 4°. Washes were performed 
as above. To elute, 200 µL 50mM Tris, pH 8.0, 1mM EDTA, 1% SDS, and 50mM NaHCO3 
was added and beads were heated to 65° for 10 minutes. This step was repeated and eluates 
combined giving 400 µL final volume. The input and samples were then treated with 21 µL 4 
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M NaCl and incubated for 12 hours at 65°. 2 µL RNase A (5 mg/mL) (Rockland 
Immunochemicals, Inc.) was added to each sample followed by incubation at 37° for 1 hour. 
EDTA was then added to a concentration of 5 mM. 2 µL Proteinase K (10 mg/mL) (Rockland 
Immunochemicals, Inc.) was then added and samples were incubated for 2 hours at 42°.  
Samples were extracted with phenol/chloroform/isoamylalcohol (Sigma) once and then with 
chloroform/isoamylalcohol (Sigma) once.  1 µL glycogen (Sigma) (20 mg/mL) was added 
followed by addition of 40 µL 3 M Na-acetate (Fisher) and 1 mL 100% ethanol (Pharmco-
AAPER). Samples were vortexed and precipitated for 12 hours at -20° followed by 
centrifugation at 14,000 rpm for 30 minutes and pellets were washed with 75% ethanol. 
Centrifugation was repeated and the pellet was allowed to dry at room temperature. Samples 
were then resuspended in 100 µL 10 mM Tris pH 7.5 for real-time PCR analysis. 
Real-time PCR – Forward and reverse primers used for real-time PCR surrounding the SV40 
origin of replication were 5’-CAGCAGGCAGAAGTATGCAAAGCA-3’ and 5’-
TACTTCTGGAATAGCTCAGAGGCCGA-3’respectively. For the pBABE-Puro vector 
region the forward and reverse primers were 5’-ACAGAGTTCTTGAAGTGGTGGCCT-3’ 
and 5’-TGGTTTGTTTGCCGGATCAAGAGC-3’ respectively. For the large t-antigen insert, 
the forward and reverse primers were 5’-ACTCCACACAGGCATAGAGTGTCT-3’ and 5’-
CCCACCTGGCAAACTTTCCTCAAT-3’ respectively. Real-time PCR analysis was 
performed using Quantifast SYBR green PCR kit (Qiagen).  PCR products were quantified 
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CHAPTER SIX 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
Part I: Introduction 
 Folate-mediated one-carbon metabolism is a requirement for the synthesis of purines, 
thymidylate, and methionine. These pathways, however, compete for a limited pool of 
available folate cofactors. This competition is most pronounced for methyleneTHF which is 
required for de novo dTMP synthesis. The enzymes required for de novo dTMP synthetic 
cycle include SHMT1, TYMS, and DHFR. SHMT1 transfers one-carbon groups from C3 of 
serine to tetrahydrofolate to form glycine and MethyleneTHF (1). MethyleneTHF is then used 
by TYMS for the reductive methylation of dUMP to form dTMP and dihydrofolate. DHFR 
catalyzes the reduction of dihydrofolate in a NADPH dependent reaction which regenerates 
THF for continuing the cycle. SHMT1 is the rate limiting enzyme in de novo dTMP synthesis 
(2) and regulates the flux of one-carbon units towards dTMP at the expense of homocysteine 
remethylation (3). SHMT1 achieves this regulation through the import of the de novo dTMP 
pathway in a SUMO dependent fashion during S and G2/M phases (4,5). Although the 
mechanisms for nuclear import are known, direct evidence of dTMP synthesis within the 
nucleus was lacking. We also wanted to understand if de novo dTMP synthesis occurs in 
mitochondria to support DNA replication within that compartment. Regulation of nuclear 
dTMP synthesis and how SHMT1 exits the nucleus was also unknown. Furthermore, how 
SHMT1 acts as a rate-limiter in de novo dTMP synthesis was investigated. The results of these 
studies and other studies in the lab show that SHMT has a central uracil misincorporation 
limiting function within the cell.  
 
Part II:  Nuclear de novo dTMP synthesis 
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 The data presented herein show directly the existence of nuclear one-carbon 
metabolism and in particular nuclear de novo dTMP synthesis. Previous work by Pardee and 
co-workers identified a nuclear multi-enzyme complex they termed the replitase which 
contained TYMS and DHFR activities (6,7). However, they never directly showed nuclear de 




 whole mouse liver nuclei treated with L-
[
3
H]-serine, nuclear de novo dTMP synthesis was observed to occur. These activities were 
inhibited by sonication of nuclei which suggested a role for nuclear architecture and/or multi-
enzyme complex formation in nuclei. Interestingly, we found that Shmt1
-/-
 whole mouse liver 
nuclei retained 25% of the activity found in wild-type mice. We were able to identify that this 
activity was due to another nuclear isoform of SHMT made from the SHMT2 gene, we termed 
SHMT2α. SHMT2α was observed to be expressed through alternate promoter usage. The 
SHMT2 gene contains a mitochondrial leader sequence in exon 1 followed by a promoter 
region that controls SHMT2α. Exon 2 contains another start methionine codon which lacks the 
mitochondrial leader sequence and is translated to make the nuclear and cytosplasmic isoform 
of SHMT2, SHMT2α.  
 These studies also solidified the mechanism of SHMT1 import to the nucleus as 
mutation of the conserved SUMO motif (K38R/K39R) on SHMT1 completely abolished 
nuclear localization. Cells expressing a human SNP of SHMT1 present in the population, 
L474F, also show a decrease in nuclear localization. The presence of another nuclear isoform 
of SHMT provided evidence for how the L474F polymorphism persisted over evolutionary 
time and gave insight into the functional redundancy of SHMT and its importance in de novo 
dTMP synthesis.  
 
Part III:  Mitochondrial  de novo dTMP synthesis  
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 We had identified that nuclear de novo dTMP synthesis occurs and that in these mice 
that nuclei were isolated from also exhibited increased uracil misincorporation in nuclear 
DNA. We formed the hypothesis that perhaps mitochondrial de novo dTMP synthesis occurs 
in order to support mtDNA replication and limit uracil misincorporation in that compartment. 
It has been reported that in plant mitochondria, de novo dTMP synthesis occurs using SHMT2 
and a bifunctional enzyme TS-DHFR which contains both activities (8). TYMS has also been 
reported in mitochondria of mammalian cells (9). SHMT2 has long been known to be a 
mitochondrial protein and is present on mtDNA (10). DHFR however, has not been identified 
in mammalian mitochondria. We set out to find a DHFR transcript with a mitochondrial 
localization signal (MLS) in the human hepatic cell line using 5’-RACE. We identified a 
transcript that was previously thought to be a pseudogene called DHFRL1. The sequence of 
DHFRL1 and DHFR are 92% identical and DHFRL1 localizes to mitochondria. We also show 
that TYMS localized to mitochondria. The submitochondrial localization of SHMT2, TYMS, 
and DHFRL1 were also determined with all of these enzymes present in the matrix and in 
association with the inner membrane. The matrix is the mitochondrial compartment that 
houses mtDNA. Treating HepG2 cells with siRNA directed towards DHFRL1 completely 
inhibited DHFR activity in mitochondrial extracts that were isolated. The mechanisms 
whereby DHFRL1 and TYMS localize to mitochondria are still unknown as no canonical 
MLS of either protein was identified.  
    We went on to show that mitochondrial de novo dTMP synthesis does occur and were able 
to isolate nascent 
3
H-dTMP made from 
3
H-serine in whole purified mitochondria. We found 
that mitochondrial de novo dTMP synthesis occurred in HepG2 cells and Chinese hamster 
ovary (CHO) cells and that this activity was markedly decreased in samples treated with the 
DHFR inhibitor methotrexate (MTX) and in the SHMT2 mutant CHO cell line, glyA. 
Furthermore, in order to see how deficiencies in mitochondrial de novo dTMP synthesis 
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affected uracil misincorporation in mtDNA, we used the glyA cell line that we knew was 
deficient in dTMP synthesis and assayed levels of uracil in mtDNA. We found 40% increased 
uracil in mtDNA in the glyA CHO cell line as compared to wild-type CHO cells. We were also 
able to complement a previously uncharacterized CHO glycine auxotroph called glyC with 
DHFRL1 cDNA, rescuing the glycine auxotrophy. This also solidifies a role for DHFRL1 in 
mitochondrial one-carbon metabolism.  
      
Part IV:  Regulation of SHMT1 through Ubiquitination 
 Previous work had shown the importance of SUMO-1 in the nuclear import of 
SHMT1. Prior observations also indicated that SHMT1 interacted with the ubiquitin E2 
conjugase, Ubc13 (4). We wanted to know how SHMT1 was regulated through the ubiquitin 
pathway and if a competition existed for the same consensus motif that is SUMOylated for 
regulation of SHMT1, as has been shown for other proteins (11). 
          We found that SHMT1 levels are most prevalent during S-phase of the cell cycle when 
it is required for dTMP synthesis in the nucleus. This was not due to an increase in mRNA 
levels and it was determined that ubiquitination was lowest during S-phase. These data 
suggested an important role for ubiquitination in regulating SHMT1 levels in the cell. We 
found that inhibition of the translational machinery using cycloheximide (CHX) showed that 
SHMT1 has a half-life of approximately 2 hours. Concomitant inhibition of the proteasome 
rescued SHMT1 levels and lead to increases in ubiquitinated SHMT1. Mutation of the 
SHMT1 SUMO site resulted in increased stability of SHMT1 and drastic decreases in 
ubiquitination at K39. Furthermore, SHMT1 co-localizes with both the 19S cap and 20S core 
of the proteasome in both the nucleus and cytoplasm suggesting that degradation can occur in 
either compartment.  
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    To determine whether degradation is compartment specific, cells were treated with the 
nuclear export inhibitor leptomycin B (LMB). Nuclei isolated from cells treated with LMB 
accumulated higher molecular weight bands which identified to be ubiquitin whereas nuclei 
isolated from cells treated with LMB and the proteosomal inhibitor Mg132 exhibited a 
prominent 75 kDa band which was determined to be a SUMO-2/3 conjugate of SHMT1. In 
conjunction with nuclear export and proteosomal inhibition, both ubiquitin and SUMO-2/3 
chains became prominent. Mixed SUMO-2/3-Ubiquitin chains have been reported to be 
important mediators of protein degradation (12) suggesting that SHMT1 proteasomal 
dependent degradation does occur in the nucleus. 
      Because Ubc13 is generally involved in K63-linkage specific poly-ubiquitin chains, which 
are not involved in proteosomal degradation, we wanted to understand the role that Ubc13 
played. We observed compartmental differences in K63 ubiquitination between the nucleus 
and cytosol. Extensive K63 polyubiquitin chains were observed in nuclei throughout S and 
G2/M phases, but were lacking in G1 phase. In the cytosol, only bands consistent with K63 
linked di-ubiquitin were present with the same cell cycle profile. We found that normal 
cycling HeLa cells exhibited decreased nuclear SHMT1 in response to Ubc13 siRNA 
treatment and in cells over-expressing Ubc13 a reduction of nuclear SHMT1 was observed. 
The reduction of nuclear SHMT1 in response to Ubc13 over-expression was partially rescued 
by treatment with LMB. This suggests that SHMT1 is exported from the nucleus in a Ubc13 
and K63 linkage specific manner as has been observed for p53(13).  SHMT1 was less stable in 
both the cytosol and nuclei of cells treated with CHX and Ubc13 siRNA whereas over-
expression of Ubc13 lead to an increase in stability of SHMT1 in the cytosol. In response to 
transfection of the mutant ubiquitin K48R which is involved in proteosomal degradation, and 
increase in stability of SHMT1 was observed in the cytosol, whereas the K63R mutant showed 
a decrease in SHMT1 stability in the nucleus. Lack of Ubc13 in siRNA treated samples lead to 
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decreased nuclear SHMT1 accumulation, suggesting that a competition between Ubc13 and 
Ubc9 does exist in the nucleus, where Ubc9 can add SUMO-2/3 to SHMT1 which is then 
selectively degraded. These data are also indicative of Ubc13 playing a role in stabilization of 
SHMT1 within nuclei and export out of nuclei. The tight regulation of SHMT1 through 
ubiquitination and SUMOylation at the same sites gives insight into the important regulatory 
events governing nuclear de novo dTMP synthesis. SHMT1 is the rate-limiter in de novo 
dTMP synthesis (2,14) so degradation of nuclear SHMT1 would serve to shut de novo dTMP 
synthesis off.   
Part V:  Lamin Binding of SHMT1 and its role in nuclear dTMP biosynthesis. 
 Because SHMT1, SHMT2α, TYMS, and DHFR are all required for de novo dTMP 
synthesis, we wanted to determine if a de novo dTMP multi-enzyme complex existed. Multi-
enzyme complexes are required for de novo purine synthesis in the cytosol (15-18) and 
nuclear complexes containing TYMS and DHFR activity has also been reported (6,7). Using a 
tandem affinity approach coupled with peptide sequencing, we were able to determine that 
SHMT1 is a lamin binding protein and also interacts with multiple proteins involved in DNA 
replication and repair. Surprisingly, TYMS and DHFR were not present in the large-scale 
tandem affinity and peptide sequencing experiment. We found that this was due to the 
requirement of DNA for the interaction of the three enzymes. The interaction of SHMT1 with 
Lamin A/C and Lamin B1 was present even under high salt conditions (650 mM NaCl) but 
TYMS and DHFR did not interact with lamins in samples treated with nucleases. 
Furthermore, we went on to find the formation of LaminB1, SHMT1, SHMT2α, TYMS, and 
DHFR co-localizing filament like structures which are present during S and G2/M phases of 
the cell cycle. 
      Unlike the purinosome, the de novo dTMP multi-enzyme complex is not sensitive to 
nucleoside levels (16). It was also shown that SHMT1 and SHMT2α are requirements for the 
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recruitment of TYMS and DHFR to LaminB1 co-localizing structures, whereas TYMS and 
DHFR are not required for SHMT1 and SHMT2α localization. 
     Previous studies in SHMT1-deficient mice (14) and cell culture models (2,3) demonstrated 
positive correlations between the expression of SHMT1 and capacity for de novo thymidylate 
synthesis, although kinetic studies do not indicate SHMT1 is catalytically rate-limiting for de 
novo dTMP synthesis (19). To distinguish between the contributions of SHMT1 catalytic 
activity and scaffold function to nuclear de novo dTMP biosynthesis, a dominant negative 
(DN2) Y82A/Y83F/K257Q mutant fluorescent SHMT1 vector and SH-SY5Y neuroblastoma 
cells lines expressing a tet-inducible DN2-SHMT1 were produced (for a full description, see 
chapter 5). The SH-SY5Y cells and HeLa cells used in these experiments both contain 
endogenous levels of SHMT1. SHMT is a tetramer, best described as a dimer of obligate 
dimers, in which amino acid residues from each monomer in the obligate dimer contribute to 
both active sites in the dimer (20,21). Cells containing endogenous SHMT1 and expressing 
dominant negative mutants would result in a statistical mixture of active and inactive SHMT1 
tetramers which would decrease SHMT1 specific activity in the cell.  The effects of these 
mutants on scaffold function and de novo dTMP synthesis were determined. DN2-SHMT1 co-
localized with LaminB1 and was similar to WT-SHMT1 localization. Surprisingly, DN2-
SHMT1 increased de novo dTMP synthesis while suppressing methionine biosynthesis. These 
data confirm the importance of SHMT1 scaffold function for the biosynthesis of dTMP and 
indicates that the scaffold function is a major contributor to nuclear de novo dTMP synthesis.  
     Because of the requirement of DNA for multi-enzyme de novo dTMP synthesis complex 
formation, and due to the interaction of multiple DNA replication and repair proteins, we 
wanted to determine if SHMT1 was present on actively replicating DNA. We have reported 
the interaction of SHMT1 with the DNA processivity factor PCNA (4). This led to the 
hypothesis that the enzymes for de novo dTMP synthesis could be synthesizing dTMP right at 
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the replication fork for processive addition. We used a model of episomally replicating DNA 
in order to understand if de novo dTMP synthesis multi-enzyme complexes exist on DNA. 
Using tandem chromatin immunoprecipitations first against PCNA and then against SHMT1, 
TYMS, and DHFR we were able to show that all the enzymes necessary for de novo dTMP 
synthesis were present in association with PCNA and DNA and were highly enriched around 
origins of replication. These data support that the entire de novo dTMP synthesis pathway is 
present during DNA replication at replication forks for the processive addition of dT in order 
to limit uracil misincorporation.   
 
Part VI:  Future Directions 
 These studies have brought to light the importance of nuclear and mitochondrial de 
novo dTMP synthesis and have informed us in the capacity of SHMT to limit uracil 
misincorporation in both nuclear and mitochondrial DNA. Many new questions arise from the 
work presented here. The identification of SHMT2α as a functional replacement for SHMT1 
in both scaffold function and activity suggests that SHMT function in the nucleus is crucial for 
maintaining cellular dTTP pools. The regulation of SHMT2α should be further investigated. 
The protooncogene, c-myc has been shown to be a regulator of both SHMT1 and SHMT2 
transcription (22), but it is still unknown whether c-myc regulates both SHMT2 and SHMT2α 
or just one of them. The SHMT2α transcript also has a long 5’-UTR, similar to SHMT1 (23), 
which may indicate post-transcriptional regulatory events through internal ribosome entry 
sites (24). The similarity of SHMT2α to SHMT1 in structure also suggests that post-
translational control of SHMT2α occurs. Understanding whether a similar interplay between 
SUMOylation and ubiquitination that exists for SHMT1 occurs for SHMT2α will further our 
understanding of the functional redundancy within this pathway. 
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     The identification of mitochondrial de novo dTMP synthesis also has brought up many new 
questions. These data have shown the importance in dTMP synthesis in mitochondria for 
limiting uracil misincorporation in mtDNA. Future research must understand the regulation of 
the novel DHFRL1 gene described here. Although we and others have reported TYMS and 
DHFRL1 localization to the mitochondria, the lack of canonical MLS in either of these genes 
suggests a new mitochondrial import pathway exists that has yet to be determined. Identifying 
what residues are required in these enzymes for mitochondrial import and what other 
chaperones or import proteins are involved in mitochondrial import is required. Research into 
whether formation of multi-enzyme complexes for de novo dTMP synthesis in mitochondria 
should also be undertaken. SHMT2 has been shown to crosslink to mtDNA (10)and therefore 
may be playing a scaffold function within mitochondria similarly to what we report within 
nuclei. Furthermore, little research has gone into understanding how uracil in mtDNA affects 
mitochondrial biology. These studies may shed light on other mechanisms which lead to 
cellular dysfunction and risk of developmental defects and other pathologies in humans. 
    The data presented here have demonstrated how SHMT1 is rate-limiting in de novo dTMP 
synthesis. The lamin binding scaffold function of SHMT1 is critical for the formation of 
multi-enzyme complexes and for efficient de novo dTMP synthesis. Tight regulation of 
SHMT1 has also been reported here with ubiquitination and SUMOylation playing a role in 
maintaining appropriate levels of SHMT1 within the nucleus. Future work must go into 
understanding what other ubiquitin pathway enzymes are required for regulation of SHMT1. 
More direct evidence of SHMT1 degradation within the nucleus should also be undertaken.  
     The data presented here regarding DN2-SHMT1 in SH-SY5Y cells indicates that the 
scaffold function of SHMT1 contributes significantly to its ability to direct de novo dTMP 
synthesis. If cytoplasmic de novo dTMP synthesis were to occur, one would expect a decrease 
in de novo dTMP synthesis efficiency as was seen with methionine, but this was not the case. 
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Methionine represents cytoplasmic folate-mediated one carbon metabolism and was 
suppressed while dT synthesis was increased. This data along with the identification of de 
novo dTMP synthesis in both compartments that require DNA synthesis suggest that 
cytoplasmic de novo dTMP synthesis is not substantial, if it occurs at all. Future work will 
need to knock out nuclear de novo dTMP synthesis completely in order to understand the 
contribution of cytoplasmic de novo dTMP synthesis, if any. This could be achieved by 
making mice with a SUMO site mutant knock-in of SHMT1, along with mutation of the start 
methionine in the SHMT2 gene which leads to the production of SHMT2α.  
     We have also presented that SHMT1 interacts with a variety of proteins and enzymes 
required for DNA replication and repair, including PCNA, UNG2, and DNA polymerases δ 
and ε. These data are indicative of an important role for SHMT1 in delivering one-carbon 
units for de novo dTMP synthesis at the replication fork both during replication and repair and 
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